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Abstract
Adenosine receptors are members of the G protein coupled receptor
(GPCR) superfamily. Neurochemical and electrophysiological experiments
point to a neuromodulatory role for adenosine. Adenosine inhibits the release
of several neurotransmitters in brain by pre- and postsynaptic actions at
adenosine A-i receptors. In this thesis the pharmacology and modulation of
adenosine Ai receptors in the central nervous system (CNS) of different
species was characterised. Rat renal adenosine A-i receptors were also
studied. In addition the central penetration by adenosine A-i receptor
antagonists following peripheral administration was investigated.
An in vitro [3H]DPCPX ligand binding assay utilising a range of
receptor agonists and antagonists, were used to compare the pharmacology
of rat, mouse, guinea pig and human adenosine A-i receptors. Standard
xanthine-based adenosine antagonists had 10-fold lower affinity in human
and guinea pig in comparison with rat and mouse. Several novel non-
xanthine A-i antagonists from the Fujisawa Pharmaceutical Co. Ltd., retained
high affinity for adenosine A-i receptors in all species, including human.
Modulation of ligand binding to adenosine and A2a receptors by
Gpp(NH)p and magnesium was examined. In common with other GPCRs,
agonists bind to high and low affinity states, with the equilibrium modified by
GTP analogues and magnesium, whereas effects on antagonist affinity are
minimal. Agonist radioligands under the conditions used labelled
predominantly the high affinity state of adenosine A-i and A2a receptors.
Gpp(NH)p and magnesium have essentially inverse effects on radioligand
(agonists and antagonists) binding to both adenosine Ai and A2a receptors.
In addition their effects on [3H]agonist and [3H]antagonist binding are
generally opposite, which is consistent with effects observed for other
I
GPCRs.
To act centrally, compounds must cross the blood brain barrier (BBB).
A modified radioreceptor assay, involving a denaturation step to overcome
the lipophilic nature of adenosine At receptor antagonists was developed.
This assay accurately measures the central penetration of adenosine At
receptor antagonists. Adenosine Ai antagonists administered peripherally at
equipotent behavioural doses, were found to be present in brain, at
concentrations between 50-500 fold greater than in vitro K( values for
adenosine Ai receptors. In addition, there was an excellent association
between antagonist affinity in vitro and antagonist brain concentrations at the
equipotent behavioural dose.
Adenosine and its receptors are widely distributed throughout the
body. It is important to determine if peripheral adenosine A-i receptors are
identical to those in the CNS. Renal adenosine Ai receptors were examined
using radioligand binding, in vitro autoradiography and in situ hybridisation.
Even using this combined approach, identification of adenosine A1 receptors
in rat kidney was not possible.
Alzheimers disease involves a myriad of neurochemical changes and
neurotransmitter deficits. By antagonising the actions of endogenous
adenosine, Ai receptor antagonists could compensate for some of these
deficits, by enhancing synaptic facilitation and increasing neurotransmitter
release. Analogues of FK453, a non-xanthine adenosine Ai antagonist,
which are BBB permeable and potent and selective for human adenosine Ai
receptors, could prove to be clinically useful compounds, by enhancing
cognition, in conditions such as Alzheimers disease.
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The physiological roles of extracellular purine nucleosides and
nucleotides have been investigated since Drury and Szent-Gyorgi, (1929) first
described a range of biological effects, including bradycardia and vasodilation.
Research for the next three decades centred around physiological rather than
pharmacological studies, and in the 1950's the cardiovascular effects of ATP
(Green & Stoner, 1950) were examined in geriatric patients (Boettge et at,
1957, quoted in Burnstock, 1993). In the 1960's, adenosine's role in regulating
coronary blood flow associated with myocardial hypoxia was postulated
(Berne, 1963; Gerlach et al., 1963, quoted in Fredholm et al., 1994a),
generating a wider interest. The possible existence of an adenosine receptor
was noted when the cardiovascular effects of adenosine were found to be
blocked by caffeine (De Gubareff & Sleator, 1965). The vasodilatory role of
ATP was not discovered until much later (De May & Vanhoutte, 1981).
Receptors for the nucleotide ADP were also recognised several decades ago
from work on blood platelets (Gaarder et at, 1961), as summarised by Haslam
& Cusack, (1981). Effects in the central and peripheral nervous system were
implied when it was shown that ATP could be released from sensory nerves
(Holton, 1959). With evidence accumulating, Burnstock (1972) in a pivotal
review on "purinergic nerves" postulated the existence of central ATP
receptors and that the principal substance released from nonadrenergic
noncholinergic (NANC) nerves was ATP. At the same time, experiments in the
CNS showed adenosine could stimulate the accumulation of cAMP in brain
slices, an effect blocked by methylxanthines (Sattin & Rail, 1970). The release
of endogenous adenosine from brain slices at concentrations sufficient to
increase cAMP provided further evidence for the existence of adenosine
receptors in the CNS (Mcllwain, 1972). In the 25 years since these seminal
observations an array of both central and peripheral effects, mediated through
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a variety of purinergic receptors, have been attributed to both nucleosides and
nucleotides (Olsson & Pearson, 1990; Jacobson et al., 1992a; Burnstock,
1993; Collis & Hourani, 1993; Jacobson et al., 1996). In light of the myriad of
effects produced by these compounds, this review concentrates primarily on
the role of adenosine receptors in the CNS.
II. Regulation of Adenosine
Adenosine is part of the metabolic machinery of all living cells and is
central to the balance of energy supply and demand (Williams, 1987).
Intracellular production of adenosine is via two distinct metabolic pathways,
both involving hydrolases (Olsson & Pearson, 1990; Bruns, 1990). The major
pathway involves the hydrolysis of the nucleotide AMP to adenosine by
5'-nucleotidase (Figure 1.1), and the other involves catabolism of
S-adenosylhomocysteine (SAH). Adenosine is released under conditions of
stress, such as hypoxia, when cellular energy is depressed and acts locally as
a metabolic regulator. The consequence of receptor activation is to restore the
tissue or cell to a normal state and to protect from over-activation. Once
released, adenosine can be eliminated by a variety of pathways, including
transport back into the cell by specific nucleoside transporters, six of which
have now been characterised (Kwong et al., 1988; Gu etal., 1995; Glass etal,
1996; Parkinson et al., 1996), passage across the membrane by simple
diffusion and deamination to the receptor inactive compound inosine by
adenosine deaminase (Olsson & Pearson, 1990). Adenosine's half-life of a few
seconds or less in the circulation (Moser et al., 1989), ensures a local action,
diffusing perhaps a millimetre from the site of release. As highlighted above,
adenosine once released acts on a range of adenosine receptors, regulating a
wide variety of physiological functions throughout the body including, CNS,














Figure1.1Purinmetabolism(fromOlss n&earson,1990).,ATP-consu ingre cti s;2oxid tiv phosphorylation;3,myokinase45'-nucleotid ;AMPdeaminase6aden succinatesy thase lyase;7,adenosinekina8ide minas ;9purinnucle dhosph rylase10x nt i dehydrogenase;11,guani ephosphoribosyltran fe a e;2e ephosphoribosyltransferase.
metabolic effects (Daly, 1982; Williams, 1987, 1993; Olsson & Pearson, 1990;
Jacobson etal., 1992a, 1996; Burnstock, 1993; Collis & Hourani, 1993).
III. A Neuromodulatory Role for Adenosine
Adenosine and ATP are both local regulators of physiological functions;
i.e. they act within the same organs and perhaps even on the very cells that
are the site of production. For over 50 years, ATP and adenosine have been
proposed to function as neuromodulators or neurohormones. Interest in the
role of purine receptors in the CNS was rekindled by the discovery that the
methylxanthines, caffeine and theophylline may exert stimulatory actions by
blocking the action of endogenous adenosine at adenosine receptors (Daly et
al., 1981). That caffeine was an adenosine receptor antagonist made it clear
that adenosine receptors are the target for the most commonly used drug in
the world (Jacobson et al., 1996). Adenosine has been characterised as an
inhibitory neuromodulator at biochemical, electrophysiological and behavioural
levels (Williams, 1987, 1993). However, the question of whether purinergic
transmission occurs in the CNS is controversial, because unlike classical
neurotransmitters such as acetylcholine (Snyder, 1985), well circumscribed
purinergic neuronal pathways have been difficult to identify (Williams, 1987).
The most convincing evidence for discrete effects of adenosine in the CNS
was the heterologous distribution of recognition sites in mammalian brain
sections (Goodman & Snyder, 1982), suggesting as originally hypothesised,
that purines play a significant role in controlling neuronal function (Snyder,
1985).
Historical precedent has defined a set of criteria which a compound
should fulfil for it to be considered a neurotransmitter (Snyder, 1985). Classical
neurotransmitters are produced by neurons, stored in synaptic vesicles, have
mechanisms for synthesis and degradation, and the effects of nerve
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stimulation should be mimicked by tissue application of the putative
transmitter. Many neurotransmitters (e.g. acetylcholine at the neuromuscular
junction) are very short acting (msec to sec) and are inactivated in the synapse
(< 1 micron from the site of release). At the opposite end of the scale, classical
circulating hormones are produced by glands and distributed by the circulation,
acting for long periods (min to hr) at distant locations throughout the body.
Based on the prototypic neurotransmitter, acetylcholine, adenosine was
classified as a neuromodulator (Snyder, 1985). Adenosine is produced by
many cell types, has well characterised synthetic and degradative pathways
(Olsson & Pearson, 1990) and is released from nervous tissue per se,
although evidence for vesicular storage is weak (Sweeney, 1996). The
mechanism by which adenosine is released from neurons has still to be fully
elucidated. There is evidence for Ca2+ dependent release, which is indicative
of release of adenosine itself, rather than just by the dephosphorylation of ATP
(Cahill et al., 1993; Umemiya & Berger, 1994; Sweeney, 1996). Modulation of
synaptic transmission by adenosine is mediated via both pre- and postsynaptic
receptors (Swanson et al., 1995; Von Lubitz et al., 1996). Early experiments
showed both adenosine and ATP reduced spontaneous and evoked release of
acetylcholine, producing evidence for the existence of prejunctional purinergic
receptors (Ginsborg & Hirst, 1972). Adenosine has subsequently been shown
to inhibit the release of a variety of neurotransmitters (Fredholm & Dunwiddie,
1988; Von Lubitz et al., 1996). Long term potentiation (LTP), which is
postulated to be an underlying event in learning and memory is also inhibited
by adenosine (Daval et al., 1991; Suzuki et al., 1993; Von Lubitz et al., 1993).
The presynaptic inhibition of neurotransmitter release, the postsynaptic
decrease in excitability and the inhibition of LTP, an electrophysiological




Extensive analysis of the literature led to a proposal which forms the
basis of currently accepted nomenclature for purinergic receptors (Burnstock,
1978). The initial receptor classification was based on the preference of
receptors for binding adenosine (P-i receptors) or adenine nucleotides (P2
receptors). Inhibition of Pi receptors by methylxanthines such as caffeine and
theophylline was used to further distinguish between P-\ and P2 receptors.
Biochemical evidence showing differing effects of adenosine analogues on
cAMP accumulation in different preparations and different agonist potencies
pointed to the existence of multiple adenosine (P-i) receptors (Londos & Wolff,
1977; Van Calker et al., 1979; Londos et a!., 1980). The two classes of
receptor were named A-i and A2, based on their ability to inhibit or stimulate
adenyl cyclase respectively (Van Calker et al., 1979). This nomenclature was
used in preference to the terminology, Rj (inhibition of adenyl cyclase) and Ra
(activation of adenyl cyclase) proposed by Londos et al., (1980). Traditionally,
this type of receptor classification was based on relative potencies and the
selectivities of agonists and antagonists. The criteria are: (1) antagonist
affinity, (2) agonist potency ratio, (3) agonist affinity and (4) relative intrinsic
agonist efficacy. The subsequent development of selective ligands (Jacobson
et al., 1992a; Suzuki et al., 1992, 1993; Peet et al., 1993), and the recent
isolation of multiple cDNA clones for both P-i and P2 receptors (reviewed in,
Fredholm et al., 1994; Palmer & Stiles, 1995; Olah & Stiles, 1995), has
necessitated expansion of the original classification.
The general advances in pharmacological and molecular techniques
over the last 15 years have resulted in the on going identification of a large
number of new receptor subtypes. In response, the International Union of
Pharmacology (IUPHAR) Committee on Receptor Nomenclature and Drug
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Classification have attempted to define how receptors should now be
classified. Pharmacological classification of receptors should be based on
combined structural and pharmacological information, with emphasis on
antagonists rather than agonists, as agonist potency is dependent on agonist
binding to the receptor and the entire signal transduction machinery (Kenakin
et al., 1992). These problems were highlighted with reference to
purinoreceptors (Abbracchio et al., 1993), where lack of selective antagonists
has resulted in a classification heavily dependent on the relative potency of
agonists. The IUPHAR subcommittee on purinoreceptors have attempted to
clarify the situation (Fredholm et al., 1994). Clarification was necessary, as
there is debate over how many different subtypes of both P-i and P2 receptors
exist. The controversy was exemplified by an almost simultaneous paper in
which further potential subtypes of both P1 and P2 receptors were shown to
exist, plus a separate class of P3 purinoreceptors (Dalziel & Westfall, 1994). As
well as the classified purinergic receptors, other proteins capable of binding
adenosine include the P-site, adenosine transporters, adetonin and SAH, a
site for the dinucleotide, diadenosinetetraphosphate and CD26 (Hutchison et
al., 1990; Schwabe et al., 1991; Olsson & Pearson, 1990; Fredholm et al.,
1994; Dalziel & Westfall, 1994; Ciruela etal., 1996).
Detailed discussion of P2 receptors are not relevant to this thesis.
Reviews on the classification and potential roles of P2 receptors can be found
(Bumstock, 1993; Fredholm etal., 1994; Dalziel & Westfall, 1994; Abbracchio
& Burnstock, 1994; Boarder etal., 1995; Kennedy & Leff, 1995).
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V. Adenosine (Pi) Receptors
All adenosine receptors have a general structure similar to that of
bacteriorhodopsin (Henderson et al., 1990) and are members of the G protein
coupled receptor superfamily. To date, four adenosine receptors subtypes, Ai,
A2a, A2b and A3 have been structurally and pharmacologically characterised
(Stiles, 1992; Jacobson et al., 1992a; reviewed in Palmer & Stiles, 1995; Olah
& Stiles, 1995). These receptors are distributed widely throughout the body
giving a variety of potential therapeutic targets for both adenosine agonists and
antagonists (Jacobson et al., 1992a; Williams, 1993). The various subtypes
and their extensive distribution necessitate that any therapeutic usefulness will
require agonists and antagonists which are selective in their actions.
Compounds used to identify the various subtypes of Pi purinoreceptors have
been summarised, along with some general information (Table 1.1). This will be
discussed in more detail in the following sections with each receptor described
structurally, pharmacologically and functionally as these parameters define the
subtypes and have physiological implications.
VI. The Adenosine Ai Receptor
Pi receptors were initially divided by the ability of adenosine to inhibit
(AO or stimulate (A2) cAMP production (Van Calker et al., 1979; Londos et al.,
1980), and their relative sensitivity to methylxanthines. The rank order of
potency of adenosine analogues in producing this effect was used to classify
these receptor subtypes, A-i: R-PIA > NECA > S-PIA and A2: NECA > R-PIA >
S-PIA. This agonist order of potency is still important in the classification of
adenosine receptors (Table 1.1). However, extensive studies on the structure
activity relationships of adenosine receptor ligands have identified structural
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for A-i and A2 receptor characterisation (Jacobson et al., 1992a) (Table 1.1).
The action of adenosine on A-i receptors and the subsequent inhibitory effect
on adenylate cyclase was shown to be G protein linked, with the A-i receptor
coupling to multiple G proteins, including Gj and G0 (Fredholm et al., 1994;
Palmer & Stiles, 1995; Asano et al., 1995). In producing its effects, the A-i
receptor couples not only to different G proteins but to multiple effector
systems (Olsson & Pearson, 1990; Collis & Hourani, 1993; Murthy & Makhlouf,
1995). A-i receptors are linked to potassium channels, calcium channels,
phospholipases A2 and C (PLC) and perhaps guanylyl cyclase, although
evidence for the latter is weak (Linden, 1991; Stiles, 1992; Olah & Stiles, 1992;
Iredale et al., 1994; Olah & Stiles, 1995). Based on evidence from other G
protein coupled receptors (GPCRs), it is likely that these effects are produced
by both the a and py subunits of the G protein (Birnbaumer, 1992; Tang &
Gilman, 1992; Freund et al., 1994; Jockers et al., 1994; Murthy & Makhlouf,
1995). For the Ai receptor, knowledge of these effector systems is important
as species homologues of the receptor can differentiate between related G
protein a-subunits (Jockers et al., 1994) and the same receptor can use
multiple effectors (Akbar etal., 1994; Freund etal., 1994).
Structural characteristics of the A-i receptor were investigated using
ligand based radioprobes. The two approaches involved labelling adenosine
receptors by indirect photoaffinity crosslinking (radiolabeled receptor ligand
contains a chemically active group, e.g. aryl amine) and direct photoaffinity
labelling (ligand preactivated for photolysis, e.g. using azido-derivatives)
(reviewed in Stiles, 1990; Jacobson eta/., 1992a). The A-, receptor binding
protein was identified in rat as having a molecular weight of ~38 kDa (Klotz et
al., 1985; Stiles, 1985, 1986; Lohse et al., 1986; Leung et al., 1988) and was
subsequently purified to homogeneity using affinity chromatography from a
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variety of sources (Nakata, 1990; Freissmuth et al., 1991a). The purified
protein had the appropriate pharmacology (R-PIA > NECA > S-PIA), was
functionally coupled to G proteins (Nakata, 1990; Freissmuth eta!., 1991a) and
appeared to be identical across tissues and species as shown by the
consistent labelling of a 38 kDa protein (Olah & Stiles, 1992). The size of the
protein was confirmed by radiation inactivation analysis (Reddington et al.,
1989). The distribution of the receptor in a number of tissues and species
has been examined using receptor autoradiography, with varying levels
expressed in brain and peripheral tissues of various mammalian species
(Goodman & Snyder, 1982; Fastbom et al., 1986; Weber et al., 1988, 1990a).
The introduction of molecular biology into the field of adenosine
research has produced an explosion of information in the last five years. The
adenosine A-i receptor originally cloned from dog (Libert et al., 1989, 1991a),
has now been cloned from rat (Mahan et al., 1991; Reppert et al., 1991;
Ungerer et al., 1992), cow (Olah et al., 1992; Tucker et al., 1992), human
(Libert et al., 1992; Townsend-Nicholson & Shine, 1992; Ren & Stiles, 1994a),
rabbit (Bhattacharya et al., 1993), guinea pig (Meng et al., 1994a), mouse
(Marquardt et al., 1994) and chick (Aguilar et al., 1995) tissue (Table 1.1 and
Figure 1.2). The clones encode a protein of 326 amino acids (AA) with the
exception of rabbit which has 328 AA (Bhattacharya et al., 1993) and chick
(324 AA) (Aguilar et al., 1995), corresponding to a protein of ~36.7 kDa, similar
to that determined using photoaffinity labelling (Stiles, 1990) and
immunological studies (Nakata, 1993). The amino acid sequence of the
homologues from different mammalian species and tissues is very similar,
showing approximately 90% homology in the transmembrane region but lower
homology with the chick receptor (80%). The cloned receptor has similar
properties to native receptors when expressed in mammalian cell lines, with








S-PIA, except the bovine A-i receptor, which has a unique pharmacology in
both native and cloned receptors: R-PIA > S-PIA > NECA, (Olah et at, 1992;
Tucker et a/., 1992; Tucker & Linden, 1993). The distribution of adenosine Ai
receptor mRNA in rat tissue has been analysed using Northern blotting, in situ
hybridisation and RT-PCR and is similar to that seen in comparable
autoradiographic (Goodman & Snyder, 1982; Weber et at, 1990a) and
immunohistochemical studies (Rivkees et ai., 1995c; Ciruela eta/., 1995). The
A-i receptor is highly expressed in rat brain (cortex, cerebellum, thalamus and
hippocampus), spinal cord and testis, with lower levels in heart and kidney
(Mahan et a!., 1991; Reppert et al., 1991; Johansson et at, 1993; Rivkees,
1994). This distribution in rat of mRNA for all four adenosine receptors (for A2a,
A2b and A3, see below) has recently been expanded in an extensive study
using in situ hybridisation and RT-PCR (Dixon et at, 1996). There would
appear to be species differences in tissue distribution, although brain and heart
are consistently labelled in dog (Libert et at, 1989), cow (Olah et at, 1992),
guinea pig (Meng eta!., 1994a), chick (Aguilar etat, 1995) and human (Ren &
Stiles, 1994a; Rivkees et at, 1995b). A clue to perhaps understanding tissue
and species variation in the properties of the adenosine A-i receptor has
recently been published (Ren & Stiles, 1994a, b). They demonstrated that
control of human A-i receptor gene expression can occur in the 5' untranslated
region by alternative splicing. The human Ai gene has six exons and five
introns, of which exons 1, 2, 3, 4 and part of 5 encode 5' untranslated regions.
This complexity is unusual with many other GPCRs not reported to have
introns (Ren & Stiles, 1994a). The differential use of exons 3 or 4 directly
effected levels of receptor expression in different tissues, with levels
considerably reduced when exon 4 is present. This exon contained two ATG
codons (and an in frame termination codon) which when mutated relieved the
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inhibition of expression. The lack of exons 1 and 2 in mature mRNA from
mammalian tissue has led recently to the renumbering of these exons (Ren &
Stiles, 1995). Techniques such as site directed mutagenesis and production of
chimeric receptors may help in understanding the amino acid residues
involved in ligand recognition, perhaps leading to the development of new
compounds (Klotz et al., 1988; Tucker et al., 1994; Olah et a!., 1994;
Townsend-Nicholson & Schofield, 1994; Rivkees et al., 1995a). This is of
greater importance for the other adenosine receptors, as lack of selective
antagonists still hampers our understanding of their pharmacological
properties. The A-i receptor was originally thought to be localised to
chromosome 22 (Libert etal., 1991b), but has now been correctly identified on
chromosome 1 (Libert, 1994; Townsend-Nicholson etal., 1995; Deckert etal.,
1995; Rivkees etal., 1995b).
There is a great deal of evidence pointing to a functional role for the
adenosine Ai receptor in a number of physiological systems. Adenosine itself
has been approved for the treatment of supraventricular tachycardia (Daval et
al., 1991; Jacobson et al., 1992a). There is also evidence for a potential role
for adenosine A-i agonists in the treatment of epilepsy, stroke and pain (Daval
et al., 1991; Jacobson et al., 1992a; Williams, 1993). Adenosine
antagonists have potential roles in both renal protection and as diuretics
(Jacobson et al., 1992a; Burnstock, 1993; Jacobson et al., 1996). Their role as
cardiac stimulants and anti-asthmatic compounds has also been investigated
(Daval et al., 1991; Jacobson et al., 1992a). In the mammalian CNS, calcium
influx via different calcium channels contributes to the release of
neurotransmitters at the presynaptic terminal. Presynaptic inhibition by
adenosine action on A-i receptors has been shown to inhibit predominantly N-
type calcium channels (Yawo & Chuhma, 1993; Mogul et al., 1993; Umemiya
& Berger, 1994), leading to inhibition of neuronal calcium uptake and
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decreased release of several neurotransmitters, such as acetylcholine,
dopamine, norepinephrine, serotonin and glutamate (Fredholm & Dunwiddie,
1988; Arvin et al., 1989; Lupica et a!., 1989; Von Lubitz et al., 1996).
Stimulation of postsynaptic A-i receptors activates potassium and chloride
conductances resulting in membrane hyperpolarisation and decreased
neuronal excitability and firing rate. Adenosine Ai antagonists enhance the
release of various neurotransmitters and prevent hyperpolarisation of
postsynaptic neurons. This mechanism may provide a way to treat cognitive
deficits in humans, such as those associated with Alzheimers disease.
VII. The Adenosine A2a Receptor
The A2a receptor is positively linked to adenylate cyclase and is also G
protein coupled. Unlike the A-i receptor, coupling is unifocally to the stimulatory
protein Gs and to its effector adenylate cyclase (Peterfreund et al., 1996).
Whereas Ai selective ligands have been available for many years (Jacobson
et al., 1992a), selective A2 ligands have only recently become available. The
initial characterisation of the A2 receptor was heavily dependent on the use of
the non-selective agonist NECA, with various strategies used to block the A-i
component (Bruns et al., 1986). The NECA derivative and agonist CGS21680
(Jarvis et al., 1989a) exhibits high A2a affinity and selectivity, and has become
the radioligand of choice when examining this receptor subtype (Jarvis et al.,
1989a; Stehle et al., 1992; Zhou et al., 1992) (Table 1.1). This ligand also
helped confirm the existence of the A2 receptor subtypes, A2a and A2b (Hide et
al., 1992; Gurden et al., 1993). The lack of highly selective A2a antagonists has
hindered receptor characterisation, as agonists like [3H]CGS21680 label both
high and low affinity states of the receptor in striatum (Wan et al., 1990;
Mazzoni et al., 1993). However, three selective antagonists KF17837, 2-[2-(4-
16
amino-3-iodophenyl)ethylamino]adenosine (l-APE) and SCH58261, which
have recently been developed as radioligands may help in further
characterising the A2a receptor (Nonaka et al., 1994; Palmer et a!., 1995c;
Zocchi et al., 1996) (Table 1.1).
Using an agonist photoaffinity probe (an azide derivative of 125|-PAPA-
APEC) and techniques similar to those described for the ^ receptor, the mass
of the A2 receptor in native tissues was found to be ~45 kDa (Barrington et al.,
1990; Nanoff & Stiles, 1993). Autoradiographic distribution in different species
demonstrated high expression in striatum with small amounts in cortex and
midbrain (Jarvis & Williams, 1987; Jarvis et al., 1989b, c; Martinez-Mir et al.,
1991). The striatum has therefore been the tissue of choice in which the
functional and pharmacological characteristics of the A2a receptor have been
examined, with the properties of the non-striatal A2a receptors initially ignored.
The recent characterisation and classification of non-striatal A2a receptor
binding sites would appear controversial (Kirk & Richardson, 1995; Luthin &
Linden, 1995; Johansson & Fredholm, 1995; Cunha et al., 1996), and may in
part be due to use of different agonist radioligands and incubation conditions.
The use of the high affinity, selective antagonist radioligands will clarify this
situation (Nonaka etal., 1994; Palmer etal., 1995c; Zocchi etal, 1996).
The A2a adenosine receptor has been cloned from canine (Maenhaut et
a!, 1990), rat (Fink et at., 1992; Chern et al., 1992), human (Furlong et al.,
1992), mouse (Marquardt et al., 1994) and guinea pig (Meng et al., 1994b)
cDNA libraries (Table 1.1 and Figure 1.3). There is a high level of homology
(82-93%) comparing the overall amino acid sequence of canine and other
receptors. Within the transmembrane domains there is 51% sequence
homology at the amino acid level between the two originally identified canine






other three receptor subtypes (409-412 AA), corresponding to a protein of ~45
kDa, confirming photoaffinity labelling data (Stiles, 1986; Barrington et al.,
1990) (Table 1.1). The functional significance of the 80-90 AA located on the
carboxy terminus has not been elucidated. Truncation of the tail produced no
appreciable difference in agonist pharmacology (Piersen et al., 1994).
Residues responsible for both agonist and antagonist binding have recently
been identified in studies using site directed mutagenisis (Kim et al., 1995).
The pharmacology of the cloned receptors on stable expression was similar to
that of native receptors (Fink et al., 1992; Furlong et al., 1992). The distribution
in different species of the A2a receptor message in brain, as analysed by
Northern blotting and in situ hybridisation studies (Fink et al., 1992; Furlong et
al., 1992; Meng et al., 1994b) was similar to the autoradiographic distribution
(Jarvis & Williams, 1989b, c). The receptor is highly expressed in striatum with
small amounts in cortex and midbrain. Interestingly, the discrete localisation in
adult animals of A2a mRNA to the striatum, contrasts with a widespread
expression during development (Weaver, 1993). In peripheral tissues, the A2a
receptor transcript is present in human heart, kidney, spleen, lung, thymus and
leukocytes (Peterfreund et al., 1996). In guinea pig, the distribution was similar
with hybridisation signals in heart, kidney and spleen, however, there was no
signal in lung (Meng et al., 1994b). The A2a receptor in human has recently
been reported to be localised to chromosome 22 (Peterfreund et al., 1996). As
with the A3 receptor (see below) and unlike the A-i receptor, it contains only
two exons and one intron. The intron occurs in the sequence corresponding to
the second intracellular loop, which lies between transmembrane domains 3
and 4. This may be a feature common to the adenosine receptor gene family
as it is present in human A-i (Ren & Stiles, 1994a), rabbit A-j (Bhattacharya et
al., 1993), chick A-\ (Aguilar et al., 1995) and rat and human A3 (Zhou et al.,
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1993; Murrison etal., 1995, 1996).
Evidence for a functional role for the A2a receptor in multiple
physiological systems is increasing. The role of adenosine in regulating blood
flow (Olsson & Pearson, 1990), and the vasodilation associated with activation
of A2a receptors, led to the proposal that selective agonists may have a role in
hypotensive therapy (Hutchison et al., 1989; Collis and Hourani, 1993). The
co-localisation of A2a receptors with dopamine receptors (Fink et al., 1992) in
striatum, and the effects of adenosine on dopamine receptor density (Williams,
1993), imply a potential therapeutic role in Parkinsons disease, schizophrenia
and Huntingtons disease (Williams, 1993; Kim etal., 1995). A potential role for
the A2a receptor in facilitating synaptic transmission through P-type calcium
channels at the presynaptic terminal may also exist (Umemiya & Berger,
1994). Expression of the receptor in mast cells, spleen, thymus and leukocytes
also indicates a potential role in immune responses (Marquardt et al., 1994;
Peterfreund etal., 1996).
VIII. The Adenosine A2b Receptor
The separation of the A2 receptor into two subtypes (Daly et al., 1983;
Bruns et al., 1986), was based on differences observed in agonist and
antagonist binding affinities for rat striatal (A2a) (Bruns et al., 1986) and human
fibroblast (A2b) adenosine receptors (Bruns, 1980, 1981). The A2a and A2b
receptors are both positively linked to adenylate cyclase, presumably through
Gs. While the high affinity A2a receptor was found primarily in striatum, the low
affinity A2b receptor is found throughout the brain (Daly et al., 1983; Bruns et
al., 1986). Although the availability of compounds like CGS21680 has enabled
the classification to be tentatively confirmed in functional studies using different
tissues and species (Jarvis et al., 1989a; Wan et al., 1990; Gurden et al.,
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1993), pharmacological data is still minimal due to the lack of receptor
selective compounds for the A2b receptor in particular.
The A2b receptor has been cloned from rat (Stehle etal., 1992; Rivkees
& Reppert, 1992), mouse (Marquardt et al., 1994) and human (Pierce et al.,
1992) cDNA libraries with >85% homology in the transmembrane spanning
regions across species (Table 1.1). There is a reasonable level of homology
(73%) between the A2b and A2a receptors in the transmembrane regions
(Stehle et al., 1992), despite being smaller than the A2a receptor and more
similar in size to the A-\ and A3 receptors, at 36.4 kDa. Identification and
characterisation of clones which potentially encode for the A2b receptor and
assessment of their functional significance is still limited by the lack of
selective compounds. Identification is generally by excluding the involvement
of the other adenosine receptor subtypes. For the A2b receptor, stimulation of
adenylate cyclase is less sensitive to adenosine agonists and more sensitive
to xanthine antagonists than the A2a receptor (Bruns et al., 1986). This
combined with specific binding using pHJNECA (non-selective agonist) and the
lack of [3H]CGS21680 (A2a agonist) or [3H]CCPA (A-i agonist) binding is used
to identify the existence of A2b receptors (Stehle et al., 1992; Rivkees &
Reppert, 1992; Pierce et al, 1992). Distribution of rat A2b receptor mRNA as
assessed by Northern blot analysis is very distinct from A1 and A2a receptors,
with greatest expression of transcripts in caecum, large intestine and urinary
bladder and lesser amounts in brain, spinal cord and lung (Stehle etal., 1992).
Localisation of the receptor using a polyclonal antibody to the human A2b
receptor has confirmed and extended this distribution map (Puffinbarger et al.,
1995). The identification and use of tissues which highly and specifically
express the A2b receptor may help to clarify the pharmacological and
functional characteristics of the receptor and confirm possible roles, such as
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mediation of the secretory action of adenosine on mast cells (Marquardt et al.,
1994). Recently the chromosomal localisation of the human A2b receptor gene
and a potential pseudogene, which shares 79% homology, has been reported
(Jacobson et al., 1995). The A2b receptor was reported to be localised to
chromosome 17p12 and the pseudogene to 1q32, both of which are distinct
from the chromosomal localisation of A-i and A2a receptors. The presence of
potential pseudogene transcripts, despite their inability to produce functional
receptors, may lead to a misinterpretation of results from in situ hybridisation
and Northern blot studies on the potential localisation of the A2b receptor.
IX. The Adenosine A3 Receptor
Based on radioligand binding studies and the physiological effects of
adenosine analogues on various tissues, the existence of A-i, A2a and A2b
receptors was postulated before cloning of the relevant cDNA sequences. This
was not the case for the A3 receptor, as screening of cDNA libraries with
degenerate oligonucleotide probes resulted in the isolation of a further and
unexpected adenosine receptor subtype. A clone isolated from a rat testis
cDNA library encoded a protein of 320 AA that displayed an overall homology
of 47 and 42% to the canine A-i and A2a receptors respectively (Meyerhof et
al., 1991). Pharmacological characterisation of a clone from a rat brain cDNA
library which was 99.5% identical to the clone from rat testis, showed a
pharmacological profile different from characterised adenosine receptors and
was called the A3 receptor (Zhou et al., 1992). Competition binding studies
using membranes from transfected cells showed that, in comparison with the
A-\ receptor, agonists had a lower affinity and a different order of potency and
that xanthine antagonists were uncharacteristically poor inhibitors. In cells
transfected with the putative A3 receptor, adenosine analogues also inhibited
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forskolin stimulated accumulation of cAMP through an interaction with a
pertussis toxin sensitive G protein, in a manner similar to the A-i receptor
(Zhou etal., 1992).
A3 receptors were subsequently cloned from sheep (Linden et al., 1993)
and human (Salvatore et al., 1993; Sajjadi & Firestein, 1993) cDNA libraries
and were more similar to each other (85%) than to rat (73%) in terms of overall
amino acid identity. The A3 receptor is similar in size to the A1 and A2b
receptors (317-320 AA, depending on species) and encodes a protein of
approximately 36.6 kDa (Table 1.1). The A3 receptor is unlike the other three
receptors because it has N-linked glycosylation sites on both the amino
terminus and the second extracellular loop; the relevance of these sites is not
known. A3 receptor homologues from different species have a greater variation
at the amino acid level than other adenosine receptors, and vary substantially
in their pharmacological characteristics and tissue distribution (Salvatore etal.,
1993). Development of selective agonists and antagonists for the A3 receptor
has confirmed these pharmacological differences, and a binding site model
has been proposed for the A3 receptor (van Galen et al., 1994; Kim et al.,
1994) (Table 1.1). Significant species differences have been confirmed in both
agonist affinity (Ji etal., 1994) and tissue distribution (Linden, 1994). In rat, the
most abundant message is in testis (Meyerhof et al., 1991; Zhou et al., 1992),
with moderate amounts of A3 receptor mRNA found in lung, kidney and heart
and lower levels in brain (Zhou et al., 1992). In sheep, higher levels were
found in brain, lung and spleen with low levels in kidney (Linden et al., 1993).
In human (Salvatore et al., 1993), the distribution profile of A3 receptor mRNA
was: lung = liver » brain = aorta > testis > heart, with none in spleen and
kidney. In contrast, Sajjedi & Firestein (1993), despite showing A3 receptor
mRNA in lung, liver and heart, did not detect transcript in brain but found a
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strong signal in kidney. The physiological role of this receptor has still not been
clearly defined although the localisation in rat testis implies a role in
reproduction (Meyerhof et al., 1991; Mazzoni eta!., 1995). The abundance of
receptor mRNA in lung suggests a role in allergic responses in the pulmonary
system (Linden et al., 1993), however roles in mediating cardiovascular and
CNS effects have also been implied (Jacobson et al., 1992b; Kim et al., 1994;
Abbracchio et al., 1995; Von Lubitz et al., 1995). A very recent study in which
the tissue distribution of receptor mRNA for all four adenosine receptors was
examined, suggested a similar distribution of the A3 receptor in rat, sheep and
human, with previous differences attributable to quantitative differences in
abundance (Dixon et al., 1996). Initial studies showed adenosine analogues
mediated effects at the A3 receptor through a pertussis toxin sensitive effect on
adenylate cyclase (Zhou et al., 1992). However, a variety of effector systems
have recently been linked with the A3 receptor. Like the A-i receptor, there is
evidence that the As receptor couples to different G protein subtypes (Palmer
et al., 1995b) and thus to protein kinase C (PKC) (Kim et al., 1994), PLC
(Abbracchio et al., 1995) and G protein coupled receptor kinases (Palmer et
al., 1995a). The human A3 receptor gene has been characterised (Murrison et
al., 1995, 1996), containing two exons separated by one intron as in rat (Zhou
et al., 1992). Unlike the A-i receptor (Ren & Stiles, 1994a, b), the A3 receptor is
unlikely to undergo alternative splicing in the 5' untranslated region. However,
considerable variation in tissue expression would imply a transcriptional control
of A3 mRNA at some level. The human A3 receptor gene (ADORA3) has been
localised to chromosome 1p and may help in determining whether mutant A3
receptor genes are candidates for diseases of the lung, vasculature or nervous
systems that map to that area (Monitto et al., 1995). Interestingly the mouse A3
receptor gene has been chromosomally located and mapped to chromosome
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3, which has a high homology with human chromosome 1 (Zhao etal., 1995).
The cloned A3 receptor discussed here is distinct from the other
putative adenosine A3 receptor described for the frog neuromuscular junction
(Ribeiro & Sebastiao, 1986). The classification of these receptor subtypes has
been the subject of much debate (Carruthers & Fozard, 1993; Ribeiro &
Sebastiao, 1994; Beaven et at., 1994; Linden, 1994). Evidence for the
neuromuscular A3 receptor (Ribeiro & Sebastiao, 1986) was considered not
compelling, whereas that of the cloned A3 receptor (Zhou et al., 1992) was and
consequently it has been accepted as a distinct adenosine receptor subtype
(Abbracchio etal., 1993; Fredholm etal., 1994).
X. Aims of the Research Project
Neurochemical and electrophysiological experiments have led to the
proposal that adenosine may act as a inhibitory neuromodulator in the CNS.
Basal CNS concentrations of adenosine in the low micromolar range suggest
that adenosine receptors are tonically activated and perhaps contribute to the
mediation of a general inhibitory tone. Adenosine is known to inhibit the
release of several neurotransmitters in brain by acting upon adenosine A-i
receptors. The neuromodulator role of adenosine may exert a specific
protective effect under conditions of enhanced neuronal activity (Schwabe et
al., 1991), but it may exacerbate the problem of neurotransmitter deficit in
conditions such as Alzheimers disease. Reversal of this tonic inhibition by an
adenosine A-i receptor antagonist may enhance neurotransmitter levels,
leading to synaptic facilitation at both pre- and postsynaptic sites and perhaps
leading to some restoration of neuronal function in diseases such as
Alzheimers (Daval etal., 1991; Suzuki etal., 1993; Von Lubitz etal., 1993).
The purpose of the work described in this thesis was to identify a
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selective, high affinity, blood brain barrier permeable adenosine A-i receptor
antagonist, using a series of novel non-xanthine antagonists (Terai et al,
1995a; Balakrishnan et al., 1996). In order to achieve this goal the following
three main areas were investigated:
In chapters 1 and 2, basic aspects of adenosine receptor pharmacology
were examined. In chapter 1, in vitro radioligand binding assays were used to
comprehensively characterise the affinity and selectivity of agonists and
antagonists for adenosine A-i receptors in rat brain. With species differences in
adenosine Ai receptor pharmacology characterised and as the ultimate goal of
this study is the discovery of a drug for use in man, adenosine A-i receptor
pharmacology was studied in human brain tissue. Adenosine receptors are
members of the G protein coupled receptor superfamily. As the ligand binding
properties of other members of the receptor family are sensitive to the effects
of cations and guanine nucleotides, chapter 2 involved an extensive
examination of the modulation of ligand binding to both adenosine A-, and A2a
receptors by the stable GTP analogue Gpp(NH)p and magnesium.
In Chapter 3, a modified radioreceptor assay was developed and
characterised to measure the concentration of adenosine Ai receptor
antagonists in rat brain following intraperitoneal administration. All drugs were
given at doses known to produce a centrally mediated behavioural effect and
drug concentrations were determined in brain and serum.
Finally, in chapter 4, peripheral adenosine A-i receptors were examined
in order to determine whether they are identical to those in the CNS. A
centrally selective adenosine A-i receptor antagonist devoid of peripheral
activity would be of obvious benefit. The pharmacology and localisation of
renal adenosine Ai receptors were examined using a combined approach of
radioligand binding, in vitro autoradiography and in situ hybridisation.
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CHAPTER ONE




It has been emphasized that antagonists rather than agonists should be
used for the pharmacological classification of receptors (Kenakin et al., 1992).
Until the late 1980s, this was not the case for purinergic receptors, with stable
adenosine analogues like N6-cyclohexyladenosine (CHA), R-PIA,
2-chloroadenosine (CADO) and NECA (Bruns et al., 1980; Murphy & Snyder,
1982; Yeung & Green, 1984) used for receptor classification. These agonists
were central to identifying the pharmacological characteristics of A-i, A2a and
A2b receptors (Jacobson et al., 1992a; Abbracchio et al., 1993; Collis and
Hourani, 1993). Extensive studies on the structure activity relationships of
adenosine receptor ligands identified further modifications on both adenosine
based agonists and xanthine antagonists that produced selective high affinity
compounds for the Ai receptor (Daly et al., 1985; Jacobson et al., 1992a; Peet
et al., 1993; Suzuki et al., 1993). The agonist, CCPA (Klotz et al., 1989;
Monopoli et al., 1994) and antagonist, DPCPX (Bruns et al., 1987), with
subnanomolar affinity and marked selectivity for A-i receptors were developed.
pH]DPCPX is now the ligand of choice when studying adenosine A-i receptors,
exhibiting consistent and marked selectivity for the A-i versus the A2a receptor
(>600 fold) and being devoid of affinity for other receptors (Bruns et al., 1987;
Lohse et al., 1987; Weber et al., 1990a; Bisserbe et al., 1992). As with other
GPCRs, agonists can bind to a high and low affinity state of the adenosine A-i
receptor, whose equilibrium is modified by ionic conditions and the presence of
guanine nucleotides. In contrast, antagonists have the advantage of
recognising both states with equal affinity (Gilman, 1987; Collis & Hourani,
1993; Casado et al., 1994). Unlike Ai receptors, studies into A2a, A2b and the
recently cloned A3 adenosine receptor have been hindered by a dearth of
useful compounds. Binding properties of the A2 receptor were initially
28
examined using the non-selective agonist [3H]NECA, with contaminating A-i
sites blocked using selective Ai antagonists or agonists, thereby increasing
the complexity of the assay (Bruns et al., 1986). The synthesis of CGS21680,
which has high affinity and selectivity for rat striatal A2a receptors, removed
this complexity and is presently the radioligand of choice when investigating
this receptor subtype (Jarvis et al., 1989a). The lack of selective A2a
antagonists has hindered the pharmacological characterisation of this receptor,
and until recently the high affinity, non-selective antagonist 9-chloro-2-(2-
furyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine (CGS15943) was the only useful
compound (Jarvis et al., 1989a; Griebel et al., 1991). New styryl based A2a
antagonists like CSC (Jacobson et al., 1993) and KF17837 (Shimada et al.,
1992; Nonaka et al., 1993), with reasonable affinity and selectivity are now
available, however neither is very stable. These compounds have recently
been superseded by a new generation of stable, high affinity and selective A2a
receptor antagonists, which when commercially available, will no doubt provide
useful pharmacological tools (Nonaka etal, 1994; Palmer et al., 1995c; Zocchi
et al., 1996). The development of selective agonists (e.g. ABMECA) and
antagonists (e.g. I-ABOPX) for the A3 receptor (Van Galen et al., 1994; Kim et
al., 1994), would appear to be proceeding faster than that of the A2b receptor,
which although recognised for more than 10 years, still lacks any suitable
ligands (Olah & Stiles, 1995).
The classification of the adenosine receptors has been complicated not
only by the lack of receptor selective ligands but by well documented species
differences in adenosine receptor pharmacology, characterised in radioligand
binding studies (Murphy & Snyder, 1982; Ferkanky et al., 1986; Ukena et al.,
1986; Stone et al., 1988; Ji et al., 1994). N6-substituted adenosine analogues
like CHA and R-PIA have a higher affinity for the adenosine Ai receptor in
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bovine, rat and mouse brain tissue compared with guinea pig and human
tissue (Murphy & Snyder, 1982; Ferkanky et al., 1986; Ukena et al., 1986). In
contrast, the presence of the 5'-ethylcarboxamido moiety in compounds like
NECA, resulted in almost equipotency across species (Ferkanky et al., 1986;
Ukena et al., 1986). These species difference have also been visualised for
adenosine A^ receptors in both central and peripheral tissues using
autoradiographic studies; for example, adenosine A^ receptors are localised in
the cortex of human kidney but are found in the medulla of guinea pig kidney
(Fastbom etal., 1986, 1987a; Palacios etal., 1987; Araki eta!., 1992).
In assessing the therapeutic potential of Fujisawa's novel non-xanthine
adenosine A-i receptor antagonists (Terai et al., 1995a; Balakrishnan et al.,
1996), it is necessary to determine both affinity and selectivity for adenosine
A-i receptors in brain tissue. The inherent problems associated with agonist
ligands (Kenakin et al., 1992), prompted the establishment of a radioligand
binding assay in rat brain using the antagonist [3H]DPCPX in a method similar
to Bruns et al., (1987). To establish whether compounds were selective for the
A-i receptor, affinity for rat striatal A2a receptors was examined using
[3H]CGS21680 in a method similar to Jarvis et al., (1989a). Unfortunately
when these studies were conducted no antagonist radioligands for the A2a
receptor were commercially available. The potential for species differences
(Ferkanky et al., 1986; Stone et al., 1988; Ji et al., 1994), and the lack of a
comprehensive pharmacological study using antagonist radioligands,
prompted modification of the pH]DPCPX binding assay for use in human
tissue in order to study species selectivity.
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1.2. Methods and Materials
1.2.1. Animals
Unless otherwise stated, animals used in these studies were male
Sprague Dawley rats (250-350 g; Charles River). Animals were given food and
water ad libitum and maintained on a 12hr light/12hr dark cycle.
1.2.1.1. Rat Brain Membrane Preparation
Crude synaptosomal P2 membranes were prepared from rat cerebral
cortex and striatum using the following procedure. Rats were killed by
decapitation, brains removed and placed in ice cold saline. Following
dissection of appropriate brain areas, tissues were dried briefly, rolled on filter
paper to remove superficial blood vessels and weighed. Tissues were
homogenised using a teflon glass homogeniser in 15 vol. (v/w) of ice cold 0.32
M sucrose and the homogenate was centrifuged at 1000 g for 10 min at 4°C in
a Burkard Coolspin. The supernatant was centrifuged at 17000 g for 20 min at
4°C and the resultant P2 pellet was lysed in 30 vol. (v/w) of ice cold glass
distilled water for 30 min. Membranes were centrifuged at 50000 g for 10 min
at 4°C in a Centrikon T-2070. The pellet was resuspended in 30 vol. (v/w) of
50 mM Tris-HCI buffer, pH 7.4 (Tris-buffer) at 4°C and centrifuged at 50000 g
for 10 min at 4°C. The final pellet was resuspended in 5 vol. (v/w) of Tris-buffer
and stored in 1.4 ml aliquots in 1.8 ml microcentrifuge tubes at -20°C until
required.
On the day of the assay membranes were resuspended in 30 vol. (v/w)
of Tris-buffer and centrifuged at 50000 g for 10 min at 4°C. The final pellet was
resuspended in 200 vol. (v/w) of Tris-buffer, then kept on ice prior to use in the
assay.
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1.2.1.2. Human Brain Membrane Preparation
All studies using human brain tissue were performed in collaboration
with Dr R.W. Horton, St. George's Hospital Medical School, London. All
procedures were carried out with strict adherence to rules laid down by the
hospital in regard to handling human tissue.
Human parietal cortex (Brodmann Area 7) (9.6 g) collected from five
separate individuals was stored separately at -20°C and was pooled for
preparation of a P2 synaptosomal fraction. All subjects were male between the
ages of 47 and 62. Death was by myocardial infarction, pulmonary embolism
or a ruptured aneurism and tissues were received with a post mortem delay of
between 17 to 68 hr. P2 synaptosomal membranes were prepared exactly as
for animal tissue (Section 1.2.1.1.), with the final pellet stored in 5 vol. (v/w) of
Tris-buffer at -20°C.
1.2.2. General Experimental Methodology for Binding Assays
1.2.2.1. Competition Experiments
For competition experiments, incubation time, membrane (receptor)
concentration and radioligand concentration are kept constant, whereas the
concentration of competing drug is varied. As the concentration of competing
drug is increased the amount of bound radioligand decreases. It is possible to
then calculate the concentration of competing drug which inhibits 50% of
specific radioligand binding (IC50) (see p37). The slope of competition binding
curves, known as the "Hill slope" or "Hill coefficient" (nH), may indicate the type
of binding model appropriate for data analysis. If nH=1, the data are probably
consistent with a simple one site model and increasing the concentration of
competing drug from one tenth to 10 times the IC50 value, should reduce the
specific binding of the radioligand from 90.9% to 9.1%. A Hill slope of less than
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unity indicates binding is not consistent with a single population of non-
interacting sites and a 2-site model may be more appropriate. As the IC50 is an
experimentally determined parameter, an inhibition constant (Kj) for the
inhibitor, which is independent of radioligand concentration can be calculated
(see p37). It is possible to determine the equilibrium dissociation constant (Kd)
and the number of binding sites (Bmax) (see p37) using the unlabelled version
of the radioligand. In this case when inhibitor is identical to radioligand,
competition (cold saturation) and 'hot' saturation experiments (see below) are
the same and should give the same KD and Bmax.
1.2.2.2. 'Hot' Saturation Experiments
As for competition experiments, receptor concentration and time are
constant and the amount of bound radioligand is measured as a function of the
free radioligand concentration at various concentrations of the radioligand. Hot
saturation, like competition experiments, when using unlabelled ligand allows
the determination of Kd and Bmax with Hill slopes again indicative of the type of
receptor binding. Ideally, concentrations of radioligand should go from 10 fold
below to 10 fold above the Kd.
1.2.2.3. Time Course Experiments: Association & Dissociation
In association experiments, receptor and radioligand concentration are
constant, with radioligand bound to the receptor measured as a function of
time. To calculate the association rate constant (k+i), a pseudo first order
method is used in which the radioligand concentration is assumed to be
constant, i.e. less than 10% of radioligand is bound. These time course
experiments allow us to determine when equilibrium has been reached,
enabling saturation and competition experiments to be performed correctly. As
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Kcpk.-i / k+1 (k.-i is the dissociation rate constant), time course experiments
provide an independent estimate of the Kd which should agree with the Kd
from equilibrium studies.
In dissociation experiments, radioligand and receptor are incubated until
equilibrium is achieved. Further association of the radioligand is prevented by
the addition of excess unlabelled drug (usually 100 x IC50) so the dissociation
of the radioligand from the receptor can be monitored and the k_i measured.
1.2.3. Adenosine Receptor Binding Assays
All drugs used in the study of adenosine receptor binding were
dissolved and diluted in DMSO, whose final assay concentration did not
exceed 1 %. (R)-1 -((E)-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)acryloyl)-2-
piperidine ethanol (FK453) and some related compounds are light sensitive
and can undergo a photochemical trans-cis isomerisation, so great care was
taken to minimise exposure to light. Drugs and membrane preparations were
stored for up to 3 months at -20°C. Buffers were prepared in Milli-Q distilled
water (d.H20) and stored at 4°C. Adenosine deaminase (ADA) was added to
all adenosine receptor binding assays to remove endogenous adenosine.
Radioligands were diluted in d.H20 to appropriate concentrations and stored at
-70°C under liquid N2 in aliquots sufficient for one experiment. Binding assays
were generally conducted at 25°C (final volume, 0.5-2 ml) in 5 mi round
bottomed polypropylene tubes (Sterlin (RT35), U.K.). A Brandel cell harvester
was used to separate bound from free ligand (with the exception of
microcentrifugation assays). The harvester can filter 24 samples
simultaneously under a vacuum pressure of 15-25 mm Hg. Whatman GF/B
filters, pre-wetted with filtration buffer, were used to separate bound
radioligand from free radioligand unless otherwise stated. Filter disks were
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transferred to scintillation vials and were incubated with 100 pi of 100% formic
acid for 10 min. Emulsifier Safe scintillant (4 ml) was then added and
equilibrated overnight. For each binding assay eight samples of the
radioactivity added to the assay were used as standards. Radioactivity was
determined in a Packard 2500TR scintillation counter with automatic quench
correction (counting efficiency approximately 50%), with samples counted for 4
min unless otherwise stated and results expressed as disintegrations per
minute (dpm) per sample.
1.2.3.1. PH]DPCPX Binding Assay - Rat Cortex
pH]DPCPX ([3H]-8-cyclopentyl-1,3-dipropylxanthine) (98.1 Ci mmoM;
NEN) binding was carried out under equilibrium conditions by preincubating
10 pi of DMSO or test drug, 290 pi of Tris-buffer and 100 pi of ADA (1u mM)
with 100 pi of 1 nM [3H]DPCPX for 2 min at 25°C. Test drugs were diluted in
DMSO to give 10 duplicate or 20 single concentrations. Total binding was
determined in the presence of 1% DMSO and 10 pM R-PIA was used to
determine non-specific binding. Addition of P2 membrane suspension (500 pi;
10-20 pg), which gave a final volume of 1 ml, initiated a 20 min incubation at
25°C. Bound and free ligand were separated using a Brandel cell harvester
and this was followed by 3 washes (3 ml) in ice cold Tris-buffer over GF/B
filters. Filter disks were then transferred to scintillation vials and the procedure
followed as described above.
1.2.3.2. PH]DPCPX Binding Assay - Human Cortex
The [3H]DPCPX binding assay was carried out as described for rat
cortex except the pHjDPCPX concentration was increased to 7 nM (final 0.7
nM) and the incubation period was extended to 120 min. Total binding was
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determined in the presence of 1% DMSO and 10 fjM R-PIA was used to
determine non-specific binding.
1.2.3.3. PH]CGS21680 Binding Assay - Rat Striatum
pH]CGS21680 ([3H](2-p-carboxyethyl)phenylamino-5'-N-carboxamido
adenosine) (40.5 Ci mmoM; NEN) binding was carried out under equilibrium
conditions by preincubating 10 fj\ of DMSO or test drug, 290 of Tris-buffer
(+10 mM MgCI2, pH 7.4) and 100 /yl of ADA (1u ml-1) with 100 jl/I of 20 nM
pH]CGS21680 for 2 min at 25°C. Test drugs were diluted in DMSO to give 10
duplicate or 20 single concentrations. Total binding was determined in the
presence of 1% DMSO and 10 /;M CADO was used to determine non-specific
binding. Addition of P2 rat striatal membrane suspension (500 fj\\ 20-40 /vg),
which gave a final volume of 1 ml, initiated a 60 min incubation at 25°C.
Bound and free ligand were separated using a Brandel cell harvester and this
was followed by 3 washes (3 ml) in ice cold Tris-buffer over GF/B filters. Filter




Competition binding curves generally comprised of 2 duplicate tubes for
both total and non-specific binding and either 10 duplicate concentrations of
competing drug or 20 single concentrations when fitting the data to a two site
model (see below). Stock drugs were diluted 1 in 10 and 1 in 3.33 followed by
serial 10 fold dilutions of both to give a series of concentrations one half a log
unit apart. The range of concentrations used in the assay were altered in
accordance with the IC50 of each compound. Data were analysed using a
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iterative, non-linear least squares curve fitting programme (Sigma Plot) to a
one site logistic model (Barlow, 1983);
Y=(M x KP) / (XP + KP) + B
where Y: is the bound pHJIigand (dpm) at [X], [X]: is the inhibitor concentration
(M), M: is the specifically bound [3H]ligand in the absence of inhibitor (dpm), K:
is the concentration of inhibitor (M) giving 50% (IC50) inhibition of binding, P: is
the Hill slope (nH) and B: is the calculated non-specific binding (dpm). The
calculated specific binding (M) and non-specific binding (B) were compared
with experimentally determined values. Values were accepted if within 10%.
For agonists and antagonists Kj values were calculated using the Cheng
Prusoff approximation (Cheng and Prusoff, 1973);
KplCso/1 +([3H]ligand/KD)
where IC50 (M): is that of the compound being tested, [3H]ligand (M) is the
concentration in the assay and Kd is the affinity of the radioligand.
When the inhibitor was the unlabelled form of the [3H]ligand (a 'cold'
saturation experiment) the Kd and Bmax were determined using;
Kd=IC5o - [3H]ligand
where IC50 (M): is that of the unlabelled ligand and [3H]ligand (M) is the
concentration in the assay.
Bmax values (mol mg-1 protein) were calculated by converting specific
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binding (M) of the radioligand bound into the number of moles bound using the
specific activity and the following equation;
Bmax=(b X IC50) / (pH]ligand x Pr)
where b: is the specific binding (moles) at the [3H]ligand concentration used in
the assay, IC50 (M) is that of the unlabelled ligand, pHjligand (M) is the
concentration in the assay and Pr: is the amount of protein added to assay
tube (mg).
1.2.4.2. 'Hot' Saturation Experiments
Radioligands were diluted to give a range of concentrations 10 fold
above and below the expected «□_ Generally 8 concentrations in duplicate
were used to determine total binding and 8 single concentrations used to
determine non-specific binding. Specific binding (bound [3H]ligand) was
determined for each point by subtracting non-specific binding from total
binding. The free pHjligand at equilibrium was calculated by subtracting
specifically bound [3H]ligand from [3H]ligand added for each concentration.
Using the specific activity of the radioligand the concentration (M) of both free
and bound pHjligand was calculated. The data were fitted using the iterative,
non-linear least squares curve fitting programme (Sigma Plot) to a hyperbolic
model and KD and Bmax values estimated;
b=(Bmax X L) / (L + Kq)
where b: is the specifically bound pH]ligand (M), L: is the free [3H]ligand (M)
concentration, KD (M) the affinity of the ligand and Bmax (M). Bmax was
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expressed in mol mg-i protein by determining the amount of protein used in the
assay (mg) of each sample.
1.2.4.3. Two-Site Model
Data were initially analysed using a one site logistic model. Data with
Hill slopes of less than unity (nH~0.5-0.7) were analysed using a 2-site model.
In determining the proportions and affinity of these two states for a select set of
drugs, 20 different concentrations of competing drug were added across an
extended range using 3 concentrations per log cycle and data fitted to a 2-site
hyperbolic model using the following equation (Barlow, 1983);
b|= b|i + b|2 = ((M1 x K-i) / (K1+ X)) + ((M2 x K2) / (K2 + X))
where bi: is the bound [3H]ligand (dpm) at [X], [X]: is the inhibitor concentration
(M), bn and b|2: is the bound [3H]ligand for the high and low affinity states
(dpm) and Ki and K2 are the IC50 (M) values for the high and low affinity
states.
A partial F test was used to determine whether the 2-site model
provided any statistical improvement over the one site model. The differential F
value was calculated using the following equation;
F=(SS1 - SS2) / (df-i - df2) / (SS2 / df2)
SS1: the sum of the square of the errors for the single site, SS2: the sum of the
square of the errors for the two site model and df-i and df2 are the degrees of
freedom for the one and two site models respectively. A two site fit was
assumed to be significantly better than a single site fit if the determined F
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value was significant (P< 0.05) (De Lean etal., 1981).
1.2.4.4. Time Course Experiments - Association Rate Constant
(kfi)
Experiments were carried out under conditions such that pseudo-first
order kinetics were applicable by ensuring that less than 10% of radioligand
added is bound through the time course. Specific binding at each time point
was determined by subtracting non-specific binding from total binding and data
fitted to a single exponential function (Bylund & Yamamura, 1990);
Bt=Be - (Be / exp(kobs.t))
where t: is time (min), Bt: is bound pHJIigand (dpm) at time t, Be: total specific
binding (dpm) at equilibrium and k0bs (min-1) is the observed constant.
The association rate constant (lq.i) was determined by estimating the
free [3H]ligand concentration (M) when maximum binding is observed and
calculated using the following equation;
k+i=(kobs - k-i) / L
where: kobs (min-i) is the observed constant, k„i (min-1) (see below) is the
dissociation rate constant and L: is the free concentration of pH]ligand (M).
1.2.4.5. Time Course Experiments - Dissociation Rate Constant
(k-i)
The dissociation rate constant (k_i) was calculated from a dissociation
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time course experiment. Specific binding at each time point determined by
subtracting non-specific binding from total binding and data fitted to the
following equation (Bylund & Yamamura, 1990);
Bt=(B0 / exp( k_i t»
where t: is time (min), Bt: is bound [3H]ligand (dpm) at time t, Bq: total specific
binding (dpm) at time 0 and k-i (min-1) is the dissociation rate constant.
1.2.4.6. Equilibrium Dissociation Constant (Kd)
The Kd (M) was calculated from the time course data using the
following equation;
Ko=k-i / k+i
where k.-i (min-1) and k+i (min-1 M-i) are the dissociation and association rate
constants respectively.
1.2.5. Protein Assay
The amount of protein was determined using a Bradford Assay
(Bradford, 1976). Standard curves were constructed using serial dilutions of
bovine serum albumin (BSA) ranging from of 10 to 200 /vg mM of protein. 50 pi
aliquots of standards or test sample were added to Nunclon 96 well plates
followed by 250 pi of Bradford reagent (10% coomassie blue (v/w), 5% of 95%
ethanol (vA/), 10% of 85% orthophosphoric acid (vA/) in d.H20; filtered twice
through Whatman filter paper and stored at 4°C). Using a Dynatech plate
reader, samples were mixed by shaking for 20 sec and absorbance measured
at an optical density of 595 nM (OD595) after 20 min. (OD595) measurements
for BSA samples fitted to a straight line through the linear portion of the curve
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and the amount of protein in each sample determined.
1.2.6. Statistical Analysis
The majority of figures displayed in the thesis are a representation of
one experiment, all of which have been carried out at least three times, unless
otherwise stated. Data in tables and text are shown as mean ± the standard
error (S.E.M.) for at least three separate experiments. Statistical tests used in
the thesis were the Students t-test, a one-way analysis of variance (ANOVA), a
two-way anova and a Dunnett's test (JMP and Sigma Stat).
1.2.7. Materials
Radioligands were purchased from New England Nuclear (NEN) and
adenosine deaminase (Type VIII) from Sigma. FK453, (R)-1-[(E)-3-(2-
phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-piperidin-2-yl acetic acid (FK352), 6-
oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-1(6H)-pyridazinebutylic
acid (FK838) and all FR compounds were synthesised by the Fujisawa
Pharmaceutical Co. Ltd, as were 8-(noradamantan-3-yl)-1,3-dipropylxanthine
(KW3902/FR144942), (R)-3,7-dihydro-8-(1-phenylpropyl)-1,3-dipropyl-1H-
purine-2,6-dione) (MDL102234/FR160502), 1 -benzyl-1 -6-(4-methoxyphenyl)-3-
propyl-1,2,3,4-tetrahydro-5H-imidazol[2',T:5,1]pyrazolo[3,4-d]pyrimidin-2,4-
dione (Takeda/FR 160492) and (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-
methylxanthine, (KF17837/FR179123). Standard adenosine agonists and
antagonists were purchased from Research Biochemicals Inc. (RBI), with the
exception of APEC and CSPA which were supplied courtesy of the NIMH
chemical synthesis programme. All other standard laboratory chemicals were
from Sigma, Fisons or BDH and were of the highest grade available.
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1.3. Results
Receptor binding assays to rat brain membranes using the potent and
selective adenosine A-i receptor antagonist [3H]DPCPX and the A2a selective
adenosine receptor agonist [3H]CGS21680, had been established in the
laboratory prior to my arrival. As a consequence, limited time course and
saturation analysis was necessary to confirm attainment of equilibrium and to
determine appropriate radioligand concentrations required for use in
competition studies. Compounds were tested in both binding assays to
determine their affinity and selectivity for the adenosine A-i receptor.
1.3.1. [3H]DPCPX Binding to Rat Cerebral Cortical Membranes
1.3.1.1. Time Course of [3H]DPCPX Binding to Rat Cerebral
Cortical Membranes
A time course (0-60 min) of pHJDPCPX (0.1 nM) binding to rat cerebral
cortex was carried out at 25°C, with equilibrium attained by 20 min (Figure
1.1). Curve fitting using non linear regression gave an observed constant (kobs)
of 0.141 ± 0.017 min-1 (n=3). Dissociation (0-60 min) of pHjDPCPX binding
was carried out after 60 min and initiated by the addition of 1 mM R-PIA.
Dissociation followed first order kinetics with a ti/2 of 4.75 min (Figure 1.2) and
a dissociation rate constant (k_-|) of 0.123 ± 0.012 min-1 (n=3). Subsequent
calculation gave an association rate constant (k+1) of 0.212 ± 0.051 min-1 M-1.
The data from these time course experiments gave an equilibrium dissociation
constant (KD) of 0.652 ±0.152 nM. In the following competition experiments
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Figure 1.1 Time Course of [3H]DPCPX Binding to Rat Cerebral
Cortical Membranes.
The data represent a typical time course experiment. Membranes were
incubated with 0.1 nM [3H]DPCPX for various times at 25°C. Total binding
was determined in the presence of DMSO and non-specific binding in the
presence of 10 ^/M R-PIA. Experiments performed as described in text with
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Figure 1.2 Time Course of [3H]DPCPX Binding to Rat Cerebral
Cortical Membranes.
The data represent a typical dissociation experiment. Membranes were
incubated with 0.1 nM [3H]DPCPX for 60 min prior to the addition of 1 mM
R-PIA to initiate dissociation. Experiments performed as described in text
with mean data obtained from three experiments (text for mean values).
45
1.3.1.2. Concentration Dependence of [3H]DPCPX Binding to
Rat Cerebral Cortical Membranes
Hot saturation analysis of [3H]DPCPX binding to rat cerebral cortex was
carried out once using increasing concentrations of [3H]DPCPX (Figure 1 3a).
Curve fitting using a hyperbolic model gave an equilibrium dissociation
constant (KD) of 0.22 nM and a Bmax of 3.37 pmol mg-1 protein.
Competition binding studies using 0.1 nM [3H]DPCPX and increasing
concentrations of unlabelled DPCPX (0.003-100 nM) (Figure 1.3b), gave a Kd
of 0.29 ± 0.01 nM and a Bmax of 1.60 ± 0.09 pmol mg-1 protein (n=44), which is
in reasonable agreement with data obtained from time course and saturation
studies.
1.3.2. [3H]CGS21680 Binding to Rat Striatal Membranes
1.3.2.1. Time Course of [3H]CGS21680 Binding to Rat Striatal
Membranes
A time course of [3H]CGS21680 (2 nM) binding to rat striatum was
carried out at 25°C, with equilibrium attained by 60 min (Figure 1.4). In all other
competition experiments [3H]CGS21680 (2 nM) binding to rat striatal
membranes was carried out at 25°C for 60 min unless otherwise stated.
1.3.2.2. Concentration Dependence of [3H]CGS21680 Binding
to Rat Striatal Membranes
Hot saturation analysis of [3H]CGS21680 binding to rat striatal
membranes was carried out once (Figure 1.5a). Curve fitting using a
hyperbolic model gave an equilibrium dissociation constant (KD) of 10.66 nM
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Figure 1.3 Concentration Dependence of Specific [3H]DPCPX
Binding to Rat Cerebral Cortical Membranes.
The results represent a single (a) hot saturation and a typical (b) cold saturation
experiment with each point performed in duplicate. For the cold saturation see









Figure 1.4 Time Course of [3H]CGS21680 Binding to Rat
Striatal Membranes.
The data represent a typical time course experiment. Membranes were
incubated with 2 nM [3H]CGS21680 for various times at 25°C. Total binding
was determined in the presence of DMSO and non-specific binding in the
presence of 10 /;M CADO. Experiments performed as described in text with
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Figure 1.5 Concentration Dependence of Specific [3H]CGS21680
Binding to Rat Striatal Membranes.
The results represent a single (a) hot saturation and a typical (b) cold saturation
experiment with each point performed in duplicate. For the cold saturation see
text for mean values.
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Competition binding studies using 2 nM [3H]CGS21680 and increasing
concentrations of unlabelled CGS21680 (0.001 nM-300 (jM) (Figure 1.5b),
gave a KD of 9.64 ± 0.85 nM and a Bmax of 4.99 ± 0.86 pmol mg-"i protein
(n=6), which was in good agreement with data from the saturation experiment.
1.3.3. Pharmacological Profile of PH]DPCPX & PH]CGS21680
Binding Sites in Rat Brain Membranes
1.3.3.1. Adenosine Receptor Antagonist Pharmacology
Competition studies using both adenosine receptor binding assays were
used to characterise adenosine antagonist receptor pharmacology. Figure 1.6
shows the structure of some of the antagonists tested and Figure 1.7 shows
inhibition of [3H]DPCPX and [3H]CGS21680 binding by a select number of
antagonists.
Antagonists exhibited the typical adenosine Ai pharmacological profile
for [3H]DPCPX binding sites in rat cortical membranes with the following order
of potency: DPCPX > CGS15943 > CPT > 1,3-diethyl-8-phenylxanthine (DPX)
> 8-phenyltheophylline (8-PT) > 1,3-dipropyl-8-sulphophenylxanthine (DPSPX)
= KF17837 > 8-(p-sulphophenyl)theophylline (8-PST) > theophylline > CSC >
caffeine, with Kj values shown in Table 1.1. DPCPX and CGS15943 were the
most potent A^ antagonists with nanomolar affinity, while caffeine had the
lowest affinity. Hill slopes were close to unity for all antagonists.
Antagonists also exhibited the typical adenosine A2a pharmacological
profile for [3H]CGS21680 binding sites in rat striatal membranes with the
following order of potency: CGS15943 > KF17837 > CSC > DPCPX > DPX >
DPSPX = 8-PT > CPT > 8-PST > theophylline > caffeine, with Kj values shown
in Table 1.1. CGS15943 and the styryl compounds KF17837 and CSC had
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Figure 1.7 Inhibition of (a) [3H]DPCPX and (b) [3H]CGS21680
Binding to Rat Brain Membranes by Adenosine Receptor
Antagonists.
The data represent a typical experiment, each point performed in duplicate
with mean data obtained from at least three experiments (Table 1.1).
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close to unity for all antagonists.
Antagonist receptor selectivity was assessed by comparing the
respective affinities (Kj ratio) of each antagonist in the two receptor binding
assays (Table 1.1). DPCPX and CPT were the most A-i receptor selective
compounds, whereas CSC and KF17837 were A2a selective antagonists.
1.3.3.2. Adenosine Receptor Agonist Pharmacology
Competition studies using both adenosine receptor binding assays were
used to characterise adenosine agonist receptor pharmacology. Figure 1.6
shows the structure of some of the agonists tested and Figure 1.8 shows
inhibition of [3H]DPCPX and [3H]CGS21680 binding by a select number of
agonists.
Agonists exhibited the typical adenosine Ai pharmacological profile for
pH]DPCPX binding sites in rat cortical membranes with the following order of
potency: CCPA = CPA s R-PIA > CHA > NECA = CADO > S-PIA > N6-p-
sulfophenyladenosine (CSPA) = APEC > CGS21680, with Kj values shown in
Table 1.2. CPA and CCPA were the most potent A-i agonists with nanomolar
affinity, while CGS21680 had the lowest affinity. Hill slopes were significantly
less than unity for all agonists, indicating the presence of two different affinity
states for the adenosine A-i receptor.
Agonists also exhibited the typical adenosine A2a pharmacological
profile for [3H]CGS21680 binding sites in rat striatal membranes with the
following order of potency: NECA = APEC > CGS21680 > CADO > R-PIA >
CPA = CHA > CCPA > S-PIA > CSPA, with Kj values shown in Table 1.2.
NECA, CGS21680 and the recently available A2a agonist APEC had
nanomolar affinity, while CSPA exhibited the lowest affinity. Hill slopes for
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Figure 1.8 Inhibition of (a) [3H]DPCPX and (b) [3H]CGS21680
Binding to Rat Brain Membranes by Adenosine Receptor
Agonists.
The data represent a typical experiment, each point performed in duplicate
with mean data obtained from at least three experiments (Table 1.2).
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(R-PIA, S-PIA and APEC) not significantly different from unity.
Agonist receptor selectivity was assessed by comparing the respective
affinities (Kj ratio) of each agonist in the two binding assays (Table 1.2). CCPA
and CPA were found to be the most A-i receptor selective compounds,
whereas APEC and CGS21680 were A2a selective agonists.
1.3.3.3. Fujisawa Adenosine Receptor Antagonist
Pharmacology
Fujisawa kindly supplied over 150 compounds from their adenosine
receptor programme. Mr T. Maemoto tested these compounds in a 2 point
screen to assess preliminary Ai receptor affinity and selectivity. Three
development compounds (FK453, FK352 and FK838), five pre-clinical
compounds (FR129946, FR160537, FR171562, FR182303 and FR182394)
and three adenosine receptor antagonists from other companies (KW3902,
Takeda (FR160492) and MDL102234) were chosen for further
pharmacological characterisation. With the exception of KW3902 and
MDL102234, all the antagonists are non-xanthines, in contrast to the standard
adenosine antagonists which are all xanthines (Figures 1.9 & 1.10).
Competition studies using the [3H]DPCPX and [3HJCGS21680 binding
assays were used to characterise Fujisawa adenosine antagonist receptor
pharmacology. Figure 1.11 shows inhibition of [3H]DPCPX binding in rat
cortical membranes and [3H]CGS21680 binding in rat striatal membranes by a
select number of antagonists. The pharmacological profile of the antagonists
for pHjDPCPX binding sites was: KW3902 > FR 160537 > DPCPX =
FR171562 > FK453 > FR129946 > FR182394 > FR182303 > FK838 >
FR160492 = MDL102234 > FK352, with Kj values shown in Table 1.3. A range
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Figure 1.11 Inhibition of (a) [3H]DPCPX and (b) [3H]CGS21680 Binding
to Rat Brain Membranes by Fujisawa Adenosine Receptor Antagonists.
The data represents a typical experiment, each point performed in duplicate with mean
data obtained from at least three experiments (Table 1.3).
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more potent than DPCPX. As with standard antagonists, Hill slopes were close
to unity in all cases.
The pharmacological profile of the antagonists for [3HJCGS21680
binding sites was: FR160492 > FR160537 = KW3902 = DPCPX > FR171562 >
FR182303 = MDL102234 = FR129946 > FK838 = FK453 > FR182394 >
FK352, with Kj values shown in Table 1.3. A range of affinities were found both
higher and lower than DPCPX. Hill slopes as for standard antagonists were
close to unity.
Antagonist receptor selectivity was assessed by comparing the
respective affinities (Kj ratio) of each antagonist in the two binding assays
(Table 1.3). FK453, FR 182394 and FK352 were the most receptor selective
compounds being 3 fold more selective than DPCPX, with a Kj ratio of greater
than 2000. FR 160537, FR 171562 and FR 129946 had similar affinities and
selectivity for the A-i receptor compared with DPCPX, whereas FR 182303 and
FK838 were slightly less selective. The three other antagonists varied with
KW3902 being both more potent and selective than DPCPX, MDL102234
showing moderate selectivity and FR 160492 showing the least selectivity of all
the non-xanthines tested.
62
1.3.4. Pharmacological Profile of [3H]DPCPX Binding Sites in
Human Cortical Membranes
As the ultimate goal of this study is the discovery of a drug for use in
man, it is essential to examine receptor pharmacology in human tissue. All
studies using human brain tissue were carried out in collaboration with Dr R.W.
Horton at St George's Hospital Medical School, London.
1.3.4.1. Time Course of [3H]DPCPX Binding to Human Cortical
Membranes
A time course of [3H]DPCPX (0.7 nM) binding to human cerebral cortex
was carried out at 25°C, with equilibrium attained by 20 min (Figure 1.12). In
subsequent competition experiments [3H]DPCPX (0.7 nM) binding to human
cortical membranes was carried out at 25°C for 120 min.
1.3.4.2. Concentration Dependence of [3H]DPCPX Binding to
Human Cortical Membranes
Hot saturation analysis of [3HJDPCPX binding to human cerebral cortex
was carried out (Figure 1.13a). Curve fitting using a hyperbolic model gave an
equilibrium dissociation constant (Kd) of 2.49 ± 0.85 nM and a Bmax of 5.68 ±
1.25 pmol mg-1 protein (n=3).
Competition binding studies using 0.7 nM [3H]DPCPX and increasing
concentrations of unlabelled DPCPX gave a Kd of 2.18 ± 0.35 nM and a Bmax
of 4.97 ± 0.98 pmol mg-1 protein (n=3) (Figure 1.13b), which is in good
































































Figure 1.12 Time Course of [3H]DPCPX Binding to
Human Cerebral Cortical Membranes.
The data represent a typical time course experiment. Membranes
were incubated with 0.7 nM pHJDPCPX for various times at 25°C
Experiments were performed as described in text with mean data
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Unlabelled DPCPX (M)
Figure 1.13 Concentration Dependence of Specific [3H]DPCPX
Binding to Human Cerebral Cortical Membranes
The results represent a typical (a) hot and (b) cold saturation experiment with
mean data obtained from three experiments (text for mean values).
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1.3.4.3. Adenosine Receptor Antagonist and Agonist
Pharmacology in Human Cortex
Adenosine receptor antagonists and agonists exhibited the typical
adenosine Ai pharmacological profile for [3H]DPCPX binding sites in human
cortical membranes. Antagonists had the following order of potency: DPCPX >
CPT > DPX > 8-PT, with Kj values shown in Table 1.4. Agonists had the
following order of potency: CCPA = CPA s R-PIA > CHA > NECA s CADO >
CGS21680, with Kj values shown in Table 1.4. The affinity of antagonists and
agonists in human cortex were lower than in rat (7-25 fold) as shown by the Kj
ratio (Table 1.4), with the exception of CGS21680 at 2.9 fold lower. The Kj of
CCPA on addition of the stable GTP analogue Gpp(NH)p (100 /jM), was
reduced to 378 ± 36 nM (nH=0.78 ± 0.02). Hill slopes were near unity for
antagonists and significantly less than unity for all agonists.
1.3.4.4. Fujisawa Adenosine Receptor Antagonist
Pharmacology in Human Cortex
In comparison with rat brain membranes, Fujisawa and xanthine based
antagonists had a slightly different adenosine A-i pharmacological profile for
pHjDPCPX binding sites in human cortical membranes. The pharmacological
profile of Fujisawa antagonists for pH]DPCPX binding sites was: FR160537 >
FR171562 = KW3902 > FK453 = FR182303 > FR182394 = FR129946 >
FK838 = FR 160492 > FK352 = MDL102234, with Kj values shown in Table
1.5. In contrast to standard agonists and xanthine based antagonists, these
non-xanthine compounds showed very little alteration in affinity between the
two species, as shown by a selective comparison in Figure 1.14 and by the Kj
ratio in Table 1.5. Results for the two xanthines, KW3902 and MDL102234
differed with the former xanthine having a similar affinity in both rat and human
66
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Figure 1.14 Inhibition of [3H]DPCPX Binding to Human and
and Rat Brain Cortical Membranes by DPCPX, FK453 and
CCPA.
The data represents a typical experiment. Experiments were performed as
described in text with mean data obtained from at least three experiments
(Table 1.4; 1.5).
69
brain membranes and the latter showing a decrease in affinity consistent with
the other xanthines. Hill slopes for all antagonists tested were close to unity.
1.3.5. Species Differences in Adenosine Receptor
Pharmacology
In comparing the data from different species I would like to
acknowledge that the data shown for mouse and guinea pig tissues were
generated by Mr T. Maemoto. Following the discovery that the Fujisawa
antagonists showed a similar affinity in rat and human cortical membranes, Mr
T. Maemoto tested a limited number of compounds against [3H]DPCPX
binding to cortical membranes from mouse and guinea pig brain.
1.3.5.1. Standard Adenosine Receptor Antagonists and
Agonists
Table 1.6 shows the affinity of both xanthine based antagonists
(DPCPX, CPT, DPX, 8-PT) and adenosine based agonists (CCPA, CPA,
R-PIA, CHA, NECA, CADO, CGS21680) in four species. As shown in Figure
1.15a, there is a direct correlation between rat and mouse Kj values with the
data best described by the equation y=0.88x+0.17 and a correlation coefficient
(r) of 0.99. The antilog of the intercept represents the average difference in
affinity of the compounds between the two species. For rat and mouse the
antilog of the intercept is equal to 1.48 with compounds having a similar affinity
in both species. Figure 1.15b shows a good correlation between rat and
human Kj values with the data best described by the equation y=0.87x+1.20
and a correlation coefficient (r) of 0.98. For rat and human the antilog of the
intercept is equal to 15.8 with compounds being about an order of magnitude
less potent in human membranes. Figure 1.15c shows a good correlation
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Figure 1.15 Correlation of the Kj values of Adenosine Antagonists
and Agonists for [3H]DPCPX Binding Sites in Cortical Membranes
from Four Different Species.
The solid line represents a linear regression through the data presented in Table 1.6.
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between rat and guinea pig Kj values with the data best described by the
equation y=0.77x+0.98 and a correlation coefficient (r) of 0.96. For rat and
guinea pig the antilog of the intercept is equal to 9.55 with compounds being
about an order of magnitude less potent in guinea pig membranes. Figure
1.15d shows a very good correlation between human and guinea pig Kj values
with the data best described by the equation y=0.89x-0.09 and a correlation
coefficient (r) of 0.99. With the antilog of the intercept equal to 0.81,
compounds would appear to have similar affinities in human and guinea pig
membranes.
1.3.5.2. Fujisawa Adenosine Receptor Antagonists
Figure 1.16 shows a good correlation between rat and human Kj values
for non-xanthine antagonists (FR160537, FR171562, FK453, FR129946,
FR182394, FR182303, FK838, FK352), with the data best described by the
equation y=1.18x-0.11 and a correlation coefficient (r) of 0.92. With a
correlation coefficient of 0.92 and the antilog of the intercept equal to 0.78,
compounds exhibit similar affinities in rat and human membranes. Table 1.7
shows the affinity of a limited number of Fujisawa antagonists tested in the four
different species. Figure 1.17a shows a very good correlation between rat and
mouse Kj values with the data best described by the equation y=1.09x+0.09
and a correlation coefficient (r) of 0.99. With the antilog of the intercept equal
to 1.23, compounds would appear to have similar affinities in both species.
Figure 1.17b shows a good correlation between rat and human Kj values with
the data best described by the equation y=1.27x-0.01 and a correlation
coefficient (r) of 0.98. With the antilog of the intercept equal to 0.98,
compounds would appear to have similar affinities in both species. Figure
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Figure 1.16 Correlation of the K; Values of Fujisawa
Antagonists for [3H]DPCPX Binding Sites in Rat and
Human Cortical Membranes.
The solid line represents a linear regression through the data
from Table 1.5 for FR160537, FR171562, FK453, FR129946,
FR182394, FR 182303, FK838 and FK352.
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Figure 1.17 Correlation of the Kj values of Fujisawa Antagonists for
[3H]DPCPX Binding Sites in Cortical Membranes from Four Species.
The solid line represents a linear regression through the data from Table 1.7 for
FR160537, FR171562, FK453, FR129946, FK838 and FK352 where appropriate.
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the data best described by the equation y=0.99x+0.09 and a correlation
coefficient (r) of 0.99. With the antilog of the intercept equal to 1.23,
compounds would appear to have similar affinities in both species. Figure
1.17d shows a good correlation between human and guinea pig Kj values with
the data best described by the equation y=0.76x+0.10 and a correlation
coefficient (r) of 0.98. With the antilog of the intercept equal to 1.26,
compounds would appear to have similar affinities in both species.
1.4. Discussion
[3H]DPCPX and [3HJCGS21680 binding assays have been used to
determine the adenosine A-i receptor affinity and selectivity in rat brain of a
range of adenosine agonists, xanthine based antagonists and Fujisawa's novel
non-xanthine antagonists. The A-i receptor affinities of a select group of
compounds were determined in the brain of three other species; mouse,
guinea pig and human.
The binding of pHJDPCPX and [3H]CGS21680 to rat brain membranes
was reversible, saturable and of high affinity. The KD and Bmax values for the
individual radioligands were similar in their respective kinetic, saturation and
competition studies. These data from kinetic and saturation studies are in good
agreement to those calculated in the original characterisation of [3H]DPCPX
(Bruns etal., 1987) and [3H]CGS21680 (Jarvis etal., 1989a) binding sites. The
reference xanthine antagonists exhibited the typical adenosine A-i
pharmacological profile for [3H]DPCPX binding sites in rat cortical membranes,
with Hill slopes not significantly different from unity and with an order of
potency identical to Bruns et al, (1987). Table 1.8 shows antagonist affinities
determined using [3H]DPCPX binding were similar to values obtained using
the agonist radioligands pH]CHA and [3HJR-PIA and to data from cloned rat
77
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brain A-i receptors (Mahan et al., 1991; Freund et al., 1994). These
antagonists also exhibited the typical adenosine A2a pharmacological profile
for [3H]CGS21680 binding sites in rat striatal membranes, with Hill slopes not
significantly different from unity and with an order of potency identical to Jarvis
et al., (1989a) (Table 1.9). These data are consistent with the recently
characterised A2a receptor antagonists [3H]SCH58261 (Zocchi et al., 1996)
and [3H]KF17837S (Nonaka et al., 1994) (Table 1.9). Receptor selectivity, as
determined by the Kj ratio, was almost identical to that described by Bruns et
al., (1987), for DPCPX (686 vs 607), CPT (130 vs 127) and DPX (8.7 vs 23.2).
For the recently characterised A2a receptor selective antagonists CSC
(Jacobson et al., 1993) and KF17837 (Shimada et al., 1992; Nonaka et al.,
1993), values were very similar at (0.001 vs 0.002) and (0.029 vs 0.018)
respectively.
The reference adenosine agonists exhibited the typical adenosine A-i
pharmacological profile for [3H]DPCPX binding sites in rat cortical membranes,
with Hill slopes significantly less than unity (nH=0.58-0.65) and with an order of
potency identical to Bruns et al., (1987) (Table 1.8). As with other G protein
coupled receptors, the shallow Hill slope is indicative that agonists recognise
high and low affinity states of the receptor, reflecting the receptor being
coupled to and uncoupled from G proteins (Gilman, 1987; Birnbaumer et al.,
1990). The lower affinity of agonists in the [3H]DPCPX binding assay in
comparison with the agonist radioligands [3H]CHA and pH]R-PIA (Table 1.8),
is because agonist radioligands recognise almost exclusively the high affinity
state of the receptor. The standard agonists exhibited the typical adenosine
A2a pharmacological profile for pH]CGS21680 binding sites in rat striatal
membranes, with an order of potency identical to Jarvis et al., (1989a) (Table
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unity for agonists and antagonists and hence one binding component. Our
data indicate that the majority of agonist Hill slopes were steeper than those in
the [3H]DPCPX binding assay but were still significantly less than unity,
suggesting that [3HJCGS21680 labels two affinity states. These data are
consistent with the recently characterised A2a antagonist [3H]KF17837S
(Nonaka et al., 1994), with shallow Hill slopes for agonists supporting the
concept that A2a receptors exist in two agonist coupling states. In the same
study [3HJCGS21680 was reported to label a large proportion of high affinity
receptors (Table 1.9). This is consistent with the present data as when
CGS21680 was examined over an extended concentration range and data
fitted to a 2-site model (although this model provided no significant
improvement using a partial Ftest, P> 0.05), a high affinity site of 7.5 ±1.6
nM (84%) and a low affinity site of 176 ± 132 nM were identified. The lack of
improvement on fitting the data to a 2-site model is perhaps not surprising as
studies indicate that 2-site models are only likely to improve the fit when the
difference in affinity between two sites is greater than the 30 fold observed in
the present study (Bruns et al., 1986, 1987). There is however controversy as
the A2a antagonist [3H]SCH58261 (Zocchi et al., 1996), labels only one low
affinity component for agonists, despite similar affinities to those obtained for
[3H]KF17837S (Nonaka et al., 1994) (Table 1.9). The reason for this
discrepancy remains to be elucidated. Receptor selectivity as determined by
the Kj ratio was almost identical to that described by Bruns et al., (1987), for
CPA (54.7 vs 58.2), CHA (34.6 vs 19.0) and R-PIA (20 vs 7.5). For the recently
characterised A2a receptor selective agonists CGS21680 (Jarvis et al., 1989a)
and APEC (Nikodijevic et al., 1991), values were very similar at (0.0002 vs
0.005) and (0.023 vs 0.029) respectively.
Species differences in A-i (Murphy & Snyder, 1982; Ferkanky et al.,
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1986; Ukena et al., 1986; Klotz et a!., 1991) arid A2a (Stone et al., 1988)
receptor pharmacology have been characterised. These studies have
predominantly used agonist radioligands, with the exception of Klotz et al.,
(1991), who used [3HJDPCPX to characterise a limited number of compounds.
This is the first comprehensive study in which an antagonist radioligand has
been used to assess adenosine receptor pharmacology. To complement and
extend these studies, Mr T. Maemoto used [3H]DPCPX to examine the Ai
receptor affinity of 11 standard agonists and antagonists in cerebral cortical
membranes of the two other most commonly used laboratory animals, the
mouse and guinea pig (Maemoto et al., 1994). The KD and Bmax values for
pHjDPCPX in mouse cortex were very similar to rat, as were the rank order of
potency and affinity of both agonists and antagonists. Similarities in the
pharmacological properties of rat and mouse brain membranes were also
observed using the agonist radioligand, [3HJCHA (Ferkanky et al., 1986).
However, for guinea pig cortex the Kd was approximately 5 fold lower than rat,
the Bmax 2 fold higher and the rank order of potency similar, with the exception
of NECA which had a similar affinity in all three species. These data are
consistent with previous data (Ferkanky et al., 1986; Ukena et al., 1986; Klotz
et al., 1991; Alexander et al., 1994). The low affinity of the guinea pig receptor
for agonists and antagonists was also studied using hippocampal tissue
(Maemoto et al., 1994). Recently an adenosine A-i receptor from guinea pig
brain was cloned and expressed, with agonist affinities even lower than native
tissues (Meng et al., 1994a). Further studies will be required to define whether
this is a distinct low affinity subtype or an artifact of the expression system.
This solid database for adenosine receptor pharmacology in different
species allowed us to confidently examine a series of novel non-xanthine
antagonists from Fujisawa. Over 150 compounds were screened using rat
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brain membranes and a two point screen for both A-i and A2a receptor binding
assays (Mr T. Maemoto, unpublished data). Eight compounds were chosen for
further characterisation. For comparison we examined three compounds from
other companies: the xanthines KW3902 (Nonaka et al., 1996) and
MDL102234 (Peet et al., 1993) and a non-xanthine Takeda compound
(FR160492). In rat brain membranes, all the compounds had high affinity and
selectivity for the A-i receptor, with the exception of the Takeda compound
which showed only 7 fold selectivity for the A-i receptor. The Fujisawa
antagonists had a range of affinities from 0.21 nM for FR160537 to 23.6 nM for
FK352. Three compounds FK453, FR182394 and FK352 were three times
more selective (> 2000 fold) than DPCPX. The Kj value for FK453 is slightly
higher than that found by Terai et al., (1995a). The affinity and selectivity for
KW3902 and MDL102234, were however in excellent agreement with that
found by Nonaka eta!., (1996) and Peet etal., (1993) respectively.
The ultimate goal of the project is to develop a clinically useful drug. In
light of characterised and reported species differences, it was therefore
essential to examine the pharmacology of the adenosine A<\ receptor in human
brain tissue. In collaboration with Dr R.W. Horton, we examined adenosine A-i
receptor pharmacology in human parietal cortex (Brodmann area 7). With
tissue in short supply, only a limited kinetic characterisation was carried out.
The binding of pHjDPCPX to human brain membranes was saturable, of high
affinity and equilibrium was attained after a 20 min incubation. The Kq and
Bmax values were similar in saturation (Kd=2.49 ± 0.85 nM; Bmax=5.68 ± 1.25
pmol mg-i protein) and competition studies (Kd=2.18 ± 0.35 nM; Bmax=4.97 ±
0,98 pmol mg-i protein). The Kq in human cortex was approximately 8 fold
lower than in rat cortex and the Bmax three fold higher. These data are
consistent with Murphy & Snyder, (1982) and Ferkanky et at, (1986) who
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found a lower KD in human brain membranes in comparison with rat; however,
the latter study demonstrated no difference in Bmax- The Kd of PHJDPCPX in
human cortical membranes in the present study is comparable to values
obtained for the cloned (Libert et al., 1992; Townsend-Nicholson & Shine,
1992; Jockers et al., 1994) and purified human brain A-i adenosine receptor
(Nakata, 1992). These data contrast with Rivkees et al., (1995b), who
demonstrated a similar affinity and binding capacity for cloned rat and human
adenosine Ai receptors using [3H]CCPA as the radioligand. The data from
cloned studies must be interpreted with caution as work within our own
laboratory (Mr T. Maemoto, personal communication), has indicated that
agonist affinity can be radically altered by changing the expression level of the
receptor. Standard agonists and antagonists inhibited [3H]DPCPX binding to
human cortical membranes with the typical adenosine Ai pharmacological
profile. However, agonist and antagonist affinities for the human receptor were
at least 7 fold lower than rat, with the exception of CGS21680 which had
negligible affinity. The differences between rat and human are larger than the
decrease shown by Murphy and Snyder, (1982) for R-PIA (2 fold) and CHA (4
fold) but are almost identical for DPX at 14.3 fold. The data is consistent with
that of the cloned brain Ai receptor (Libert et al., 1992). These data do
however contrast with Ferkanky etal, (1986), who showed a variable profile of
effects when comparing rat and human receptor pharmacology. The possibility
that the receptor is functionally uncoupled from its G protein would seem
unlikely, as the Hill slope for agonists is significantly less than unity and
addition of Gpp(NH)p, the stable GTP analogue, produced an 8 fold decrease
in affinity for CCPA. This 8 fold decrease in affinity in the presence of
Gpp(NH)p was accompanied by an increase in Hill slope. However, the value
was still significantly less than unity, presumably reflecting an incomplete shift
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to the low affinity state. In contrast, Libert et a!., (1992) and Nanoff et a!.,
(1995), demonstrated a complete shift to the low affinity state for the cloned
human A-i receptor. Interestingly when the cloned human brain Ai receptor
was expressed in £ coli that contain no endogenous G proteins (Jockers et
a/., 1994) and therefore only the low affinity state for agonists is detectable, the
affinity of CPA, R-PIA, NECA and CADO was 5-7 fold lower than our data and
is similar to values we would expect on addition of Gpp(NH)p.
The pharmacological profile of the 8 non-xanthine Fujisawa antagonists
in human brain tissue was the same as rat. In contrast to adenosine based
agonists and xanthine based antagonists, the affinity of these novel
compounds in rat and human brain tissue was almost identical. The non-
xanthine Takeda compound (FR160492) also had a similar affinity in rat and
human brain tissue. As with the other xanthine based antagonists, MDL102234
(Peet et ai, 1993) had a Kj value approximately 5 fold lower in human brain
tissue than in rat. However, the xanthine KW3902 (Nonaka et at., 1996) had a
similar affinity in both rat and human tissue.
The rank order of potency for adenosine agonists and xanthine based
antagonists in inhibiting [3H]DPCPX binding to brain membranes was similar in
all four species. There was however differences in affinity for agonists and
antagonists, with guinea pig pharmacology sharing the closest resemblance to
human. This is consistent with Ferkanky et a!., (1986), who despite having
different values for the affinity of the compounds, reached a similar conclusion.
It may therefore be more appropriate to assess the pharmacology of these
compounds in guinea pig tissue rather than rat or mouse when trying to
extrapolate to man. For the non-xanthine Fujisawa adenosine antagonists so
far examined, it would appear that pharmacological characteristics can be
assessed in rat, mouse and guinea pig, as the affinity of these compounds in
brain tissue was almost identical to that of human cortex. The cloning of
85
multiple adenosine receptor subtypes, now makes it possible to identify the
receptor domains responsible for binding certain functional groups present on
specific ligands. Compared with other GPCRs, the understanding of how
ligands bind to adenosine A^ receptors and which amino acids are involved in
the binding of agonists and antagonists is still in its infancy. It has been shown
for the 5-HT-ib receptor that a single amino acid is responsible for major
pharmacological differences between human and rodent receptors (Oksenberg
et al., 1992). Replacement of threonine at residue 355 in the human 5-HT-ib
receptor by the equivalent asparagine residue in the rodent 5-HTib receptor
renders agonist and antagonist pharmacology almost identical. This is not
uncommon for GPCRs, with single amino acids important for conferring
species specificity in pharmacological properties of (^-adrenergic, 5-HT2,
cholecystokinin and neurokinin receptors (Link et al., 1992; Kao et al., 1992;
Jensen et al., 1993). Binding models postulate that the ligand binding sites of
adenosine Ai receptors are within the transmembrane regions, as with
adrenergic (a and p), muscarinic, dopamine and serotonin receptors
(Ostrowski et al., 1992; Olah et al., 1994). Unlike these biogenic amines,
adenosine is uncharged at physiological pH and is bulkier, so all the features
required for binding may not be conserved (Palmer & Stiles, 1995). One
example of this would be the aspartate residue (Asp113), which is conserved
in all GPCRs that bind biogenic amines but is not present in adenosine
receptors (Tota et al., 1991). The role of histidine residues in adenosine A-i
receptor ligand binding was first investigated in a study in which rat brain
membranes were chemically modified by treatment with diethylpyrocarbonate
(Klotz et al., 1988). This study provided the first evidence for agonists and
antagonists occupying separate domains at the binding site and a role for
multiple histidine residues within the transmembrane domains. A more specific
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study, where the two histidine residues in transmembrane six and seven (TM6
and TM7) were altered by site directed mutagenesis, again pointed to a role for
the residues in agonist and antagonist binding (Olah et al., 1992). Recent
studies, using site directed mutagenesis and chimeric receptors, have
indicated a role for multiple regions of the adenosine A-i receptor in ligand
recognition. This has included regions within the transmembrane domains and
on the extracellular loops, with a considerable degree of overlap in structural
features for agonist and antagonist binding (Olah et al., 1994; Tucker et al.,
1994; Townsend-Nicholson & Schofield, 1994). This is unlike the ^-adrenergic
receptor where discrete sequences have been found to be responsible for
binding specific functional groups (Ostrowski etal., 1992). There are, however,
differences with individual amino acids important in the binding of ligands to
adenosine Ai receptors in different species. The amino acid at position 277 is
able to interact with the 5'-ribose moiety (Townsend-Nicholson & Schofield,
1994; Tucker et al., 1994) and amino acid 270 is able to interact with the N8-
substituted adenosine analogues and C8-substituted xanthines (Tucker et al.,
1994). These two amino acids have been reported to be important in
conferring species selectivity in ligand binding to A-i receptors. As with the 5-
HT1b receptor (Oksenberg et al., 1992), these amino acids are located in TM7.
In the case of the 5-HT2 and a2-adrenergic receptors, important structural
amino acids are located in TM5 (Link etal., 1992; Kao etal., 1992). Consistent
with amino acid 270 being important for C8 and N8-substituted ligands, the rat
and mouse adenosine A-, receptors have the same residue as the bovine
receptor, whereas the human and guinea pig receptors, which show lower
affinities for these compounds both have threonine residues (Townsend-
Nicholson & Shine, 1992; Meng et al., 1994a; Marquardt et al., 1994). The
canine receptor, which has an even lower affinity, has a methionine residue at
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amino acid 270 (Townsend-Nicholson & Shine, 1992; Tucker et al., 1994).
These observations are consistent with our data, in that the affinity of agonists
and xanthine based antagonists, were similar in human and guinea pig
membranes and higher in rat and mouse brain membranes. These studies
primarily focused on sites within TM's 5-7, with species dependent binding
properties conferred primarily by the carboxyl third of the receptor. However a
very recent study, has pointed to a role for TM's 1-4, which also contain
important determinants for adenosine Ai receptor agonist and antagonist
binding and ligand specificity (Rivkees et al., 1995a). It is not difficult to
speculate that these regions may also contain determinants important in
conferring species selectivity. It is also tempting to speculate that the non-
xanthine Fujisawa antagonists do not interact with amino acid 270, thereby
explaining the maintenance of affinity across species, although confirmation of
this requires further studies at the molecular level.
Despite greater than 90% receptor identity at the amino acid level (see
main introduction), this and earlier studies demonstrate that the pharmacology
of adenosine A-i receptors differs markedly between species (Murphy &
Snyder, 1982; Ferkanky et al., 1986; Ukena et al., 1986; Stone et al., 1988;
Klotz et al., 1991). Multiple facets may be involved in accounting for these
species differences, including changes in the amino acid sequences of the
different receptors (as discussed above), the ability to couple to different G
proteins and hence different signal transduction pathways (Jockers et al.,
1994), or in the case of the human receptor posttranslational modifications
(Ren & Stiles, 1994a). It may be possible to continue to identify areas involved
in ligand recognition and hence explain why Fujisawa antagonists retain their
affinity for the human brain adenosine A-i receptor by using a combined
approach of creating chimeric receptors and site directed mutagenisis (Tucker
eta!., 1994; Olah etal., 1994; Townsend-Nicholson & Schofield, 1994).
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CHAPTER TWO
MODULATION OF LIGAND BINDING TO ADENOSINE Ai AND
A2a RECEPTORS BY Gpp(NH)p AND MAGNESIUM
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2.1. Introduction
Adrenergic (Ostrowski, et al., 1992) and muscarinic (Hulme, et al.,
1990) receptors, are two extensively characterised GPCRs from which most
generalities of receptor structure-function relationships are based. Adenosine
receptors all fit the structural motif typical of GPCRs (Birnbaumer et al., 1990).
The structures have seven stretches of hydrophobic a-helical regions,
composed of ~22-26 AA's, that cross the cell membrane. The amino terminus
and AA's connecting the membrane spanning domains 2-3, 4-5 and 6-7
(known as extracellular loops 1, 2 and 3 respectively) are extracellular,
whereas the carboxyl terminus and regions connecting transmembrane
domains 1-2, 3-4 and 5-6 (intracellular loops 1, 2 and 3 respectively) are
cytoplasmic. The c-terminal portion of the receptor and the third intracellular
loop are supposedly important in binding G proteins (Linden, 1994). Portions of
these loops may interact directly with a (Figure 2.1) and possibly Py subunits of
G proteins producing receptor activation and regulation by phosphorylation
(Fredholm et al., 1994; Murthy & Makhlouf, 1995). In comparison with other
GPCRs, Ai, A2b and A3 receptors have short amino termini and are small in
size. In native tissues, A-i and A2a receptors have been identified as
glycoproteins (Stiles, 1990). In common with other GPCRs, adenosine A-t and
A2a receptors have two glycosylation sites on the putative second extracellular
loop and none on the amino-terminal tail (Palmer & Stiles, 1995). Other
common features include residues important in sodium regulation, disulphide
bond formation and palmitoylation (Olah & Stiles, 1995). There are differences
however; A1, A2a and A2b receptors do not have an aspartic (Asp113) acid
residue in the third transmembrane domain which is present in muscarinic,
adrenergic, serotonergic and dopaminergic receptor proteins and is important









conservation in the features required for ligand binding may be due to
adenosine being bulkier and uncharged at physiological pH, unlike
endogenous biogenic amines (Palmer & Stiles, 1995).
On activation, adenosine receptors display a number of characteristics
associated with G protein mediated transmembrane coupling (Gilman, 1987;
Olah & Stiles, 1992). Two areas which have been the focus of numerous
contradictory studies are the guanine nucleotide and magnesium dependence
of adenosine agonist and antagonist binding. For many GPCRs including the
adenosine A^ (Lohse et al., 1984; Klotz et al., 1991; Casado et al., 1994) and
A2a (Stone et al., 1988; Wan et al., 1990; Luthin et al., 1995) receptors, two
different high and low affinity states exist for agonist binding (Birnbaumer eta!.,
1990). However, for the A2a receptor this is controversial with studies reporting
the existence of only one high affinity state for agonists (Jarvis et al., 1989a;
Kirk & Richardson, 1995). For the A-i receptor, guanine nucleotides or their
non-hydrolysable analogues uncouple the G protein from the receptor-G
protein complex, so in the presence of the nucleotides the low affinity agonist
state is predominant (Lohse et al., 1984; Stroher et al., 1989). For the A2a
receptor, the situation is less clear cut with the receptor apparently more
resistant to the effects of guanine nucleotides (Nanoff & Stiles, 1993; Zocchi et
al., 1996). The finding that high affinity agonist binding for At and A2a receptors
is not completely abolished by guanine nucleotides, or by receptor
solubilisation (Gavish et al., 1982; Stiles, 1985; Nanoff & Stiles, 1993), is
indicative of both receptors forming a tighter association with their G proteins
than other GPCRs (Stiles, 1985; Freissmuth et al., 1991a). Unlike agonists,
antagonists at A-i and A2a receptors recognise both coupled and uncoupled
states of the receptor with equal affinity (Yeung & Green, 1983; Klotz et al.,
1991; Nonaka et al., 1994). If true, guanine nucleotides should not modulate
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antagonist binding. Preliminary studies with the new A2a antagonists,
[3H]SCH58261 (Zocchi et al., 1996) and [3HJKF17837S (Nonaka est al., 1994),
appear consistent with this hypothesis with no alteration in KD or Bmax values
on addition of GTP. Results for the A-, receptor are conflicting. Some groups
have shown guanine nucleotides have no effect on Bmax or Kd (Lohse et al.,
1984; Klotz et al., 1986; Leid et al., 1988; Stiles, 1988; Olah & Stiles, 1990),
whereas others found an increase in Bmax with no change in Kd (Yeung &
Green, 1983; Klotz etal., 1990; Nakata, 1990; Freissmuth etal., 1991a). There
have also been studies demonstrating an increase in Bmax and a decrease in
Kpand vice versa (Ramkumar & Stiles, 1988; Stroher et al., 1989; Lorenzen et
al., 1993). The possibility that antagonists unlike agonists destabilise the
receptor-G protein complex and bind preferentially to the uncoupled form of
the receptor (Leung & Green, 1989; Leung et al., 1990), was strengthened
when receptors purified using antagonist affinity chromatography were found
to be uncoupled from their G proteins (Nakata, 1990). In contrast, Reddington
et al., (1989) found that antagonists can bind to both coupled and uncoupled
receptors.
Studies on ligand-receptor-G protein interactions indicate binding
reactions are strongly influenced by anions, proteins and Mg2+ (Gilman, 1987;
Birnbaumer et al., 1990; Strader et al., 1994). Mg2+ is known to increase
agonist binding at many receptors including, adrenergic (a-i, a2 and p),
dopamine and muscarinic receptors (Parkinson & Fredholm, 1992). Ligand
binding studies indicate that Mg2+ influences both agonist and antagonist
binding at A-i and A2a receptors (Goodman et al., 1982; Olah & Stiles, 1990;
Johansson et al., 1992; Mazzoni et al., 1993). As with guanine nucleotides,
there are contrasting results with Mg2+ reported to increase (Johansson et al.,
1992; Mazzoni et al., 1993) and decrease (Fastbom & Fredholm, 1990;
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Parkinson & Fredholm, 1992) agonist binding at adenosine receptors.
The contrasting effects seen for guanine nucleotides and Mg2+ at A-\
and A2a receptors requires further clarification. We examined the influence of
the stable GTP analogue, Gpp(NH)p, which is not subject to Mg2+ sensitive
hydrolysis (Johansson et al., 1992) and MgCI2 on [3H]DPCPX and
pH]CGS21680 binding. When these studies were conducted, the A2a receptor
antagonists, [3H]SCH58261 (Zocchi eta!., 1996) and [3H]KF17837S (Nonaka
et al., 1994), were not available to compare with pH]DPCPX. The use of
PHjCCPA (Klotz et al., 1989), a high affinity selective A1 agonist radioligand,
allowed us to directly compare and contrast the effects of Gpp(NH)p and
MgCI2 on antagonist and agonist binding at the A-i receptor and agonist
binding at both and A2a receptors.
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2.2. Methods and Materials
2.2.1. Membrane Preparation
P2 synaptosomal membranes were prepared from rat cortical and
striatal tissue as described in Chapter 1 (see 1.2.1.1.), for use in the following
radioligand binding assays.
2.2.2. [3H]DPCPX and PH]CGS21680 Binding Assays
PHJDPCPX and [3H]CGS21680 binding assays were carried out as
described in Chapter 1 (see 1.2.3.1. & 1.2.3.3.) and [3H]CCPA binding as
described below. Addition of Gpp(NH)p, Mg2+ or Na+ ions to the binding
assays was accommodated by altering the volume of Tris-buffer without
changing total assay volume.
2.2.3. [3H]CCPA Binding Assay
[3H]CCPA ([3H]2-chloro-N6-cyclopentyladenosine) (30 Ci mmoM; NEN)
binding was carried out under equilibrium conditions by preincubating 10 pi of
DMSO or test drug, 290 pi of Tris-buffer and 100 pi of ADA (1u ml-1) with 100
pi of 2 nM [3H]CCPA for 2 min at 25°C. Test drugs were diluted in DMSO to
give 10 duplicate or 20 single concentrations. Total binding was determined in
the presence of 1% DMSO and 10 pM R-PIA was used to determine non¬
specific binding. Addition of P2 rat cortical membrane suspension (500 pi; 20-
40 pg), which gave a final volume of 1 ml, initiated a 120 min incubation at
25°C. Bound and free ligand were separated using a Brandel cell harvester
and this was followed by three washes (3 ml) in ice cold Tris-buffer over GF/B
filters. Filter disks were then transferred to scintillation vials and the procedure
followed as described for pFI]DPCPX binding.
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2.2.4. [3H]CCPA Microcentrifugation Assay
pHJCCPA (30 Ci mmoM; NEN) binding was carried out under
equilibrium conditions in microcentrifuge tubes, by preincubating 5 /7l of DMSO
or test drug, 95 ij\ of Tris-buffer and 50 /vl of ADA (1u mM) with 50 /vl of 2 nM
[3H]CCPA for 2 min at 25°C. Test drugs were diluted in DMSO to give 14
single concentrations. Total binding was determined in the presence of 1%
DMSO and 10 /vM R-PIA was used to determine non-specific binding. Addition
of P2 rat cortical membrane suspension (300 fj\] 80-100 jyg), which gave a final
volume of 0.5 ml, initiated a 120 min incubation at 25°C. Incubation was
terminated by centrifugation at 15000 g for 2 min at 4°C in a Beckman
microcentrifuge. Tubes were immediately put on ice and the clear supernatant
removed under vacuum, using a fine tipped pasteur pipette. The insides of the
tubes were carefully swabbed with a cotton bud, to remove residual
radioactivity and wiped before transfer to scintillation vials. Pellets were
digested by addition of 100% formic acid (100 /jI) for 30 min and radioactivity
determined as described for [3HJDPCPX binding.
2.2.5. Data Analysis
Standard inhibition curves were constructed as in Chapter 1 (see
1.2.2.1.), for all radioligand binding experiments with [3H]DPCPX,
[3H]CGS21680 and [3H]CCPA. The appropriate pharmacological parameters
were determined using the equations described in Chapter 1 (see 1.2.4.) and
an iterative curve fitting programme (Sigma plot).
2.2.6. Statistical Analysis
Although the majority of figures displayed are a representation of one
experiment, all experiments have been carried out at least three times, unless
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otherwise stated. Data in tables and text are shown as mean ± the standard
error (S.E.M.), for values obtained for at least three different experiments.
Statistical tests used were the Students t-test, a Dunnett's test and a one-way
analysis of variance (ANOVA).
2.2.7. Materials
Radioligands were purchased from New England Nuclear (NEN) and
adenosine deaminase (Type VIII) from Sigma. Standard adenosine agonists
and antagonists were purchased from Research Biochemicals Inc. (RBI). All
FR compounds were synthesised by the Fujisawa Pharmaceutical Co. Ltd. All
other standard laboratory chemicals were from Sigma, Fisons and BDH and
were of the highest grade available.
2.3. Results
2.3.1. [3H]DPCPX Binding to Rat Cerebral Cortical Membranes
2.3.1.1. Concentration Dependent Effect of MgCfe & Gpp(NH)p
on [3H]DPCPX Binding to Rat Cerebral Cortical Membranes
MgCI2 produced a significant concentration dependent decrease in
pH]DPCPX binding, with a maximal reduction of 44% at 10 mM MgCI2 (Figure
2.2a). Gpp(NH)p produced a small but significant concentration dependent
increase in [3H]DPCPX binding, plateauing at concentrations above 3
(Figure 2.2b). Further studies to determine the effects on the affinity of
adenosine receptor antagonists and agonists were carried out, in the absence
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Figure 2.2 Concentration Dependence of (a) Mg2+
and (b) Gpp(NH)p on [3H]DPCPX Binding.
The data are the mean of three experiments. The statistical
comparisons were made using a one way anova followed by
a Dunnett's test between control and each dose. *: P< 0.05.
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2.3.1.2. Effect of MgCI2 and Gpp(NH)p on the KD and Bmax of
[3H]DPCPX Binding Sites
Parallel binding studies using 0.1 nM [3H]DPCPX and increasing
concentrations of unlabelled DPCPX gave a Kd of 0.35 ± 0.04 nM (nH=0.91 ±
0.08) and a Bmax of 2.00 ± 0.22 pmol mg-1 protein (n=9) in the absence of
MgCI2 and a KD of 0.42 ± 0.05 nM (nH=0.91 ± 0.09) and a Bmax of 1.28 ± 0.19
pmol mg-i protein (significantly different, P < 0.05, in a t-test) in the presence
of 10 mM MgCl2-
Parallel binding studies gave a Kd of 0.25 ± 0.01 nM (nH=0.98 ± 0.03)
and a Bmax of 1.17 ± 0.07 pmol mg-1 protein (n=15) in the absence of
Gpp(NH)p and a KD of 0.26 ± 0.02 nM (nH=0.99 ± 0.03) and a Bmax of 1.47 ±
0.12 pmol mg-1 protein (significantly different, P < 0.05, in a t-test) in the
presence of 10^M Gpp(NH)p.
2.3.1.3. Effect of MgCfe and Gpp(NH)p on Adenosine
Antagonist and Agonist Receptor Pharmacology
The pharmacological profile of [3H]DPCPX binding sites was examined
in the absence and presence of 10 mM MgCI2. Figure 2.3 shows inhibition of
[3H]DPCPX binding by DPCPX and CCPA in the absence and presence of 10
mM MgCI2. Both antagonists and agonists exhibited the typical adenosine A-i
pharmacological profile for [3H]DPCPX binding in the absence and presence of
10 mM MgCI2. For antagonists the rank order of potency was: DPCPX >
CGS15943 > CPT > DPX > 8-PT and for agonists was: CCPA = CPA s R-PIA
> CHA > NECA = CADO > CGS21680, with Kj values shown in Table 2.1.
Antagonist affinity was not significantly different in the presence of MgCI2. Hill
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Figure 2.3 The Effect of Mg2+ on the Inhibition of [3H]DPCPX
Binding by (a) DPCPX and (b) CCPA.
The data represent a typical experiment, each point performed in duplicate
with mean data obtained from at least three experiments (Table 2.1).
100








































































asmean±S.E.M.(ns3)Kjratioibetweenthv luewithMg2+pr tndco r ljt tis ica comparisonswerem dusi gat-t tbe weecontrold10MMgC^feachc mpou d.*:P<0.05.
showed a significant 2 fold increase in affinity with the exception of CGS21680
which increased more than 10 fold. Hill slopes were approximately 0.6 for all
agonists under both conditions.
Binding studies using the pH]DPCPX binding assay in the absence and
presence of 10 /jM Gpp(NH)p were examined. Figure 2.4 shows the inhibition
of [3HJDPCPX binding by DPCPX and CCPA in the absence and presence of
10 ijM Gpp(NH)p. Both antagonists and agonists exhibited the typical
adenosine A1 pharmacological profile for pH]DPCPX binding in the absence
and presence of 10 /vM Gpp(NH)p. For antagonists the rank order of potency
was. DPCPX > CGS15943 > CPT > DPX > 8-PT and for agonists was: CCPA
= CPA ;» R-PIA > CHA > NECA = CADO > CGS21680, with Kj values shown in
Table 2.2. Antagonist affinity was not significantly different in the presence of
Gpp(NH)p. Hill slopes were close to unity for all antagonists under both
conditions. Agonists showed a significant 5 fold decrease in affinity with the
exception of CADO which decreased more than 10 fold. Hill slopes appeared
to increase slightly in the presence of Gpp(NH)p but only attaining significance
for R-PIA.
As Gpp(NH)p was supplied as a sodium salt, it was possible that the
effects observed with Gpp(NH)p, were due to the presence of Na+ ions. NaCI
at concentrations up to 1 mM, did not affect [3H]DPCPX (0.1 nM) binding.
Addition of 10 /vM NaCI had no effect on the affinity of CCPA, in a study where
10 /vM Gpp(NH)p produced the expected decrease in affinity (data not shown).
The effect of 10 /jM Gpp(NH)p was also tested using two Fujisawa non-
xanthine antagonists to contrast with the xanthine antagonists shown in Table
2.2. FR129946 had a Kj of 1.10 ± 0.12 nM (nH=1.03 ±0.13) in the absence
and a Kj of 0.92 ± 0.17 nM (nH=1.06 ± 0.10) in the presence of 10
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Figure 2.4 The Effect of Gpp(NH)p on the inhibition
of [3H]DPCPX Binding by (a) DPCPX and (b) CCPA.
The data represent a typical experiment which was performed as
described in the text. Mean data was obtained from at least three
different experiments (Table 2.2).
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absence and a Kj of 0.18 ± 0.01 nM (nH=1.24 ± 0.06) in the presence of 10 jUM
Gpp(NH)p. Therefore the Fujisawa antagonists appeared to behave in a
similar manner to xanthine antagonists with Gpp(NH)p having no significant
effect on their affinity.
2.3.1.4. Effect of Gpp(NH)p on the Kinetic Parameters of
[3H]DPCPX Binding
For confirmation that addition of Gpp(NH)p produced no alteration in the
Kd of [3H]DPCPX, the kinetics of radioligand binding were studied in the
absence and presence of 10 jl/M Gpp(NH)p. A time course of [3H]DPCPX (0.1
nM) binding to rat cerebral cortex was carried out at 25°C, with equilibrium
attained by 20 min (Figure 2.5a), under both conditions. Curve fitting using non
linear regression gave an observed constant in the absence (Kobs)=0.141 ±
0.017 min-i (n=3) and presence (KObs)=0.152 ± 0.008 min-1 of 10
Gpp(NH)p, respectively.
Dissociation of [3H]DPCPX binding was carried out at equilibrium (after
incubation for 60 min) and initiated by the addition of 1 mM R-PIA. Dissociation
followed first order kinetics (Figure 2.5b), with a dissociation rate constant in
the absence (K-0^0.123 ± 0.012 min-1 and presence (K.-|)=0.132 ± 0.007 min-1
of 10 jivM Gpp(NH)p, respectively. Subsequent determination gave an
association rate constant in the absence of Gpp(NH)p of (K+1)=0.212 ± 0.051
min-1 m-1 and the resultant equilibrium dissociation constant (Kd)=0.652 ±
0.152 nM. In the presence of 10 /jM Gpp(NH)p the association rate constant
was (K+1)=0.239 ± 0.074 min-1 M-1 and the resultant equilibrium dissociation
constant (KD)=0.665 ±0.194 nM. As with data obtained in competition studies,
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Figure 2.5 Effect of Gpp(NH)p on the (a) Association and
(b) Dissociation of [3H]DPCPX (0.1 nM) Binding.
The data represent a typical experiment. Dissociation initiated by adding
1 mM R-PIA after a 60 min incubation. Each point performed in duplicate
with mean data obtained from three experiments (text for mean values).
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2.3.1.5. Two-Site Modelling of the Effects of Gpp(NH)p and
MgCb on [3H]DPCPX Binding to Rat Brain Membranes
For many GPCRs, including the adenosine A-i receptor, high and low
affinity states exist for agonist binding. The two states are supposed to reflect
receptors being coupled to and uncoupled from G proteins. Shallow Hill slopes
(nH~0.6) for agonist inhibition of [3H]DPCPX binding may be indicative of their
existence. The decrease in agonist affinity on addition of 10 pM Gpp(NH)p to
the [3H]DPCPX binding assay (Table 2.2) was investigated further. Increasing
amounts of Gpp(NH)p (1-100 j/M) were added to study the concentration
dependence of the effect. The agonists CCPA and R-PIA were examined
using 20 drug concentrations (3 concentrations per log cycle) to increase
accuracy when trying to fit a two site model. The concentration dependent
effect of Gpp(NH)p (1-100 ^M) on inhibition of [3H]DPCPX binding by CADO
was also examined due to the large decrease in the affinity of this agonist on
addition of 10 juM Gpp(NH)p (Table 2.2). For this compound, data were not
examined using the two site model as only 10 duplicate concentrations were
used. Table 2.3 shows the concentration dependent effect of Gpp(NH)p on the
affinity of the agonists CCPA, R-PIA and CADO in the [3H]DPCPX binding
assay when fitted to the one site logistic model. There was a significant
concentration dependent decrease in affinity in the presence of Gpp(NH)p for
all three agonists. This was accompanied by a small increase in the Hill slope
which attained significance for R-PIA. CADO behaved in a similar manner to
CCPA and R-PIA with an approximate 5 fold decrease in affinity in the
presence of 10 pM Gpp(NH)p, which is consistent with the data shown for
other agonists (Table 2.2). The decrease in agonist affinity seen in rat
membranes on addition of 100 pM Gpp(NH)p (Table 2.3) was similar to that for
human cortical membranes with the affinity of CCPA reduced from 47.6 ± 10.9
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Table 2.3 The Effect of Increasing Concentrations of Gpp(NH)p
on [3H]DPCPX Binding
Gpp(NH)p K; (nM) (nH) Ratio
CCPA Control 3.18 ±0.22 0.66 ±0.04 —
1 ijM 7.96 ± 1.92* 0.66 ±0.01 2.50
10 jl/M 15.3 ±1.07* 0.67 ±0.01 4.81
100 20.9 ±1.92* 0.71 ± 0.03 6.57
R-PIA Control 5.13 ±0.35 0.59 ±0.03 —
1 j/M 14.6 ± 1.16 * 0.69 ±0.03* 2.85
10/vM 28.4 ±3.67* 0.70 ± 0.02 * 5.54
100 [jM 43.6 ± 8.00 * 0.77 ± 0.03 * 8.50
CADO Control 27.4 ± 2.09 0.60 ± 0.04 —
1 /;M 73.5 ±3.30* 0.62 ± 0.03 2.68
10 146 ± 14.3 * 0.66 ± 0.05 5.33
100 /;M 279 ±31.2* 0.70 ± 0.01 10.2
Kj values and Hill slope (nH) determined for competition assays as
described in the methods. Data for CCPA, R-PIA and CADO were fitted
to a 1 site model as described in the methods. Values expressed as
mean ± S.E.M. (n^3). Ratio shown against control Kj. Statistical
comparisons were made using a t-test between control and each
concentration of Gpp(NH)p for each compound. *: P< 0.05.
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nM to 378 ± 36 nM (7.94 fold). The effect of increasing concentrations of
Gpp(NH)p on [3H]DPCPX binding to mouse and guinea pig cerebral cortical
membranes was examined only once (data not shown). The affinity of CCPA
and R-PIA in both species was reduced in a manner similar to that observed
for rat.
The data for CCPA and R-PIA were fitted to a two site hyperbolic model
(Figure 2.6) to determine how the addition of Gpp(NH)p resulted in a decrease
in agonist affinity. The two site model provided no significant improvement (P>
0.05) over the one site model when using a partial F test. The decrease in
agonist affinity on addition of Gpp(NH)p was apparently due to a decrease in
the proportion of the high affinity state labelled with no significant alteration in
the affinity of the agonists for the high or low affinity states (Table 2.4).
Data for CCPA and R-PIA in the presence of 10 mM MgC^ were fitted
to the two site hyperbolic model. The reduction in binding and greater variation
in the data meant the two site model provided no significant improvement (P>
0.05) over the one site model when using a partial Ftest. Despite this, the data
indicated magnesium increased the proportion of the high affinity state
labelled. For CCPA the proportion of the high affinity state labelled, increased
from the control level of 65% described in Table 2.4 to 74.3 ± 4.65 (n=3), with
Kj values of 0.88 ± 0.13 nM and 47.7 ± 9.69 nM for high and low affinity states
respectively. For R-PIA the proportion of the high affinity state was 75.2 ±2.18
(n=4), with Kj values of 1.81 ± 0.32 nM and 108.9 ± 24.7 nM for the high and
low affinity states respectively.
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Figure 2.6 The Effect of Gpp(NH)p on the Inhibition of
[3H]DPCPX Binding by (a) CCPA and (b) R-PIA.
The data represent a typical experiment, with mean data obtained
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2.3.2. [3H]CCPA Binding to Rat Cerebral Cortical Membranes
2.3.2.1. Time Course of [3H]CCPA Binding to Rat Cerebral
Cortical Membranes
A time course of pHJCCPA (0.2 nM) binding to rat cerebral cortical
membranes was carried out at 25°C, with equilibrium attained by 120 min
(Figure 2.7). In all other experiments, pHJCCPA (0.2 nM) binding to rat cortical
membranes was carried out at 25°C for 120 min, unless otherwise stated.
2.3.2.2. Concentration Dependence of [3H]CCPA Binding to Rat
Cerebral Cortical Membranes
Hot saturation analysis of pHJCCPA binding to rat cerebral cortical
membranes was carried out once using increasing concentrations of
pHJCCPA (Figure 2.8a). Curve fitting using a hyperbolic model gave an
equilibrium dissociation constant (KD) of 0.90 nM and a Bmax of 2.35 pmol mg-1
protein.
Competition binding studies using 0.2 nM PHJCCPA and increasing
concentrations of unlabelled CCPA (Figure 2.8b) gave a Kd of 0.47 ± 0.03 nM
(nH=0.95 ± 0.03) and a Bmax of 1.37 ± 0.14 pmol mg-1 protein (n=9), which is in
reasonable agreement with the data obtained from the hot saturation study.
2.3.2.3. Concentration Dependent Effect of MgCh & Gpp(NH)p
on [3H]CCPA Binding to Rat Cerebral Cortical Membranes
MgCl2 produced a significant concentration dependent increase in
PHJCCPA binding with a maximal increase of 72% at 1 mM MgCl2 (Figure




















































Figure 2.7 Time Course of [3H]CCPA Binding to
Rat Cerebral Cortical Membranes.
The data represent a typical experiment. Membranes were
incubated with 0.2 nM [3H]CCPA for various times at 25°C.
Experiments performed as described in text with mean data
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Figure 2.8 Concentration Dependence of [3H]CCPA
Binding to Rat Cerebral Cortical Membranes.
The results represent a single (a) hot saturation and a typical (b)
cold saturation experiment. For the cold saturation experiments
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Figure 2.9 Concentration Dependence of (a) Mg2+
and (b) Gpp(NH)p on [3H]CCPA Binding.
The data are the mean of three experiments. The statistical
comparisons were made using a one way anova followed by
a Dunnett's test between control and each dose. : P< 0.05.
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pH]CCPA binding, up to 85% at 1 mM Gpp(NH)p (Figure 2.9b). Further
studies to determine the effects on the affinity of adenosine receptor
antagonists and agonists were carried out in the absence or presence of 10
mM MgCI2 or 10 /;M Gpp(NFi)p, for direct comparisons with studies using
[3H]DPCPX.
2.3.2.4. Effect of MgCI2 and Gpp(NH)p on the Kd and Bmax of
[3H]CCPA Binding Sites
Parallel binding studies using 0.2 nM phl]CCPA and increasing
concentrations of unlabelled CCPA gave a KD of 0.52 ± 0.02 nM (nFI=1.03 ±
0.05) and a Bmax of 1.21 ± 0.01 pmol mg-1 protein (n=3) in the absence of 10
mM MgCI2 and a KD of 0.41 ± 0.04 nM (nH=1.01 ± 0.02) (significantly different,
P< 0.05, in a t-test) and a Bmax of 1.42 ± 0.04 pmol mg-1 protein (significantly
different, P< 0.05, in a t-test) in the presence of 10 mM MgCI2.
Parallel binding studies gave a Kd of 0.41 ± 0.04 nM (nH=0.86 ± 0.03)
and a Bmax of 1.31 ± 0.36 pmol mg-1 protein (n=3) in the absence of 10 pM
Gpp(NH)p and a KD of 0.98 ± 0.15 nM (nH=0.80 ±0.10) (significantly different,
P < 0.05, in a t-test) and Bmax of 0.66 ± 0.22 pmol mg-1 protein (significantly
different, P< 0.05, in a t-test) in the presence of 10 ^M Gpp(NH)p.
2.3.2.5. Effect of MgCfe and Gpp(NH)p on Adenosine
Antagonist and Agonist Receptor Pharmacology
The pharmacological profile of [3H]CCPA binding sites was examined in
the absence and presence of 10 mM MgCI2. Figure 2.10 shows inhibition of
[3FI]CCPA binding by DPCPX and CCPA in the absence and presence of 10
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Figure 2.10 The Effect of Mg2+ on the Inhibition of
[3H]CCPA Binding by (a) DPCPX and (b) CCPA.
The data represent a typical experiment, with mean data
obtained from at least three experiments (Table 2.5).
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pharmacological profile for [3H]CCPA binding sites, in the absence and
presence of 10 mM MgCI2. For antagonists the rank order of potency was:
DPCPX > CGS15943 > CPT > DPX > 8-PT and for agonists was: CCPA =
CPA s> R-PIA > CHA > NECA = CADO > CGS21680, with Kj values shown in
Table 2.5. Antagonist affinity was marginally lower in the presence of MgCI2,
although only attaining significance for 8-PT. Hill slopes were close to unity for
all antagonists under both conditions. Antagonist affinities were similar to
values obtained for [3H]DPCPX binding (Tables 2.1 & 2.2). Agonist affinity,
despite a similar rank order of potency, was 5-17 fold higher when compared
with [3HJDPCPX binding (Tables 2.1 & 2.2). Hill slopes for agonists were near
unity in [3H]CCPA binding studies, in contrast to data from [3H]DPCPX binding
(nH=0.6). On addition of MgCI2, agonists showed a significant 2 fold increase
in affinity, with the exception of CGS21680 which increased 10 fold. Hill slopes
were near unity for agonists in the presence of MgCI2.
Binding studies using the [3H]CCPA binding assay in the absence and
presence of 10 fjM Gpp(NH)p, were examined. Figure 2.11 shows inhibition of
[3H]CCPA binding by DPCPX and CCPA in the absence and presence of 10
[iM Gpp(NH)p. Both antagonists and agonists exhibited the typical adenosine
^ pharmacological profile for [3H]CCPA binding, in the absence and presence
of 10 Gpp(NH)p. For antagonists the rank order of potency was: DPCPX >
CGS15943 > CPT > DPX > 8-PT and for agonists was: CCPA = CPA s R-PIA
> CHA > NECA = CADO > CGS21680, with Kj values shown in Table 2.6.
Antagonist affinity was similar in the presence of Gpp(NH)p. Hill slopes were
close to unity for antagonists under both conditions. Agonists showed a
generally significant 2-5 fold decrease in affinity in the presence of Gpp(NH)p.
The majority of Hill slopes for agonists were close to unity in [3HJCCPA binding
studies, in contrast to data from [3H]DPCPX binding (nH=0.6).
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Figure 2.11 The Effect of Gpp(NH)p on the Inhibition
of [3H]CCPA Binding by (a) DPCPX and (b) CCPA.
The data represent a typical experiment, with mean data obtained
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2.3.2.6. Two-Site Modelling of the Effects of Gpp(NH)p and
MgCl2 on [3H]CCPA Binding to Rat Brain Membranes
The majority of Hill slopes observed for agonist inhibition of [3H]CCPA
binding were closer to unity than those observed in the [3H]DPCPX binding
assay. Under the conditions used, this may indicate that the agonist
radioligand [3H]CCPA predominantly labels the high affinity state rather than
both the high and low affinity states labelled by [3HJDPCPX. The decrease in
agonist affinity on addition of 10 /LyM Gpp(NH)p to the pHjCCPA binding assay
(Table 2.6) was investigated further. Increasing amounts of Gpp(NH)p (1-100
^M) were added to study the concentration dependence of this effect. The
agonists CCPA and R-PIA were examined using 20 drug concentrations (3
concentrations per log cycle) to increase accuracy when trying to fit a two site
model. With data fitted to a one site model the decrease in affinity on addition
of Gpp(NH)p was not significant, with little alteration in the Hill slope (Figure
2.12; Table 2.7). This concentration dependent reduction in agonist affinity by
Gpp(NH)p was more variable than that seen for [3H]DPCPX binding, with no
clear concentration dependence.
The data for inhibition of [3H]CCPA binding by CCPA and R-PIA was
fitted to a two site hyperbolic model. Under control conditions in the absence of
Gpp(NH)p, this provided no significant improvement over the one site model
(P > 0.05), when using a partial F test. Variation in the data made any
interpretation of the two site data impossible. The reduction in binding in the
presence of Gpp(NH)p made 2-site modelling impossible
The addition of 10 mM MgCh and the resultant increase in [3H]CCPA
binding did not make it possible to fit the data for CCPA and R-PIA to the two
site model. Again the two site model did not provide any significant
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Figure 2.12 The Effect of Gpp(NH)p on the inhibition
of [3H]CCPA Binding by (a) CCPA and (b) R-PIA.
The data represent a typical experiment, with mean data obtained
from three experiments (Table 2.7).
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Table 2.7 The Effect of Increasing Concentrations of
Gpp(NH)p on [3H]CCPA Binding
Gpp(NH)p Kj (nM) (nH) Ratio
CCPA Control 0.41 ±0.04 0.86 ±0.03
1 jUM 0.64 ±0.07 0.79 ±0.03 1.56
10 pM 0.98 ±0.15 0.80 ±0.09 2.39
100 0.80 ±0.10 0.78 ±0.03* 1.95
R-PIA Control 1.10 ±0.13 0.82 ±0.11
1 //M 1.96 ±0.53 0.81 ±0.09 1.78
10^M 4.57 ± 1.87 1.05 ± 0.22 4.15
100 juM 3.09 ±0.66 0.90 ±0.04 2.81
Kj values and Hill slope (nH) determined for competition assays as
described in the methods. Data for CCPA and R-PIA are fitted to a 1 site
model as described in the methods. Values expressed as the mean ±
S.E.M. (n^3). Ratio shown against control Kj. Statistical comparisons
were made using a t-test between control and each concentration of
Gpp(NH)p for each compound. *: P< 0.05.
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It would appear that under the conditions used [3H]CCPA predominantly
labels the high affinity state of the receptor. Further data in support of this
comes from competition studies using [3H]CCPA and [3H]DPCPX and their
respective unlabelled ligands. In parallel studies the Bmax for [3H]DPCPX was
2.09 ± 0.38 pmol mg-1 protein (n=3) and for [3H]CCPA, 1.21 ± 0.01 pmol mg-1
protein. The Bmax of [3HJCCPA is approximately 60% of pH]DPCPX. These
data are consistent with the proportion of receptors (65%) deemed to be in the
high affinity state under control conditions using [3H]DPCPX (Table 2.4). The
Kj value of CCPA for the high affinity state in the [3H]DPCPX binding assay at
approximately 1 nM (Table 2.4) is also very similar to the KD of pH]CCPA at
0.47 nM (Section 2.3.2.2.).
2.3.2.7. PH]CCPA Microcentrifugation Assay
Inhibition of pHJDPCPX binding by CCPA gave Kj values of 1.2 and
31.5 nM, for the high and low affinity states respectively (Table 2.4). As CCPA
can differentiate between both states we examined why we were unable to
detect the low affinity state in the [3H]CCPA binding assay, under the
conditions used. A microcentrifugation assay was used which allows the
separation of bound from free ligand at equilibrium, in an attempt to detect the
low affinity state of the receptor-ligand complex. This method should avoid the
problem of the low affinity state dissociating too rapidly to be detectable using
a filtration assay.
Inhibition of [3H]CCPA binding by CCPA using a microcentrifugation
assay gave a KD value of 0.84 ±0.12 nM, (nH=0.90 ± 0.03) (n=3). Addition of
10 /;M Gpp(NH)p was tested only once, with the level of [3HJCCPA binding
reduced by 80% and the affinity of CCPA reduced from 0.80 to 2.38 nM (2.98
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fold). These data were consistent with those obtained in the filtration assay for
the reduction in the level of binding (Figure 2.9) and the decrease in affinity of
CCPA (Table 2.7). As with the filtration assay, the low affinity state was not
detected under the conditions used.
Using the data generated for both [3H]DPCPX and [3H]CCPA binding
assays it is possible to try and theoretically model why the low affinity state for
CCPA was not measurable in the [3H]CCPA binding assay. Inhibition of
[3HJDPCPX binding by CCPA under control conditions (Table 2.4) gave 65% of
receptors in the high affinity state and 35% in the low affinity state, with
respective Kj values of 1.2 and 31.5 nM. Using the following equation;
Bt = Bi + B2 = ((Bmaxi x F) / (KD1 + F)) + ((Bmax2 x F) / (Km + F))
where Br is the total amount of receptors, Bi and B2 are the respective high
and low affinity components and F is the free ligand concentration. Then at the
pHjCCPA concentration used (0.2 nM) for the experiments, the amount bound
to the high and low affinity states at this concentration would be;
= ((65% x 0.2)/ (1.2 + 0.2)) + ((35% x 0.2)/(31.5+ 0.2)
= (9.29) + (0.221)
Therefore the relative proportion of high affinity receptors labelled at 0.2 nM
[3H]CCPA, would be 9.29 / (9.29 + 0.221) = 97.7%. Repeating the same
calculation with [3H]CCPA at ligand concentrations of 2 and 20 nM, decreases
the relative proportion of high affinity receptors to 95.1% and 81.9%
respectively. Detection of the low affinity state using 0.2 nM [3H]CCPA would
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therefore be highly unlikely.
These calculations may help explain why Gpp(NH)p has a smaller effect
on agonist affinity in the [3H]CCPA binding assay in comparison with the shift
seen for pHJDPCPX binding. The relative proportion of low affinity receptors
detectable using 0.2 nM pHJCCPA, on addition of Gpp(NH)p would remain
low. As the proportion of low affinity receptors is theoretically increased to
about 20% for 20 nM [3H]CCPA, it might be that sensitivity to Gpp(NH)p is
increased. We tested this once by comparing the effects of 10 Gpp(NH)p
on the affinity of CCPA using [3H]CCPA at 0.2 and 20 nM. Using 0.2 nM
pHJCCPA, 10 j/M Gpp(NH)p decreased the affinity of CCPA by 2.99 fold which
is consistent with the data on Table 2.7, whereas with 20 nM [3H]CCPA the
decrease in affinity for CCPA was 6.84 fold.
2.3.3. [3H]CGS21680 Binding to Rat Striatal Membranes
[3H]CGS21680 binding is carried out in the presence of 10 mM MgCl2
as described in Chapter 1 (see 1.2.3.3.), as binding is very difficult to measure
in the absence of MgCI2. The effects of Gpp(NH)p were therefore examined in
the presence of 10 mM MgCI2 unless otherwise stated. Striatal tissue is in
short supply, so only seven of the eleven compounds examined previously
were tested.
2.3.3.1. Concentration Dependent Effect of MgCI2 & Gpp(NH)p
on [3H]CGS21680 Binding to Rat Striatal Membranes
MgCI2 produced a significant concentration dependent increase in
[3H]CGS21680 binding reaching a maximum of 112% at 10 mM MgCI2 (Figure
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Figure 2.13 Concentration Dependence of (a) Mg2+ and
(b) Gpp(NH)p on [3H]CGS21680 Binding.
The data are the mean of three experiments. Statistical comparisons
were made using a one way anova followed by a Dunnett's test
between control and each dose. *: P< 0.05.
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pH]CGS21680 binding reaching 85% at 1 mM Gpp(NH)p (Figure 2.13b).
Further studies to determine the effects on the affinity of adenosine receptor
antagonists and agonists were carried out as described above.
2.3.3.2. Effect of MgCI2 and Gpp(NH)p on the Kp and Bmax of
[3H]CGS21680 Binding Sites
Parallel binding studies using 2 nM [3H]CGS21680 and increasing
concentrations of unlabelled CGS21680 in the presence of 10 mM MgCI2 gave
a Kd of 10.8 ± 0.93 nM (nH=0.83 ± 0.05) and a Bmax of 6.86 ± 0.08 pmol mg-1
protein (n=3) and in the absence of 10 mM MgCI2 a Kq of 53.4 ± 8.52 nM
(nH=0.77 ±0.16) with a Bmax of 7.13 ± 0.96 pmol mg-1 protein (Table 2.8).
In the same study, in the presence of both 10 mM MgCI2 and 10 fjM
Gpp(NH)p the Kq was 34.7 ± 4.05 nM (nH=0.86 ± 0.04) with a Bmax of 7.92 ±
0.73 pmol mg-1 protein (n=3). In the absence of MgCI2, but in the presence of
10 fjM Gpp(NH)p, the KD was 138 ± 49.3 nM (nH=0.95 ± 0.14) with a Bmax of
11.8 ± 3.26 pmol mg-1 protein (Table 2.8).
2.3.3.3. Effect of MgCI2 and Gpp(NH)p on Adenosine
Antagonist and Agonist Receptor Pharmacology
The pharmacological profile of [3H]CGS21680 binding sites was
examined in the absence and presence of 10 mM MgCI2. Figure 2.14 shows
inhibition of PH]CGS21680 binding by CGS15943 and CGS21680 in the
absence and presence of 10 mM MgCI2. Antagonists and agonists exhibited
the typical adenosine A2a pharmacological profile for [3H]CGS21680 binding in
the absence and presence of MgCI2. For antagonists the rank order of potency
was: CGS15943 > DPCPX and for agonists was: NECA s> CGS21680 > CADO
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Table 2.8 Comparison of the Effects of Mg2+ and Gpp(NH)p
on [3H]CGS21680 Binding to Rat Striatal Membranes
Kd (nM) Bmax
(pmol mg-1 protein)
6.86 ±0.08+ Mg2+(Control) 10.8 ±0.93
- Mg2+ 53.4 ± 8.52 7.13 ±0.96
+ Mg2+ + Gpp 34.7 ± 4.05*
-Mg2+ + Gpp 138 ±49.3
7.92 ±0.73
11.8 ±3.26
Kq and Bmax values determined from competition assays as described
in the methods. Data for CGS21680 fitted to a one site model as
described in the methods. Values expressed as the mean ± S.E.M.
(m>3). Statistical comparisons were made using a t-test between





Figure 2.14 Effect of Mg2+ on the inhibition of [3H]CGS21680
Binding by (a) CGS15943 and (b) CGS21680.
The data represent a typical experiment, with mean data obtained from at
least three different experiments (Table 2.9).
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> R-PIA > CCPA, with Kj values shown in Table 2.9. CGS15943 was
unaffected by the addition of MgCI2 while the affinity of DPCPX decreased. Hill
slopes were close to unity for antagonists under both conditions. Agonists
showed a significant increase in affinity from 2 to 4.5 fold on addition of MgCl2.
Hill slopes were approximately 0.8 for agonists under both conditions.
Binding studies using the pH]CGS21680 binding assay (all in the
presence of 10 mM MgCI2) in the absence and presence of 10 ijM Gpp(NH)p
were examined. Figure 2.15 shows inhibition of pH]CGS21680 binding by
CGS15943 and CGS21680 in the absence and presence of 10 /l/M Gpp(NH)p.
Both antagonists and agonists exhibited the typical adenosine A2a
pharmacological profile for pH]CGS21680 binding sites in the absence and
presence of 10 /l/M Gpp(NH)p. For antagonists the rank order of potency was:
CGS15943 > DPCPX and for agonists was: NECA CGS21680 > CADO >
R-PIA > CCPA, with Kj values shown in Table 2.10. The two antagonists had
similar affinities in the absence and presence of Gpp(NH)p, with Hill slopes
near unity under both conditions. Agonists showed a significant decrease in
affinity from 3.2 to 8.6 fold. Hill slopes were approximately 0.8 for agonists
under both conditions.
2.3.3.4. Two-Site Modelling of the Effects of Gpp(NH)p and
MgCfe on [3H]CGS21680 Binding to Rat Brain Membranes
Inhibition of [3H]CGS21680 binding by agonists is unusual in that the
Hill slope is approximately 0.8. Addition of 10 /yM Gpp(NH)p (Table 2.10)
decreases agonist affinity, without significant alteration in the Hill slope. To
establish whether two binding components exist, CGS21680 was tested over
an extended concentration range in the absence and presence of 10 mM
MgCI2 and 10 /vM Gpp(NH)p (Figure 2.16a). Removal of MgCI2 from the assay
132


















































Figure 2.15 Effect of Gpp(NH)p on Inhibition of [3H]CGS21680
Binding by (a) CGS15943 and (b) CGS21680.
The data represent a typical experiment, with mean data obtained from at
least three different experiments (Table 2.10).
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Figure 2.16 Comparison of the Effects of Mg2+ and Gpp(NH)p
on Inhibition of [3H]CGS21680 Binding by CGS21680.
The data are from the same experiment: graph (a) shows the shift in affinity
and (b) shows the effect of the conditions on the level of [3H]CGS21680
(0.2 nM) binding. The data represent a typical experiment, with mean data
obtained from three experiments (Table 2.11).
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caused a decrease in affinity of CGS21680 (Table 2.11). Gpp(NH)p caused a
similar decrease in affinity for CGS21680 in the absence and presence of 10
mM MgCI2 (Table 2.11). With the exception of standard conditions i.e. in the
presence of 10 mM MgCI2 and the absence of Gpp(NH)p, it was not possible
to fit these data to the 2-site hyperbolic model due to the large reduction seen
in [3H]CGS21680 binding on removal of MgCI2 or on addition of Gpp(NH)p
(Figure 2.16b). The data indicated the proportion of high affinity receptors was
83.9 ± 2.8% (n=3) with the affinity of the high and low states equal to 7.5 ±1.6
nM and 176 ± 132 nM, respectively. The large error in the low affinity
component necessitates further experimentation to determine whether this is in
fact real or an artifact of the modelling procedure.
The pHJDPCPX and [3H]CCPA binding assays are routinely carried out
in the absence of MgCI2 unlike the [3H]CGS21680 binding assay. Preliminary
investigations were performed to study the effects of Gpp(NH)p in the absence
of MgCI2 on [3H]CGS21680 binding. The concentration dependence of the
effect of Gpp(NH)p on [3H]CGS21680 binding in the absence of MgCI2 was
studied (Figure 2.17a), with the effects in the presence of MgCI2 shown for
comparison (Figure 2.17b). Gpp(NH)p reduced [3H]CGS21680 binding in a
concentration dependent manner in the absence and presence of MgCI2. The
larger errors in the absence of MgCI2 and the resultant lack of significance, is a
consequence of the 75% reduction in total binding and a reduction in specific
binding from 85 to 50% of total binding.
Gpp(NH)p appeared to shift the affinity of CGS21680 to an even lower
value in the absence of MgCI2 (Table 2.11). The concentration dependent
effect of Gpp(NH)p on agonist affinity was examined only once in the absence
and presence of MgCI2 for CCPA and NECA (Figures 2.18 and 2.19). As
shown in Table 2.12, there appears to be a concentration dependent reduction
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Table 2.11 Comparison of the Effects of Mg2+ and Gpp(NH)p
on [3H]CGS21680 Binding to Rat Striatal Membranes
Kd (nM) (nH) Ratio
CGS21680
+ Mg (Control) 10.8 ± 0.93 0.83 ± 0.05
+ Mg + Gpp 34.7 ±4.05* 0.86 ±0.04 3.21
- Mg





Kd values and Hill slope (nH) determined for competition assays as
described in the methods. Data for CGS21680 fitted to a one site model
as described in the methods. Values expressed as the mean ± S.E.M.
(n=3). Ratio shown against KD in absence of Gpp(NH)p. Statistical
comparisons were made using a t-test between control (+ Mg2+) and
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Figure 2.17 Concentration Dependence of Gpp(NH)p on
[3H]CGS21680 Binding in the (a) Absence and (b) Presence
of 10 mM MgCI2-
The data is the mean of three experiments. The statistical comparisons
were made using a one way anova followed by a Dunnett's test between






Figure 2.18 The Effect of Gpp(NH)p on the Inhibition of
[3H]CGS21680 Binding by (a) CCPA and (b) NECA in the
Presence of MgCI2.
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Figure 2.19 The Effect of Gpp(NH)p on the inhibition of
[3H]CGS21680 Binding by (a) CCPA and (b) NECA in the
Absence of MgCI2.
The data represent a single experiment (Table 2.12).
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Table 2.12 The Effect of Gpp(NH)p on PH]CGS21680 Binding
to Rat Striatal Membranes in the Absence and Presence of
MgCI2
Gpp(NH)p Ki (nM) (nH) Ratio
CCPA
+ 10 mM MgCI2 Control 313 0.68 —
1 /;M 875 0.67 2.80
10 1200 0.64 3.83
100 /vM 1550 1.04 4.95
No MgCI2 Control 2090 0.85 —
1 /;M 5030 0.83 2.41
10 jUM 1400 0.73 0.67
100 fjM 6410 0.48 3.07
NECA
+ 10 mM MgCI2 Control 5.66 0.77 ~
1 32.3 0.81 5.71
10/vM 41.9 0.71 7.40
100 /vM 60.0 0.81 10.6
No MgCI2 Control 46.7 0.66 —
1 /vM 25.0 1.75 0.54
10/vM 162 0.56 3.47
100/vM 30.7 1.49 0.66
Kj values and Hill slope (nH) determined for competition assays as
described in the methods. Data for CCPA and NECA are fitted to a one
site logistic model as described in the methods. Values are from one
experiment. Ratio shown against control Kj for each condition.
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in affinity for both drugs on addition of Gpp(NH)p in the presence of MgCI2;
however, in the absence of MgCI2 the effect is more difficult to interpret.
2.4. Discussion
In this chapter the effects of MgCI2 and Gpp(NH)p on the binding of
adenosine A-i and A2a antagonist and agonist radioligands have been
examined. As the effects observed were different for both agonists and
antagonists I will discuss each ligand separately. It has been generally agreed
that antagonists recognise the coupled and uncoupled form of the receptor
with equal affinity and that guanine nucleotides or their analogues have no
effect on antagonist binding (Stroher et al., 1989; Casado et a/., 1994). This
has not always been the case, with guanine nucleotides producing a wide
range of effects (see Introduction), including increasing the level of antagonist
binding in membranes (Yeung & Green, 1983; Klotz et al, 1990, 1991;
Freissmuth et al., 1991a; Casado et al., 1994) and in cloned rat brain A-i
receptors (Mahan et al., 1991). An effect of guanine nucleotides on antagonist
binding has been interpreted as supporting the existence of 'negative efficacy'
i.e. the concept that antagonists bind preferentially to uncoupled receptors
(Leung & Green, 1989; Leung et al., 1990; Freissmuth et al., 1991a; Schutz &
Freissmuth, 1992). For adenosine receptors, Reddington et al., (1989),
demonstrated that antagonists recognise both coupled and uncoupled forms of
the receptor and in the present study and others (Bruns et al., 1987; Lohse et
al., 1987; Klotz et al., 1990), competition by agonists for [3H]DPCPX binding,
clearly shows that the radioligand recognises both G protein coupled and
uncoupled receptors. That both states are recognised with equal affinity can
only be assumed with caution as Casado et al., (1994) demonstrated two
kinetic components for pH]DPCPX binding to membranes from pig brain by
143
decreasing the ionic strength of the medium. The concept of 'negative efficacy'
and the potential for 'inverse agonism' is the focus of current debate, with new
models proposed to account for the interaction between receptors and G
proteins (Bond etal., 1995; Black & Shankley, 1995; Leff, 1995, Milligan etal.,
1995). Although our data provide no direct evidence for the concept of inverse
agonism, [3H]DPCPX binding was significantly higher in the presence of
guanine nucleotides. The 20% increase in PHJDPCPX binding in the presence
of Gpp(NH)p, with no alteration in antagonist affinity is consistent with data
from other studies (Klotz et al., 1990; Prater et al., 1992; Casado et al., 1994;
Cohen et al., 1996), but contrasts with groups who observed an increase in
Bmax and a decrease in Kq (Stroher et al., 1989) or no effect (Klotz et al., 1986;
Leid et al., 1988; Stiles, 1988; Olah & Stiles, 1990). The magnitude of the
increase in binding is variable and appears to reflect species differences and
assay conditions (Lohse et al., 1984; Stiles, 1988; Klotz etal., 1990; Prater et
al., 1992; Parkinson & Fredholm, 1992; Casado et al., 1994; Nanoff et al.,
1995). We omitted Mg2+, as cations may counteract the effects of Gpp(NH)p.
Omission of a chelator in the assay could complicate interpretation of the
results, as endogenous cations may have played a role. Klotz et al., (1990)
noted that pretreatment of rat brain membranes with EDTA did not qualitatively
change the effects of guanine nucleotides on PH]DPCPX binding. It has been
suggested that guanine nucleotides increase antagonist radioligand binding by
decreasing the affinity of the receptor for adenosine trapped in vesicular
'cryptic' binding sites hidden from adenosine deaminase action (Prater et al.,
1992). If correct, the pore forming antibiotic alamethicin, which increased
pH]CGS21680 binding (Luthin et al., 1995), should increase [3H]DPCPX
binding as adenosine deaminase could access these 'cryptic pools'. However,
Lorenzen et al., (1996) found that alamethicin had no effect on [3H]DPCPX
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binding in rat brain membranes, which would indicate this cannot be the full
explanation. As the authors themselves noted, there was a pool of adenosine
resistant to detergent solubilisation, which could only be released by acetone
(Prater et at., 1992). Recently, Cohen et at., (1996), investigated the effects of
saponin (which can permeabilise both plasma membranes and intracellular
membrane vesicles) on pH]DPCPX binding. Their interpretation of the
increase in antagonist binding was that adenosine forms siowiy reversible and
pseudoirreversible receptor-G protein complexes, resistant to adenosine
deaminase and sensitive to guanine nucleotides. Guanine nucleotides would
increase the dissociation of adenosine and effectively generate an increase in
receptor sites which is detected as an increase in Bmax without changing
affinity (Cohen et at., 1996). It is possible that the 20% increase in binding
observed in this study was due to a small increase in the affinity of [3H]DPCPX
that was not detected. To obtain a 20% increase in binding the KD of the
antagonist would only have to increase from 0.25 nM to 0.19 nM. Whether the
increase in A-[ antagonist binding is due to one or a combination of the above
effects requires further clarification.
The addition of 10 /jM Gpp(NH)p to the [3H]DPCPX binding assay had
no effect on antagonist affinity, consistent with data from other A-i antagonist
radioligands (Goodman et at., 1982; Lohse et at., 1984). These data were
consistent with kinetic studies, with Gpp(NH)p producing no significant
alteration in association or dissociation rate constants. A similar observation
was made by Klotz et at., (1990).
The decrease in agonist affinity in the presence of Gpp(NH)p is
characteristic of all GPCRs (Gilman, 1987). The decrease in affinity of more
than 5 fold was similar to data in membranes (Goodman et at., 1982; Bruns et
at, 1987) and cloned receptors (Mahan et at., 1991). This effect was
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associated with an increase in Hill slope which attained significance for R-PIA.
The incomplete transition to one low affinity state for agonists in the presence
of guanine nucleotides is consistent with earlier data (Stroher et at, 1989;
Prater et at, 1992; Nanoff et at, 1995) and appears to reflect tight coupling of
the adenosine A-i receptor and its G protein (Stiles, 1985; Ramkumar & Stiles,
1988; Nanoff et at, 1995). These data contrast with earlier studies on
adenosine (Stiles, 1986, 1988; Leung et al., 1988; Klotz et ai., 1990; Gerwins
et at, 1990; Jockers et al., 1994) and other G protein coupled receptors
(Birnbaumer et al., 1990; Samama et at, 1993), in which a complete transition
to the low affinity state for agonists was observed. In whole cells, intracellular
GTP concentrations seem sufficient to produce a full shift (Gerwins et at,
1990). Incomplete transition to a low affinity state for agonists was also
observed for mouse, guinea pig (Mr K. Finlayson & Mr T. Maemoto,
unpublished observations) and human cortex, with an 8 fold decrease in the
affinity of CCPA on addition of 100 pM Gpp(NH)p in human cortical
membranes (see Chapter 1). This effect does not seem to be organ or species
specific (Stroher et at, 1989). The transfer between high and low affinity states
has been investigated using solubilised preparations in which the A-i receptor
retains its pharmacological properties (Stroher et at, 1989; Klotz et at, 1990;
Olah & Stiles, 1990; Oliveira et at, 1991; Prater et at, 1992). Stroher et at,
(1989) demonstrated that the affinity of the receptor for the G protein is
enhanced on solubilisation and that lower concentrations of guanine
nucleotides are required for conversion to a low affinity state. Recently, Nanoff
et at, (1995) identified a coupling co-factor in brain membranes responsible for
the incomplete transition from the high to low affinity state in rat and bovine
membranes. In contrast to our data, Nanoff and colleagues suggest that the
protein present in human membranes has lower affinity and does not block the
complete transition to a low affinity state. A significant increase in Hill slope
146
was observed for CCPA on addition of Gpp(NH)p to human cortical
membranes (0.52 to 0.78), however, the greater variability in binding data did
not permit 2-site modelling. Interestingly, Nanoff et a/., (1995) noted that
addition of the co-factor from human to rat or bovine membranes blocks the
transition from the high to low state. Concentration response curves to
Gpp(NH)p, indicate the decrease in agonist affinity is associated with a
decrease in the proportion of the high affinity state labelled, with no effect on
affinity for high or low states (Finlayson et al., 1994). The 30 fold difference in
affinity between the two states was similar in rat (20-45 fold, Bruns etal., 1987)
and bovine brain membranes (15-30 fold, Lohse et al., 1987). The proportion
and affinities of the high and low states are in good agreement with numerous
authors (Lohse et al., 1984; Klotz et al., 1986, 1991; Stroher et al., 1989;
Lorenzen et al., 1993, 1996) and are consistent with data from peripheral
tissues (Peachey et al., 1994) and cloned receptors (Mahan et al., 1991;
Freund et al., 1994) (Table 2.13). Although examined only once, the effect of
Gpp(NH)p was similar in mouse and guinea pig membranes (data not shown).
The reduction in agonist affinity observed in mouse and guinea pig
membranes was again due to a reduction in the proportion of the high affinity
state labelled, however further studies would be required to confirm this
observation. As Gpp(NH)p was supplied as the sodium salt and monovalent
cations modulate binding (Gilman, 1987; Birnbaumer et al., 1990), we
examined the concentration dependent effect of sodium ions on [3H]DPCPX
binding. At concentrations up to 1 mM, NaCI had no effect on the level of
binding or agonist affinity. These data are in agreement with those of
Goodman et al., (1982) and Casado et al., (1994), but contrast with data from
Stiles, (1988) and Leung et al., (1988) and with data from other GPCRs (Clark
& Hill, 1995). Our inability to detect any effect of this cation also contrasts with
the existence of a putative sodium binding site on the cloned adenosine A-i
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receptor (Palmer & Stiles, 1995).
The effects of MgCI2 on pHJDPCPX binding appear complex. The 40%
decrease in pH]DPCPX binding caused by 10 mM MgCI2 is accompanied by a
small decrease in Kd (0.35 to 0.42 nM). In accounting for a 40% decrease in
binding, the Kd of the antagonist would have to decrease from 0.35 nM to 0.65
nM. As such a shift in affinity should be detectable, other factors may be
involved. It has been argued that the effect of MgCI2 may be due to the
promotion of the high affinity state of the receptor, a state not preferred by the
antagonist (Parkinson & Fredholm, 1992; Casado etal., 1994). The increase in
agonist affinity and the proportion of the high affinity state labelled as shown
for CCPA (65.3% to 74.3%) (Table 2.14), may reflect increased receptor-G
protein coupling (Birnbaumer etal., 1990). This is also consistent with the Bmax
for pH]DPCPX in the presence of 10 mM MgCI2 being similar to the Bmax of
[3H]CCPA (Table 2.14), which almost exclusively labels the high affinity state
of the receptor (see below). The increase in affinity seen for agonists is
consistent with the modulatory role of Mg2+ on GPCRs (Gilman, 1987;
Bimbaumer et a!., 1990); however, it was not accompanied by an increase in
Hill slope. The data from the two site model indicate that the increase in affinity
is due to an increase in the proportion of high affinity states labelled with no
significant alteration in affinity of either state (Table 2.14). The 10% (74.3% to
65.1%) decrease in proportion of high affinity states labelled by [3H]DPCPX on
removal of MgCI2 (Table 2.14) is much smaller than that seen by Stroher eta!.,
(1989). This may reflect species differences or higher levels of endogenous
cations in our assay. MgCI2 had very little effect on antagonist affinity which is
consistent with other studies using A1 antagonist radioligands (Goodman et a/.,
1982).
The binding of [3H]CCPA to rat brain membranes was saturable, of high
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affinity and with equilibrium attained by 120 min. The KD (0.47 ± 0.03 nM) and
Bmax (1 -37 ± 0.14 pmol mg-i protein) values were similar in both saturation and
competition studies. These data are consistent with the original
characterisation of [3H]CCPA (Kd=0.2 nM and Bmax=0.86 pmol mg-i protein)
(Klotz et al., 1989) and with the Kd (0.43 nM) from cloned rat brain A1
receptors (Rivkees etal., 1995b). In contrast to [3H]DPCPX, MgCl2 produced a
concentration dependent increase in [3H]CCPA binding. This has been
observed for other A^ agonist radioligands such as [3HJCHA and [3H]R-PIA
and for other agonist ligands binding to GPCRs (Goodman et al., 1982; Klotz
et al., 1986; Gilman, 1987). In contrast, Traversa et al., (1994), saw no
increase in [3H]CHA binding on addition of 1 mM MgCl2. The increase in
[3H]CCPA binding on addition of MgCl2 appears to be due to a slight increase
in ligand affinity (0.52 to 0.41 nM) (Table 2.14). Agonists and antagonists
exhibited the typical adenosine A-i pharmacological profile, with agonist
affinities 5-17 fold higher than values obtained using [3H]DPCPX binding
(Table 2.15). The data for [3H]CCPA binding are consistent with Klotz et al.,
(1989) and other agonist radioligands (Table 2.15). Both agonists and
antagonists had Hill slopes not significantly different from unity, indicating the
existence of predominantly one affinity state. These data are similar to other
agonists radioligands like [3H]R-PIA (Lohse et al., 1984; Klotz et al., 1986;
Allende et at, 1991; Casado et al., 1990, 1991) and [3H]CHA (Yeung & Green,
1983). The KD of [3H]CCPA is similar to the high affinity (Kh) state identified for
CCPA inhibition of [3H]DPCPX binding (Table 2.14). On addition of MgCl2 to
the [3H]CCPA binding assay two site modelling was attempted and only one
high affinity site could be detected. The Bmax for [3H]CCPA in the absence and
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which is in excellent agreement with the proportion of high affinity receptors
identified using [3H]DPCPX (Table 2.14). These data for the two radioligands
are consistent with Klotz et al., (1991) and all point to [3H]CCPA almost
exclusively labelling the high affinity state identified in the [3HJDPCPX binding
assay.
Gpp(NH)p caused a concentration dependent decrease in [3HJCCPA
binding up to 85% at 1 mM Gpp(NH)p. A similar level of reduction has been
described for other A-i agonist radioligands in membranes (Goodman et al.,
1982; Lohse et al., 1984; Klotz et al., 1986; Leung et al., 1988; Freissmuth et
al., 1991b) and cloned receptors (Reppert et al., 1991). The level of reduction
probably reflects assay conditions and species differences in sensitivity to
guanine nucleotides (Lohse et al., 1984; Stiles, 1988; Wiener & Maayani,
1991). The 50% reduction in binding observed for CCPA is a consequence of
the 58% decrease in agonist affinity, rather than a decrease in the number of
binding sites (Table 2.14). This contrasts with Yeung & Green (1983), who
attributed the reduction in [3HJCHA binding by Gpp(NH)p to a decrease in
Bmax The decrease in agonist affinity on addition of Gpp(NH)p was less
pronounced than that observed for [3HJDPCPX binding, only achieving
significance for four agonists. This contrasts with Klotz et al., (1989) who noted
a large reduction in the affinity on addition of GTP, although levels vary
depending on what is compared. The lack of significance for some agonists
reflects the large reduction in [3HJCCPA binding seen in the presence of
Gpp(NH)p and greater variability in the data. As with [3H]DPCPX binding,
addition of Gpp(NH)p had very little effect on antagonist binding (Lohse et al.,
1984). Increasing concentrations of Gpp(NH)p reduced agonist affinities to
values similar to the high affinity state identified using [3H]DPCPX binding.
However, the reduction in binding and variability in the data meant no
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significance was obtained. The decrease in the Hill coefficient for CCPA on
addition of Gpp(NH)p would be expected if agonists were being shifted from a
predominantly high affinity state to a mixed high/low or low affinity state for the
receptor. These data are consistent with those of Lohse et al., (1984) for
[3H]R-PIA.
As with pHJCCPA, MgCl2 increased [3H]CGS21680 binding to rat
striatal membranes in a concentration dependent manner. The concentration
dependence and two fold increase in binding at 10 mM MgCI2 is similar to that
shown by Mazzoni et al., (1993). This contrasts with Jarvis et al., (1989a),
who, when originally characterising the radioligand showed 10 mM MgCI2
increased [3H]CGS21680 binding by 10%. Johansson et al., (1992), reported a
concentration dependent increase, greater than 10 fold at 10 mM MgCI2, in
both ligand binding and autoradiographic studies. These researchers
postulated that differences were due to the presence of a chelator in their
study. This may be a factor but it cannot totally explain the variations seen, as
Mazzoni et al., (1993) included a chelator throughout their studies and their
data was similar to the present study. The increase in specific binding can be
produced by assorted divalent cations, apparently acting at the level of the
receptor and not directly with the G protein (Johansson et al., 1992; Mazzoni et
al., 1993). The addition of 10 mM MgCI2 to the assay, produced a 4.9 fold
increase in the «□ of CGS21680 from 53.4 to 10.8 nM, almost identical to the
4.7 fold increase (37.5 to 7.9 nM) described by Mazzoni et al., (1993). They
did, however, report an increase in Bmax on addition of MgCI2, whereas we
noted no significant difference. The affinity of all agonists increased on addition
of 10 mM MgCI2. The effect being more pronounced for the A2a selective
compounds, CGS21680 and NECA. A similar effect is seen for other GPCRs
(Birnbaumer et al., 1990). The removal of MgCI2 from the assay and the shift
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to a low affinity state was associated with a slight increase in Hill slope,
although this only attained significance for CADO. Interestingly, for
antagonists, addition of MgCI2 produced a significant decrease in the affinity of
DPCPX which did not occur for CGS15943. The difference may be structural,
as CGS15943 is a non-xanthine antagonist (Jarvis et al., 1989a). However,
further investigations would be required to determine the significance of this
effect.
The effect of guanine nucleotides on [3H]CGS21680 binding was
generally investigated in the presence of 10 mM MgCI2 because binding was
almost undetectable in the absence. Gpp(NH)p produced a concentration
dependent decrease in binding reaching 85% at 1 mM Gpp(NH)p. These data
were similar to Mazzoni et al., (1993), using stable GTP and GDP analogues.
This reduction was greater than that described by Jarvis et al., (1989a) and
Johansson et al., (1992). The magnitude of the effect of guanine nucleotides
does appear very sensitive to cations (Mazzoni et al., 1993; Luthin et al.,
1995). In contrast, Nanoff & Stiles (1993), reported [3H]CGS21680 binding to
the bovine A2a receptor was insensitive to guanine nucleotides. The lack of
effect of guanine nucleotides on bovine A2a striatal binding had been described
previously using the A2a agonist [125|]PAPA-APEC (Barrington et al., 1990)
and was confirmed by Mazzoni et al., (1993). These results indicate that the
bovine A2a receptor is even more tightly coupled to a G protein than in rat
(Nanoff & Stiles, 1993). The addition of 10 pM Gpp(NH)p produced a 3.2 fold
decrease in the KD of CGS21680 from 10.8 to 34.7 nM. A similar decrease in
affinity with no alteration in Bmax was reported by other groups (Hide et al.,
1992; Mazzoni et al., 1993; Cunha et al., 1996). The addition of 10 /vM
Gpp(NH)p produced a significant decrease in affinity for all agonists tested,
being marginally smaller for CGS21680. The shift towards a low affinity state
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for agonists in the presence of Gpp(NH)p was even more pronounced on
removal of MgCI2 from the assay. The decrease in agonist affinity on addition
of Gpp(NH)p to the [3H]CGS21680 binding assay, was similar to the shift seen
for [3H]DPCPX binding but was larger than for [3H]CCPA binding. The affinity
of CCPA, R-PIA and NECA in the presence of Gpp(NH)p is similar to the low
affinity state observed with the A2a antagonists [3H]SCH58261 (Zocchi et al.,
1996) and [3H]KF17837S (Nonaka et al., 1994) (Table 1.9). The affinity of
CGS21680 is not as similar but this is probably a reflection of Gpp(NH)p
having a smaller effect. The shift towards the low affinity state, is not
accompanied by a significant increase in Hill slope. The low level of specific
binding in the presence of Gpp(NH)p and larger variations in data, make
accurate determination of Hill slopes more difficult. As with the other
radioligand binding assays, addition of Gpp(NH)p produced no significant
alteration in antagonist affinity. Since [3HJCGS21680 binding is strongly
influenced by both guanine nucleotides and Mg2+, we examined the
interdependence of these effects using a extended concentration range for
CGS21680. In the absence and presence of 10 mM MgCI2, addition of 10 /iM
Gpp(NH)p produced a similar 3 fold decrease in affinity for CGS21680. These
effects may therefore be independent of each other (Johansson et al., 1992).
In contrast, Mazzoni et al., (1993), showed no effect of stable GTP analogues
in the absence of MgCI2. The lack of a chelator in our assay and the presence
of residual divalent cations may account for these differences. In attempting to
model the interconversion between high and low affinity states, in the absence
and presence of both MgCI2 and Gpp(NH)p, we fitted the data to a 2-site
model, despite no significant improvement (P> 0.05) when assessed using a
partial Ftest. Only under control conditions when MgCI2 was present were we
able to generate any data, as removal of MgCI2 or addition of Gpp(NH)p
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significantly reduced binding. In the presence of 10 mM MgCI2, 82.3 ± 1.4% of
the receptors were in the high affinity state, with K| values of 7.5 ± 1.6 and 176
± 132 nM for the high and low affinity states respectively. These data, although
variable, appear consistent with those of Mazzoni et al., (1993) and Luthin et
al, (1995). The low affinity state appears different to the very low affinity state
described by Wan et al., (1990). The latter site probably reflects labelling of Ai
and possibly A2b receptors. The Kj value for the low affinity state appears to
correlate with the low affinity site labelled by antagonist radioligands (Nonaka
etal., 1994; Zocchi et al., 1996) (Table 1.9). It is also very similar to the affinity
of CGS21680 in the absence of MgCI2 and the presence of Gpp(NH)p. As
Gpp(NH)p appeared to shift the affinity for CGS21680 to a even lower value in
the absence of MgCI2, preliminary studies were performed to examine this
effect. Gpp(NH)p produced a similar concentration dependent decrease in
pH]CGS21680 binding in the absence of MgCI2. However, due to low levels of
binding and the reduction in specific binding, significance was only obtained at
the highest concentration of Gpp(NH)p. One study using CCPA and NECA,
showed that in the presence of MgCI2, Gpp(NH)p reduced the affinity of both
agonists in a concentration dependent manner, to values similar to that
determined by antagonist radioligands (Nonaka et al., 1994; Zocchi et al.,
1996) (Table 1.9). However in the absence of MgCI2, no consistent reduction
in affinity was seen and further studies would be required to examine this
effect. Contrasting results on the existence of this low affinity state have been
demonstrated for the antagonist radioligands, with Nonaka et al., (1994),
showing GTP produced a further shift to the right for CGS21680 (130 to 340
nM) and Zocchi etal., (1996), reporting no effect.
It is clear that the guanine nucleotide and magnesium dependence of
adenosine receptor binding is highly variable and dependent on the system
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and species used (Wiener & Maayani, 1991; Jockers et al., 1994). Whether
this is due to an atypically tight coupling of the receptor (Stiles, 1985; Nanoff &
Stiles, 1993), or perhaps factors like vesicle formation (Prater et al., 1992;
Luthin etal., 1995), pH (Askalan & Richardson, 1994) or temperature (Borea et
al., 1991; Luthin & Linden, 1995; Lorenzen et al., 1996) still requires to be
elucidated. The final identification of the 'coupling cofactor', (Nanoff et al.,
1995), or the use of saponins may help clarify the situation (Cohen et al.,
1996). The new selective adenosine A2a antagonist ligands (Nonaka et al.,
1994; Palmer et al., 1995; Zocchi et al., 1996), when commercially available,
will undoubtedly help in the further characterisation of the A2a receptor.
158
CHAPTER THREE
MEASUREMENT OF ADENOSINE RECEPTOR ANTAGONISTS
IN RAT BRAIN USING A MODIFIED RADIORECEPTOR ASSAY
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3.1. Introduction
Electrophysiological and functional evidence (Fredholm & Dunwiddie,
1988; Jacobson et al., 1992a; Suzuki et ai, 1993) have pointed to a
neuromodulator role for adenosine at pre- and postsynaptic adenosine Ai
receptors (Snyder, 1985; Williams, 1993). The inhibition by adenosine of LTP
and the release of several neurotransmitters is strong evidence for an
inhibitory neuromodulator role (Fredholm & Dunwiddie, 1988). These actions
of adenosine and the central stimulation produced by caffeine (Daly et al.,
1981; Jarvis & Williams, 1988), imply that selective and potent adenosine A-i
antagonists may be beneficial in enhancing cognition by enhancing synaptic
transmission (Jacobson et al., 1992a; Suzuki et al., 1993). Central stimulation
by adenosine A1 antagonists and the reversal of behavioural depression
induced by adenosine agonists (Nikodijevic et al., 1991), ensures a continuing
interest in the development of adenosine Ai antagonists (Peet et al, 1993;
Suzuki et al., 1993; Terai et al., 1995a). In attributing any beneficial effect to
adenosine Ai antagonists in behavioural models, it is essential to demonstrate
the presence of drugs in brain tissue, at concentrations sufficient to mediate
pharmacological effects. A number of different techniques have been used to
measure central penetration of drugs, including HPLC, ex vivo binding and
radioreceptor assays (Janis et al., 1983). HPLC is limited for use as a high
throughput assay capable of making quick and easy determinations, as
conditions need to be established for individual compounds and active
metabolites (Patel et al., 1994a). On the other hand, ex vivo binding and
radioreceptor assays are quick, simple and relatively easy to establish if
suitable radioligand binding assays are available. The principles behind ex vivo
binding and radioreceptor assays are similar to radioimmunoassays. They are
based on the fact that specific binding of a radioactive ligand to a receptor site
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is a quantitative function of the amount of unlabelled ligand present. In
essence, drugs which interact with receptors in situ can be detected after
tissue homogenisation and incubation in vitro (Burki, 1986). There are,
however, a number of major differences between the two assays. In ex vivo
binding assays the tissue in which the drug concentration is to be determined
must be capable of binding a suitable radioligand for the system under
investigation. A standard curve can be generated by conducting a binding
assay using control (i.e. untreated) tissue in the presence of known quantities
of ligand which interferes with radioligand binding to the receptor. The amount
of ligand in a drug treated tissue sample can then be estimated by determining
the level of binding in the treated sample and comparing this to the standard
curve. The method assumes that the tissue used from each animal has the
same density of receptors and ligand affinity for those receptors (Heffez et at,
1985). Radioreceptor assays avoid these problems by 'extraction' of the ligand
from the treated tissue. The ligand is then added as a 'competing drug' in a
conventional in vitro radioligand binding assay, where one standard source of
membranes is used. The amount of ligand can then be estimated by
determining the percent inhibition of binding and comparing this to an
appropriate standard curve generated by the addition of known quantities of
unlabelled ligand. The use of one standard source of membranes to determine
drug concentrations in treated samples should avoid variations in both affinity
and receptor density. The radioreceptor assay also allows the determination of
drug concentrations in tissues or preparations such as serum or plasma which
may contain no endogenous receptors for the system under investigation.
Unfortunately, neither radioreceptor or ex vivo binding assays are capable of
distinguishing between parent drug and pharmacologically active metabolites.
The use of both techniques is widespread, with ex vivo binding used to
determine the blood brain barrier (BBB) permeability of calcium antagonists
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(Heffez et al., 1985; Watson et a!., 1994), opioids (Richards & Sadee, 1985;
Barber et al, 1994), muscarinic agents (Sethy & Francis, 1988; Freedman et
at., 1989; Bymaster et al., 1993a, b), psychoactive drugs (Burki, 1986; Hyttel et
al., 1992), angiotensin antagonists (Marshall et al., 1993), histamine
antagonists (Taylor et al., 1992; Barnes et al., 1993), CCKB antagonists (Patel
et al., 1994a, b) and adenosine antagonists (Baumgold et al., 1992).
Radioreceptor assays have been used to measure a variety of substances
(reviewed in Enna, 1978; Gould et al., 1983; Janis et al., 1983), with y-
aminobutyric acid (GABA), the first neurotransmitter measured (Enna &
Snyder, 1976). For GABA, a water soluble compound, extraction from tissue
samples is by simple centrifugation (Enna, 1978). Unfortunately, adenosine
receptor antagonists show varying degrees of lipophilicity and therefore
centrifugation of tissue samples may not result in all the drug appearing in the
supernatant. To avoid developing separate extraction procedures for every
drug, we attempted to develop a procedure in which the drug is left intact in the
tissue sample and any other factors capable of interfering with binding are
eliminated. This allows drug concentrations present in tissue samples to be
assayed by simple addition to an in vitro radioligand binding assay.
Drug present in the vascular system of the brain may contaminate
tissue samples taken from brain (Patel et al., 1994a). We incorporated a
transcardiac perfusion step to minimise the presence of drug from the vascular
system of the brain. Transcardiac perfusions have been used in studies on
calcium antagonists (Heffez et al., 1985), muscarinic agents (Freedman et al.,
1989), angiotensin antagonists (Marshall et al., 1993), histamine antagonists
(Taylor et al., 1992; Barnes et al., 1993) and CCKB antagonists (Patel et al.,
1994a, b) but not when adenosine receptor antagonists were measured in
mouse brain using ex vivo binding (Baumgold et al., 1992). This chapter
describes the development and characterisation of a modified radioreceptor
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assay capable of measuring central penetration of adenosine receptor
antagonists in rat brain following intraperitoneal administration.
3.2. Methods and Materials
3.2.1. Ex vivo Binding
Rats were injected intraperitoneal^ (i.p.) with vehicle or appropriate
dose of DPCPX (0.01-1.0 mg kg-1). Animals were anaesthetised with 4%
halothane in oxygen and nitrous oxide (30:70 v:v). At 20 min the cortex was
immediately dissected and rolled on filter paper to remove superficial blood
vessels, weighed and homogenised in 9 vol. (v:w) of Tris-buffer using a teflon
glass homogeniser. Appropriate volumes were removed for experimentation
on fresh homogenate and samples were stored in microcentrifuge tubes in 1
ml aliquots at -20°C. Prior to use in the assay, brain homogenate was
incubated for 60 min at 37°C in the presence of ADA (6 u mM), to remove
endogenous adenosine (Baumgold etal., 1992).
pHJDPCPX ex vivo binding was carried out under equilibrium conditions
by preincubating 10 pi of DMSO or DPCPX and 840 pi of Tris-buffer with 100
pi of 1 nM pHJDPCPX for 2 min at 25°C. DPCPX was diluted in DMSO to give
10 duplicate concentrations. Total binding was determined in the presence of
DMSO and 10 pM R-PIA was used to determine non-specific binding. Addition
of brain homogenate (50 pi: 10 vol. (v:w)) to give a final volume of 1 ml,
initiated a 20 min incubation at 25°C. Bound and free ligand were separated
using a Brandel cell harvester and this was followed by 3 washes (3 ml) in ice
cold Tris-buffer over GF/B filters. Filter disks were transferred to scintillation
vials and incubated with 100 pi of 100% formic acid for 10 min prior to addition
of Emulsifier Safe scintillant (4 ml) and equilibrated overnight. Radioactivity
was determined using the Packard 2500TR scintillation counter, with samples
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counted for 4 min and results expressed as dpm per sample.
For ex vivo binding, pHJDPCPX standard curves were constructed by
incubating 50 pi of control brain homogenate (10 vol. (v:w)) from vehicle
treated rats, with increasing concentrations of DPCPX (0.003-100 nM) as
above. Estimation of the DPCPX concentration in each brain sample from
treated animals was done by determining total and non-specific binding for that
sample and comparing the level of specifically bound pHjDPCPX to the
standard curve. For each DPCPX dose given to treated animals, DPCPX
concentrations in brain were determined in duplicate using at least three
animals. Taking into account dilutions within the assay and assuming the drug
is freely distributed within the tissue and hence 1.05 g of brain tissue
corresponds to 1 ml, potential concentrations in the brain were calculated.
3.2.2. Radioreceptor Binding Assay
Standard and Modified PHJDPCPX Binding Assays
P2 synaptosomal membranes were prepared from rat cortical tissue as
described in Chapter 1 (see 1.2.1.1.), for use in the [3H]DPCPX binding
assays.
Rats were injected i.p. with vehicle or the appropriate dose of drug. At
various times post-injection and 2 min prior to the collection of tissue samples
animals were anaesthetised with 4% halothane in oxygen and nitrous oxide
(30:70 v:v). Venous blood (7 ml) was collected from the inferior vena cava, 1
min before removal of cortex; the blood was left to clot at 4°C overnight in
tubes containing glass beads and the resultant serum was stored in 200 pi
aliquots at -20°C (serum samples were subsequently diluted 10 fold in Tris-
buffer before any procedure, unless otherwise stated). Immediately prior to
removal of the cortex, animals received a transcardiac perfusion of saline for
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30 seconds (flow rate: 35 ml min-1), by inserting a needle through the left
ventricle and into the aorta, unless otherwise stated. After perfusion, the cortex
was immediately removed and the tissue homogenate prepared as described
for the ex vivo binding assay. In some experiments, tissue supernatant was
collected and tested, by centrifugation of brain homogenate samples at 17000
g for 20 min at 4°C.
The standard [3HJDPCPX binding assay was carried as described in
Chapter 1 (see 1.2.3.1.). Briefly, 10 pi of DMSO or test drug, 290 pi of Tris-
buffer, 100 pi of ADA (1 u mM) and 100 pi of 1 nM [3H]DPCPX were
preincubated for 2 min at 25°C. Test drugs were diluted in DMSO to give 10
duplicate concentrations. Total binding was determined in the presence of
DMSO and 10 pM R-PIA was used to determine non-specific binding. Addition
of P2 rat cortical membrane suspension (500 pi; 20-40 pg), which gave a final
volume of 1 ml, initiated a 20 min incubation at 25°C. Bound and free ligand
were separated using a Brandel cell harvester and this was followed by 3
washes (3 ml) in ice cold Tris-buffer over GF/B filters. Filter disks were
transferred to scintillation vials and the procedure followed as for ex vivo
binding.
The brain tissue from vehicle and drug treated animals contains
adenosine A-i receptors and hence has [3H]DPCPX binding capacity. This
pH]DPCPX binding capacity must be removed in order to determine the drug
concentration in brain homogenate. Complete denaturation of vehicle and drug
treated samples should remove this [3H]DPCPX binding capacity, allowing the
amount of drug present in treated samples to be determined in the standard
pHJDPCPX binding assay. A number of conditions were tested including
heating samples to 56°C for 60 min and sonication for 30 min. Removal of the
[3H]DPCPX binding capacity of the vehicle and drug treated brain
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homogenates was achieved by incubation of homogenates at 80°C for 15 min.
Although not strictly necessary for serum or tissue supernatant samples, which
should have no intrinsic binding, consistency was maintained by treating all
samples at 80°C. Drug stability at 80°C was checked by constructing two
[3H]DPCPX standard curves using washed P2 membranes over an appropriate
concentration range for each drug, with one set of drugs having been
preincubated at 80°C for 15 min in the presence of Tris-buffer. Following
treatment at 80°C, samples were left to cool on ice and then incubated for 60
min at 37°C in the presence of ADA (6 u mM) to remove endogenous
adenosine (Baumgold et al., 1992). pH]DPCPX binding in the presence of
denatured samples was carried out as described above for the standard
assay, by reducing the volume of buffer to 240 /yl and adding 50 pi of
denatured brain homogenate, serum or tissue supernatant. To increase
sensitivity, the volume of the assay was reduced to 0.5 ml, without altering the
amount of denatured sample added.
Two [3HJDPCPX standard curves using washed P2 membranes were
constructed for each drug over an appropriate concentration range in the
absence and presence of denatured control brain homogenate, serum or
tissue supernatant from vehicle treated rats as appropriate. The standard
curve for each drug which contained no denatured brain homogenate, serum
or tissue supernatant acted as an internal control to check that addition of
denatured samples from vehicle treated animals had no effect on drug affinity
or the level of specific binding. Estimation of drug concentrations in brain
homogenate, serum or tissue supernatant samples from treated animals was
calculated as for ex vivo binding by determining the total and non-specific
binding for that sample and comparing the percent of specifically bound
[3H]DPCPX for each sample with the appropriate standard curve. For each
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drug dose given to treated animals, drug concentrations in brain, serum and
tissue supernatant were determined in duplicate using at least three animals.
Taking into account dilutions within the assay and assuming the drug is freely
distributed within the tissue and hence 1.05 g of brain tissue corresponds to 1
ml, potential concentrations in the brain were calculated.
3.2.3. [14C]lnulin Tracer Study
[i4C]lnulin (2.6 mCi g-1; NEN) was used as a trace marker for blood
plasma in a method similar to Patel et al., (1994a). Rats were anaesthetised
with 4% halothane in oxygen and nitrous oxide (30:70 v:v) and placed in a
incubator on a heated blanket to maintain body temperature. PE50 catheters
were inserted into the femoral vein for p4C]inulin infusion and the ipsilateral
femoral artery for removal of blood samples. Animals were injected with 2.5
pCi of F4C]inulin in 600 pi of saline over a 30 sec period, followed by a 100 pi
flush with saline. At 3 min, blood samples were removed from the femoral
artery; for whole blood and plasma preparations, samples were collected in
pre-heparinised (10 u mM) Beckman microcentrifuge tubes and for serum
preparation, blood was collected in microcentrifuge tubes containing glass
beads. Plasma was obtained by centrifugation of blood at 10000 g for 2 min in
a Beckman microcentrifuge. For each animal duplicate (50 pi) aliquots of
whole blood and plasma sample were pipetted onto 1 cm glass fibre filter disks
and transferred to 20 ml glass scintillation vials. Hydrogen peroxide (200 pi)
was added dropwise, followed 30 min later by soluene (1 ml). Hionic Fluor
scintillant was added (20 ml) two hours later. Serum was prepared by leaving
blood samples overnight at 4°C, followed by centrifugation (10000 g, 2 min at
4°C), with 50 pi aliquots of serum added to small filter disks and treated as
above.
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At 4 min after p4C]inulin infusion, animals were perfused with saline via
the aorta for 15, 30 or 60 sec. The cortex was immediately dissected and a
tissue sample from either side of the brain (approximately, 100 mg) was
removed from each animal, placed in glass scintillation vials and tissue weight
determined. Following addition of soluene (1 ml), samples were incubated at
56°C for 120 min then left overnight at room temperature before addition of
Hionic Fluor scintillant (20 ml). Radioactivity in blood samples and brain tissue
was measured in a 2500TR Packard scintillation counter using automatic
quench correction, with samples counted for 10 min and results expressed as
dpm per sample.
3.2.4. In Vivo Distribution of the Radioligands [3H]DPCPX and
[3H]Flunitrazepam
The in vivo distribution in brain of [3H]DPCPX was assessed and
compared with [3H]flunitrazepam, a compound known to cross the BBB.
[3H]DPCPX (98.1 Ci mmoM; NEN) and [3H]flunitrazepam (84 Ci mmoM; NEN)
were diluted with their respective cold ligands and were given at doses known
to be pharmacologically active. Rats were anaesthetised with 4% halothane in
oxygen and nitrous oxide (30:70 v:v) and placed in a incubator on a heated
blanket to maintain body temperature. PE50 catheters were inserted into the
femoral vein and animals infused with 20 /vCi of [3H]DPCPX (0.25 mg kg-1) or
10 /7Ci of [3H]flunitrazepam (0.17 mg kg-t) in 500 /7l of saline over a 30 sec
period. At 20 and 60 min for [3H]DPCPX, and 20 min for [3H]flunitrazepam,
blood samples (7 ml) were removed from the inferior vena cava through
heparinised syringes and collected in heparinised (10 u mM) blood pots.
Duplicate (50 y\) aliquots of whole blood were added to 20 ml glass scintillation
vials. Hydrogen peroxide (200 /vl) was added dropwise, followed 30 min later
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by soluene (1 ml). Hionic Fluor scintillant (20 ml) was added two hours later.
After collection of blood samples, the brain was removed and seven
different brain regions (frontal cortex, rear cortex, hippocampus, striatum, brain
stem, midbrain and cerebellum) were immediately dissected and tissue
samples from each side of the brain (approximately, 30-200 mg per area) were
removed from each animal, placed in glass scintillation vials and tissue weight
determined. Following addition of soluene (1 ml), samples were incubated at
56°C for 120 min and left overnight at room temperature, before addition of
Hionic Fluor scintillant (20 ml). Radioactivity in blood and brain tissue was
measured in a 2500TR Packard scintillation counter using automatic quench
correction, with samples counted for 10 min and results expressed as dpm per
sample.
3.2.5. Data Analysis
For all competition experiments, the appropriate [3H]DPCPX standard
curves were constructed for test compounds, IC50 values were determined
using the iterative curve fitting programme Sigma plot and Kj values were
calculated (Cheng and Prusoff, 1973). Drug concentrations in samples from
treated animals were calculated as described in the methodology of each
assay. For each drug dose given to treated animals, drug concentrations in
brain, serum and tissue supernatant were determined in duplicate using at
least three animals and shown as a mean ± SE.M.
For the [i4C]inulin data, results were expressed as dpm g-1 brain tissue.
The amount of plasma in the brain (brain plasma) was determined at each
timepoint by dividing dpm g-1 (brain samples) by dpm (plasma samples).
Values for serum and whole blood were obtained in a similar manner to
plasma. Statistical analysis was conducted by a one-way analysis of variance
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(ANOVA) followed by a Dunnett's test.
For the [3HJDPCPX and [3H]flunitrazepam in vivo distribution studies,
results were expressed as percent injected dose per gram of brain tissue.
Values for each brain area were obtained from both halves of four animal
brains and expressed as a mean ± S.E.M. Using the specific activity of each
radioligand and the exact tissue weight, values were then expressed as a
potential concentration in brain tissue.
3.2.6. Statistical Analysis
Data in tables and text are shown as mean ± the standard error
(S.E.M.) for at least three separate experiments for Kj values and for three
animals or more for drug concentrations. Statistical analyses used were the
Students t-test, a one-way analysis of variance (ANOVA), a two-way anova
and a Dunnett's test (JMP and Sigma Stat).
3.2.7. Materials
Radioligands were purchased from New England Nuclear (NEN) and
adenosine deaminase (Type VIII) from Sigma. All FK and FR compounds were
synthesised by the Fujisawa Pharmaceutical Co. Ltd, as were KW3902
(FR144942), MDL102234 (FR160502) and Takeda (FR160492). Standard
adenosine agonists and antagonists were purchased from Research
Biochemicals Inc. (RBI). The vehicles in which drugs were dissolved for
intraperitoneal injection were Oil of Arachis (DPCPX, FR 144942, FR 160492,
FR 160502), cyclodextrin (DPSPX, 8-PST, DPX, OPT, 8-PT, FK838, FK453,
FR 160537, FR 171562) and saline (FK352, FR129946, FR182303, FR182394).
All other standard laboratory chemicals were from Sigma, Fisons and BDH and
were of the highest grade available.
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3.3. Results
3.3.1. Measurement of Adenosine Receptor Antagonists in Rat
Brain Using Ex Vivo Binding
A pilot study was conducted to assess if DPCPX, when given at
behaviourally relevant doses (i.e. doses known to produce a reversal of the
hypolocomotion induced by the adenosine agonist CPA, Dr H.M. Marston,
personal communication), could be measured in rat brain following i.p.
administration. Four groups of animals were given vehicle or DPCPX (0.01, 0.1
and 1.0 mg kg-1), the brain removed and the cortex dissected and
homogenised 20 min post-injection. In order to estimate DPCPX
concentrations in brain homogenate from treated animals, four [3H]DPCPX
standard inhibition curves using increasing concentrations of unlabelled
DPCPX and control brain homogenate from four separate vehicle treated
animals were constructed and results averaged to generate one standard
curve. DPCPX (0.01 mg kg-1) was not detectable in brain homogenate,
however, at the higher doses of 0.1 and 1.0 mg kg-1, brain concentrations were
69.7 ± 2.3 nM and 202.8 ± 10.7 nM respectively (Figure 3.1). The final
concentrations shown take into account the initial 10 fold dilution of the
homogenate and the 20 fold dilution in the assay; i.e. concentrations
determined from the standard curve are multiplied 200 fold. The use of this
crude cortical homogenate for generating standard curves, rather than P2
cortical synaptosomes, used in our standard pHjDPCPX binding assay
(Kd=0.33 ± 0.02 nM; Bmax=1-90 ± 0.08 pmol mg-1 protein), gave different
pharmacological parameters with a KD of 0.61 ± 0.01 nM and a Bmax of 2.32 ±
0.10 pmol mg-i protein. Since drug levels measured are dependent on the
affinity of the compound and the level of specific binding from standard curves,




0.01 mg 0.1 mg 1.0 mg
DPCPX (mg kg1)
Figure 3.1 DPCPX Concentration in Brain Tissue Measured
at 20 min After i.p. Injection by Ex Vivo Binding.
Drug concentrations for each dose are determined from the (a) standard
curve with (b) mean values ± S.E.M. for four animals shown.
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very difficult to modify this assay to allow the detection of samples which fall
below the detection limit of the assay. In an attempt to enhance sensitivity, to
avoid potential inter-animal variation and to be able to determine drug
concentrations in other tissues we developed a modified radioreceptor assay.
3.3.2. [14C]lnulin Tracer Study
Contamination of brain tissue by drug present in residual cerebral blood
may complicate determination of drug concentrations. A transcardiac perfusion
step can be used to reduce potential contamination. The efficiency of perfusion
and the minimum time required to remove maximal blood from brain
vasculature was assessed using [i4C]inulin, a non-penetrating marker for
blood plasma. Measurements of [14C]inulin were made for brain tissue, whole
blood, plasma and serum. In control (unflushed) rats, assuming radioactivity
present is due solely to the presence of residual blood within the CNS, the
blood content in brain was 21.5 ± 0.17 ^l g-i (n=3) (Figure 3.2). A maximal
reduction was seen after perfusion with saline for 30 sec, with the blood
content of brain significantly reduced to 8.15 ± 0.72 y\ g-i (n=3: P < 0.05).
Results for plasma and serum were almost identical, following a similar profile
to that of blood. The reason for the [14C]inulin content in whole blood per gram
of brain tissue being approximately double that of plasma and serum is
because of the cellular content of blood. The level of contamination of brain
tissue drug concentrations from drug present in residual cerebral blood would
therefore be in the order of 1-2% with this being reduced a further 62% by the
introduction of a transcardiac flush. In measuring the drug concentrations in
brain tissue of treated animals we assumed free penetration within tissues and
a specific gravity of 1.05 g mM. Based on the assumption of free penetration
within tissues, drug concentrations in blood would be equivalent to that of
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Time (sec)
Figure 3.2 Effect of Increasing Transcardiac Perfusion Time.
[14C]lnulin content in o plasma, Y serum and □ whole blood of rat
brain. Brain content calculated as described in methods. Results expressed
as mean ± S.E.M at each time point. Statistical comparisons made using a
Dunnett's test between non-perfused (time 0 s) and each time point, within
each group, *: P< 0.05.
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plasma and serum and as a consequence serum concentrations were routinely
determined for all treated animals. Subsequently all animals routinely received
a transcardiac flush unless otherwise stated.
3.3.3. Measurement of Adenosine Receptor Antagonists in Rat
Brain Using a Modified Radioreceptor Assay
Competition studies using the standard [3H]DPCPX binding assay and
rat brain P2 cortical membranes showed binding was to a single population of
receptors (nH=1), with a BmaX of 1.90 ± 0.08 pmol mg-1 protein and a Kp of
0.327 ± 0.024 nM. Kj values for DPCPX, DPSPX and 8-PST were consistent
with binding to the adenosine A-\ receptor (Table 3.1).
Addition of brain homogenate from vehicle and drug treated animals as
a 'competing drug' to the [3H]DPCPX binding assay is complicated as the
tissue also binds [3H]DPCPX. To remove the intrinsic binding capacity of this
brain homogenate, sonication for 30 min and treatment at 56°C for 60 min was
assessed. Neither treatment completely abolished the binding capacity of brain
homogenate (data not shown). However, incubation at 80°C for 15 min
completely abolished the specific [3H]DPCPX binding capacity of brain
homogenate. Treatment at 80°C did not, however, affect drug stability (Figure
3.3).
Addition of denatured control brain homogenate or serum from vehicle
treated animals to [3H]DPCPX standard curves using washed P2 membranes
did not alter the total amount of specific binding despite a 30% increase in non¬
specific binding for the brain homogenate (Figure 3.4), or the affinity of test
drugs, as shown for DPCPX (Table 3.1).
Known concentrations of DPCPX were added to denatured control brain
homogenate from vehicle treated animals. These samples were then added to
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Table 3.1. pH]DPCPX Receptor Pharmacology
K; (nM) (nH)
DPCPX 0.33 ± 0.02* 1.04 ±0.01
DPSPX 91.6 ±2.73 0.97 ±0.05
8-PST 1380± 86.5 0.94 ±0.06
DPCPX + control brain 0.35 ± 0.03 * (n=7) 0.96 ± 0.06
DPCPX + control serum 0.36 ± 0.02 * (n=10) 1.08 ± 0.03
Kj and Hill slope (nH) determined from competition experiments,
as described in the methods. Values expressed as mean ± S.E.M
(m>3). Kj values for DPCPX in the presence of denatured control
brain homogenate and serum from vehicle treated animals were
determined as for competition experiments. Numbers shown in
brackets are for direct comparisons with DPCPX alone. Not
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Figure 3.3 Effect of Treatment at 80°C on Adenosine Antagonists.
The data represent a typical experiment, each point performed in duplicate. Drugs
were treated in the presence of buffer for 15 min at 80°C with Kj values determined




Figure 3.4 Effect of Denatured Control (a) Brain Homogenate
and (b) Serum Samples on inhibition of [3H]DPCPX Binding.
The data represent a typical experiment, each point performed in duplicate
with mean data obtained from at least three experiments (Table 3.1).
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the pHJDPCPX binding assay to determine the detection limits for the assay.
Addition of DPCPX to denatured control brain homogenate at concentrations
causing < 10% or > 90% inhibition of [3H]DPCPX binding in the standard (1 ml)
assay were less reliable (Table 3.2). Brain and serum concentrations for drugs
were subsequently accepted for samples which gave between 10% and 90%
inhibition of [3H]DPCPX binding, giving a 100 fold concentration range over
which drug concentration can be reliably measured. For samples of DPCPX
treated control brain homogenate causing < 10% or > 90% inhibition of
pHJDPCPX binding, assay conditions were altered. For samples of DPCPX
treated control brain homogenate causing > 90% inhibition of [3H]DPCPX
binding, a simple 10 fold dilution of the homogenate with untreated control
brain homogenate could be used to accurately determine drug concentration
(Table 3.2). For samples causing < 10% inhibition, attempts were made to
increase sensitivity by (a) reducing the volume of the assay and by (b) adding
increased amounts of homogenate. Reducing the assay volume from 1 ml to
0.5 ml, without altering the amount of homogenate added was attempted. A
concentration of DPCPX (0.3 nM) which caused approximately 50% inhibition
was initially tried (Table 3.2). As the results of the 1 ml and 0.5 ml assays were
similar when compared directly, this would appear to be a valid way of
doubling the sensitivity of the assay (Table 3.2). An upper limit is reached on
adding increasing volumes of homogenate as anything above 70 /7l of 10 vol.
of brain homogenate blocks filtration. Alteration from GF-B to GF-C filters
provided no further improvement (data not shown). To overcome this problem,
brain homogenate with known concentrations of DPCPX added was
centrifuged and DPCPX concentration measured in tissue supernatant as
described for GABA (Enna, 1978). Detection of DPCPX in tissue supernatant
was possible at 0.3 and 1 nM, however, supernatant concentrations were only
41.6 and 30.9% of respective brain homogenate concentrations. DPCPX
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concentration in serum samples was determined in the same way as brain
homogenate. For serum samples which cause > 90% inhibition of [3H]DPCPX
binding, samples were diluted. For those causing < 10% inhibition of
PHJDPCPX binding, adding increased amounts of serum did not block
filtration. However, data indicate that unless serum samples receive a 5 fold
dilution before addition to the assay (hence a 100 fold final dilution) specific
binding is reduced (data not shown).
DPCPX (0.01-1.0 mg kg-1) was administered i.p. to two groups of
animals, with one group receiving a transcardiac perfusion with saline.
Standard [3H]DPCPX inhibition curves using washed P2 membranes were
constructed in the absence and presence of denatured control brain
homogenate or serum from vehicle treated rats using a range of DPCPX
concentrations (0.003-100 nM). The DPCPX concentration in samples of brain
homogenate and serum from drug treated animals were determined from the
appropriate standard curve and values multiplied by 200 fold to take into
account the dilutions of brain and serum in the assay. In both groups, there
was a dose dependent increase in DPCPX concentration measured in brain
and serum (Figure 3.5). For both groups, DPCPX concentrations in brain
tissue were measured using the ex vivo binding and radioreceptor assays
(Table 3.3). For flushed and unflushed rats (groups 1 & 2), DPCPX was
undetectable at 0.01 and 0.03 mg kg-1 using ex vivo binding (as in the pilot
study: see 3.3.1.), whereas using the radioreceptor assay DPCPX
concentrations were measurable at all five doses in brain tissue for both
groups (Table 3.3). In groups 1 (unflushed rats) and 2 (flushed rats), for
concentrations of DPCPX that were measurable in brain by both methods,
there was no significant difference between methods when assessed using a
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Figure 3.5 Dose Dependence of DPCPX Concentration in (a)
Brain and (b) Serum in Flushed and Unflushed Animals.
The data represent the mean ± S.E.M. of duplicate determinations from at
least three different animals for all concentrations. Concentrations were
determined as described in the methods at 20 min after i.p. injection.
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increase in DPCPX concentration for groups 1 (F(2,44)=165.4, P< 0.05) and 2
(F(2,26)=55.7, P< 0.05). Taking the radioreceptor assay and comparing flushed
and unflushed groups of animals there appears to be a reasonable overall
agreement in DPCPX concentrations in brain and serum (Table 3.3). Flowever,
DPCPX concentrations in brain are lower at 0.01 and 0.03 mg kg-i and higher
at 0.1 and 0.3 mg kg-i in the flushed group than the unflushed group. Higher
values in the flushed group would be unexpected as flushing should reduce
the overall brain concentration by either reducing the contribution from drug in
blood or possibly by reversing the blood-brain concentration gradient and
flushing drug out of the brain. A similar pattern to brain was also observed with
serum concentrations for the two groups of animals. As the brain to serum
ratios in the radioreceptor assay are quite similar in both flushed and unflushed
groups for DPCPX, any differences observed may be attributable to
differences between the groups rather than an effect of the flushing. The
possibility of drug being flushed out of the brain seems unlikely as DPCPX
concentrations in unflushed rats in group 2 at 1mg kg-1 were not significantly
different from flushed rats (in a t-test, P < 0.05) (Table 3.3). This was also
observed for FR129946, FR160537 and FR171562 (see 3.3.5. & Table 3.5).
Fresh and frozen brain and serum samples from treated animals gave similar
results (data not shown). All animals subsequently received a 30 sec
transcardiac perfusion with saline prior to the removal of cortex and the
radioreceptor assay was routinely used to measure brain homogenate and
serum concentrations of drugs.
Animals were given DPCPX (1 mg kg-i) to determine the DPCPX
concentration in brain homogenate and serum at various time points. There
was a time dependent decrease (Figure 3.6) in DPCPX concentration in brain
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Figure 3.6 Time Dependence of DPCPX (1 mg kg1)
Concentration in (a) Brain and (b) Serum.
The data represent the mean ± S.E.M. of duplicate determinations
from at least three different animals for each time point. The DPCPX
concentrations were determined as described in the methods.
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min and 47.1 min respectively.
The brain penetration of DPSPX and 8-PST, two adenosine receptor
antagonists reported not to cross the BBB, was tested to further validate the
assay. Standard [3H]DPCPX inhibition curves using washed P2 membranes
were constructed in the absence and presence of denatured control brain
homogenate or serum from vehicle treated rats using an appropriate
concentration range for DPSPX and 8-PST. Injection (i.p.) of DPSPX (5.6 mg
kg-1) and 8-PST (20 mg kg-t), gave serum concentrations of 56 ± 3 and 52
± 8.3 \iM respectively, when measured 20 min post-injection. Despite high
serum concentrations, neither drug was detectable in brain at this time point.
Estimated brain to serum ratios were calculated on the basis that samples of
brain homogenate containing DPSPX and 8-PST caused < 1% inhibition of
pH]DPCPX binding (Table 3.4).
3.3.4. In Vivo Distribution of [3H]DPCPX & [3H]Flunitrazepam
An independent assessment of DPCPX penetration into the CNS was
made by giving pHjDPCPX intravenously. [3H]Flunitrazepam, a compound
known to cross the BBB, was used as a positive control, with both compounds
measured in various brain regions. DPCPX (0.25 mg kg-1) and flunitrazepam
(0.17 mg kg-1) when given at pharmacologically active doses crossed the BBB
as shown for frontal cortex (Figure 3.7). DPCPX concentration decreased with
time in frontal cortex, however blood levels were not significantly different at
the two time points. A brain to blood ratio at 20 min of 0.18, is similar to values
for unflushed (0.25) and flushed (0.35) animals, at a comparable dose of 0.3
mg kg-1, determined using the radioreceptor assay (Table 3.3). The brain to
blood ratio of 0.08 at 60 min, is similar to that of 0.16 in the radioreceptor
assay (Figure 3.6), despite a four fold difference in dose. For flunitrazepam,
186
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Figure 3.7 [3H]DPCPX and [3H]Flunitrazepam Shown as Percent
of Injected Dose in Frontal Cortex (F.C) and Whole Blood.
Values are the mean ± S.E.M of duplicate tissue samples from four animals.
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the brain to blood ratio at 20 min was 1.06 with brain levels of this compound
being more than double DPCPX. Conversion of the data from % injected dose
per gram tissue to nanomolar, is shown for various brain regions and whole
blood (Figure 3.8). Each drug showed similar concentrations in all brain
regions tested, which decreased in a time dependent manner for DPCPX. The
DPCPX concentration in brain at the 20 min time point of approximately 140
nM is similar to that measured in the radioreceptor assay (126 nM: Table 3.3)
at 0.3 mg kg-T Also the DPCPX concentration in brain at the 60 min time point
of about 90 nM is similar to that measured in the radioreceptor assay of 110
nM (Figure 3.6), despite the four fold difference in dose. The percentage of
injected dose for flunitrazepam was approximately 2 fold higher in all brain
regions compared with DPCPX.
3.3.5. Adenosine Antagonist Concentrations in Rat Brain
Having characterised this modified radioreceptor assay, the
characteristics of the three lead Fujisawa antagonists, FR129946, FR160537
and FR171562 were examined. As stated above, all animals received a 30 sec
transcardiac perfusion prior to removal of the cortex. FR129946 (0.01-10 mg
kg-1), FR160537 (0.01-1.0 mg kg-1) and FR171562 (0.01-1.0 mg kg-1) were
administered i.p. to 3 groups of animals. These doses cover a range of doses
known to reverse CPA induced hypolocomotion for each individual drug (Dr
H.M. Marston, personal communication). All three drugs were examined at 1
mg kg-1 to determine drug concentrations in brain homogenate and serum at
various time points. Standard [3H]DPCPX inhibition curves, using washed P2
membranes, were constructed in the absence and presence of denatured
control brain homogenate and serum from vehicle treated rats, over an
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Figure 3.8 Concentration in Brain and Blood of DPCPX at
(a) 20 min and (b) 60 min and Flunitrazepam at (c) 20 min.
1-Frontal Cortex: 2-Rear Cortex: 3-Hippocampus: 4-Striatum: 5-Brain stem
6-Midbrain: 7-Cerebellum: 8-Whole brain and 10-Whole blood.
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alteration in affinity when incubated at 80°C, prior to determining Kj values
(data not shown). FR129946, FR160537 and FR171562 all showed a dose
dependent increase in concentration in brain and serum when measured 20
min after i.p. injection and a time dependent decrease (Figures 3.9, 3.10 and
3.11). Assuming the time dependent decrease is a first-order process t-i/2
values for time course studies were; 33.5 min and 26.8 min in brain and serum
respectively for FR129946, 54.1 min and 21.1 min in brain and serum
respectively for FR160537 and 94.9 min and 15.5 min in brain and serum
respectively for FR171562. These compare with t-i/2 values of 35.2 min and
47.1 min in brain and serum respectively for DPCPX. As with DPCPX, addition
of denatured control brain homogenate or serum from vehicle treated animals
produced no significant alteration in affinity (in a t-test, P < 0.05) of the three
Fujisawa compounds (Tables 3.5 & 3.6). Flushing had no significant effect on
any of these compounds when measured at 1 mg kg-1 in brain or serum
(Tables 3.5 & 3.6). As blood samples are collected before flushing no
difference in the serum results would have been expected. Brain
concentrations of FR160537 and FR171562 were similar to DPCPX, whereas
FR129946 was undetectable at 0.01 and 0.03 mg kg-1 and the concentration
determined at 0.1 mg kg-1 lower than that determined for the other three drugs
(Table 3.5). This is reflected in their ED50 values, i.e. the dose of drug which
inhibits 50% of [3H]DPCPX binding (Figure 3.12). DPCPX, FR 160537 and
FR 171562 all have similar in vitro affinities and ED50 values, whereas
FR 129946 has a 4-5 fold lower in vitro affinity and ED50. A similar effect was
observed for the in vivo dose response curves (data supplied by Dr H.M.
Marston), which follow a similar profile to the in vitro dose response curves,
with FR 129946 to the right of the other 3 compounds (Figure 3.13). Serum
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Figure 3.9 The (a) Dose and (b) Time Dependence of
FR129946 Concentration in Brain and Serum.
The data represent the mean ± S.E.M. of duplicate determinations
from at least three different animals for all concentrations and time
points. Concentrations were determined as described in the methods
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Figure 3.10 The (a) Dose and (b) Time Dependence of
FR160537 Concentration in Brain and Serum.
The data represent the mean ± S.E.M. of duplicate determinations
from at least three different animals for all concentrations and time
points. Concentrations were determined as described in the methods
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Figure 3.11 The (a) Dose and (b) Time Dependence of
FR171562 Concentration in Brain and Serum.
The data represent the mean ± S.E.M. of duplicate determinations
from at least three different animals for all concentrations and time
points. Concentrations were determined as described in the methods
at 20 min after i.p. injection in (a) and at various time points in (b).
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Figure 3.12 Estimation of the Dose of Drug Which Will Cause
50 Percent Inhibition (ED50) of [3H]DPCPX Binding.
The data was fitted to a one site logistic model and the ED50 determined. The
data represent the mean ± S.E.M. of duplicate determinations from at least
three different animals for each dose.
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Figure 3.13 Relationship between the ED50 in vitro and
the Reversal of the Behavioural Depression in vivo.
The values shown are the mean of duplicate determinations for at
least three animals at each dose. Data shown for o DPCPX, •
FR129946, V FR160537 and T FR171562. Solid lines are for
in vitro data and dashed lines are for in vivo data.
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FR129946, FR160537 and FR171562 (Table 3.6); for example, at 1 mg kg-1
the concentrations were 1370 nM, 111 nM, 310 nM and 448 nM respectively.
This is reflected in the variable brain to serum ratios (Table 3.7).
A range of adenosine antagonists known to reverse the behavioural
depression induced by CPA (Dr FI.M. Marston, personal communication),
were measured in brain and serum at behaviourally relevant doses, in order to
determine whether the antagonists could be detected in brain. All drugs were
given at a behaviourally equivalent equipotent dose, i.e. a dose known to
produce approximately 80% reversal of CPA-induced hypolocomotion. Six
standard xanthine antagonists, 8 Fujisawa antagonists and three adenosine
antagonists from other companies were tested (Table 3.8). Standard
PFI]DPCPX inhibition curves using washed P2 membranes were constructed in
the absence and presence of denatured control brain homogenate and serum
from vehicle treated rats over an appropriate concentration range for each
drug. All drugs showed no alteration in affinity when incubated at 80°C, prior to
determining Kj values (data not shown). The standard xanthine antagonists
DPCPX, DPX, CPT and 8-PT were all detectable in brain and serum and
showed similar brain to serum ratios. The two peripheral adenosine
antagonists DPSPX and 8-PST were not detectable in brain, despite
micromolar serum concentrations. The Fujisawa antagonists showed a
variable profile. Two drugs FK838 and FR182394, despite being given at
behaviourally active doses were not measurable in brain, at 20 min post-
injection. The other six Fujisawa compounds were detectable in both brain and
serum. Brain to serum ratios were similar for FK453, FR129946, FR160537
and FR171562, however FK352 and FR 182303 were substantially higher and
lower respectively. The three adenosine antagonists from other companies
were all detectable in brain but only MDL102234 was detectable in serum, with
a similar ratio (0.8) to the other xanthine antagonists. For the majority of drugs,
199



























Brain to serum ratios shown for each drug are from the data generated in
Tables 3.4 to 3.6. For DPCPX ratio shown for unflushed (U) and flushed
(F) preparations. (N.D. - not detectable within assay limitations). (N.T. - not
tested).
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brain concentrations were well in excess of their individual Kj values and would
appear to be sufficient to account for the observed behavioural effects (Table
3.9). The anomalies shown for FK838 and FR182394 were investigated
further. FK838 was given at a higher dose of 3 mg kg-1 and studied at both 10
and 20 min, whereas FR182394 was given at the same dose and tested at the
10 min time point. FK838 showed a dose dependent increase in serum levels
from 455 ± 91.4 nM (1 mg kg-1) to 4330 ± 594 nM (3 mg kg-1) at 20 min post-
injection and at 3 mg kg-1 showed a time dependent increase in serum levels
from 1880 ± 173 nM at 10 min to 4330 ± 594 nM at 20 min. Despite this,
FK838 (3 mg kg-1) was still below the limits of detection in brain at both time
points. FR182394, unlike FK838, had higher serum levels at 10 min (370 ±
47.3 nM) but was still below the limits of detection in brain at this time point.
The potential for an association between pharmacological and
behavioural data was investigated. There was a very poor correlation between
in vitro Kj and equipotent dose (Figure 3.14a), with a correlation coefficient,
r2=0.52. There was some association between brain and serum concentrations
at the equipotent dose with a correlation coefficient, r2=0.71 (Figure 3.14b).
There was no association between brain concentration and equipotent dose
(r2=0.41) (Figure 3.15a). There was however a better correlation between
serum concentration and equipotent dose (r2=0.70) (Figure 3.15b). There were
good correlations between brain (r2=0.81) and serum (r2=0.80) concentrations
at the equipotent dose and the in vitro Kj (Figure 3.16).
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Table 3.9 Relationship Between In Vitro Kj and Brain
Concentration at the Equipotent Behavioural Dose
Drug In Vitro Kj 10 x Kj Brain (nM) Brain/10
(nM) (nM) Ratio
DPCPX 0.33 ± 0.01 3.3 17.7 ± 2.0 5.36
DPSPX 91.6 ± 2.73 916 <238 --
8-PST 1380± 86.5 13800 <3580 ~
DPX 29.7 ± 2.47 297 1430± 190 4.81
CPT 8.08 ± 0.52 80.8 4060± 416 50.2
8-PT 44.2 ± 1.41 442 3420± 1130 7.74
FK838 5.62 ± 0.30 56.2 <146 ~
FK352 23.5 ± 0.56 235 3220± 487 13.7
FK453 0.53 ± 0.02 5.3 104 ± 12.2 19.6
FR129946 1.10 ± 0.05 11.0 487 ± 93.0 44.3
FR160537 0.22 ± 0.01 2.2 21.3 ± 2.33 9.68
FR171562 0.28 ± 0.01 2.8 85.6 ± 15.3 30.6
FR182303 4.10 ± 0.56 41.0 80.9 ± 40.7 1.97
FR182394 2.03 ± 0.34 20.3 <52.8 —
KW3902 0.16 ± 0.01 1.6 17.1 ± 2.01 10.7
Takeda 8.51 ± 0.96 85.1 1160± 76.2 13.6
MDL102234 7.68 ± 0.24 76.8 607 ± 52.8 7.90
Kj values were determined in the standard pH]DPCPX binding assay
(ns>3). At ten times the Kj concentration it can be calculated (in the absence
of agonist) that the drug would occupy 90.9% of the receptors. Drug
concentrations were measured in the [3H]DPCPX radioreceptor binding
assay for brain samples. Values expressed as mean ± S.E.M of duplicate
determinations for at least three different animals. The ratio is equivalent to
the concentration of drug in brain divided by the drug concentration
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Figure 3.14 Association Between (a) the Behaviourally
Equivalent Dose and In Vitro K; and (b) Brain and Serum
Concentrations Determined at that Dose.
Kj values determined as in methods (ns>3). Brain and serum concentrations
were determined using the radioreceptor assay. Each concentration is the
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Figure 3.15 Association Between the Behaviourally
Equivalent Dose and (a) Brain and (b) Serum
Concentrations Determined at that Dose.
Brain and serum concentrations determined using the radioreceptor































ttttT 11M m 11V l| TTTTJ




Figure 3.16 Association Between (a) Brain and (b) Serum
Concentration at the Behaviouraliy Equivalent Dose and
InVitro Kr
K| values determined as in methods (ns3). Brain and serum concentrations
were determined using the radioreceptor assay. Each concentration is the
mean of duplicate determinations from at least three animals.
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3.4. Discussion
Therapeutically useful CNS drugs must cross the BBB in sufficient
quantities to mediate a pharmacological effect. This chapter describes the
characterisation of a modified radioreceptor assay and an ex vivo binding
assay. These assays are capable of measuring brain concentrations of
adenosine receptor antagonists following i.p. drug administration. Ex vivo
binding assays use each animal as the source of drug and receptors which
could introduce potential inter-animal variation. This type of assay also
requires the tissue in which the drug concentration is to be measured to have a
sufficient level of binding to conduct the experiment. The radioreceptor assay
avoids the biological variation inherent in ex vivo binding assays, by using
brain homogenate from drug treated animals as a 'competing drug' in a
conventional in vitro radioligand binding assay. This method therefore allows
drug concentrations to be measured in serum which contains no endogenous
receptors. These techniques detect the presence, rather than the function, of a
particular compound in the brain. The final drug concentrations presented are
calculated from the concentration of drug detected in the binding assay for
brain homogenate and serum. These calculated values are an approximate
conversion, made assuming an equal distribution of drug through tissue. This
is unlikely, but in the absence of more detailed information on distribution, the
estimate provides a comparison between both methods. The drug
concentrations in brain homogenate probably reflect the minimum estimated
concentration if most of the drug is extracellular. This is because the
extracellular space represents approximately one seventh of the area in the
brain and hence the concentration of drug available to the receptors could be
higher.
A pilot study in which DPCPX concentration was estimated in brain
homogenate using ex vivo binding, indicated that at behaviourally relevant
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doses of DPCPX, drug was detectable in brain at 20 min post-injection.
However, the lack of flexibility in the ex vivo binding assay, the inability to
measure drug concentrations in other tissues and the potential for inter-animal
variation (Heffez et al., 1985; Jarvis & Williams, 1988; Florio et a!., 1994),
prompted the development of a modified radioreceptor assay.
Contamination of brain tissue from drug present in residual cerebral
blood may complicate determination of drug concentrations in both ex vivo
binding and radioreceptor assays. A transcardiac perfusion has been used by
a variety of groups to reduce the level of contribution from drug present in
blood (see Introduction). [i4C]lnulin, a non penetrating marker for blood
plasma, was used to examine the blood content of brain. Blood content of
brain was maximally reduced by 62% from 21.5 /vl g1 to 8.15 fj\ g-1, after
perfusion with saline for 30 sec. These data are consistent with other groups
(Patel et al., 1994a). Assuming free penetration within tissues and a specific
gravity of 1.05 g ml-1 this would mean the blood content of brain is reduced
from 2.26% to 0.86% after a 30 sec transcardiac flush with saline. This
indicates blood concentrations of drug would have to be 44.2 times higher than
brain tissue before flushing and 116.3 times higher than brain tissue after
flushing, before vascular contamination of brain homogenate samples could
account for the drug concentration measured.
In vitro competition binding studies using a standard [3HJDPCPX
binding assay have demonstrated that this ligand binds to a single population
of sites in rat brain that exhibit the pharmacological characteristics of the
adenosine A-i receptor (see Chapter 1; Finlayson et al., 1994; Maemoto et al.,
1994). To add brain homogenate from drug treated animals as a 'competing
drug' in the pHjDPCPX binding assay, we incorporated a denaturation step
(80°C, 15 min). This removed the inherent binding capacity of these samples,
without affecting the stability of any drug tested. Standard curves for
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pHJDPCPX binding using washed P2 membranes showed no alteration in
affinity for any antagonists tested, following addition of denatured control brain
homogenate or serum from vehicle treated animals. As expected, addition of
denatured control brain homogenate but not serum produced an increase in
non-specific binding with no effect on the amount of specific binding. The
portion of all standard curves which are most sensitive to changes in
concentration are the extremes. The range over which drug concentrations
have been determined for radioreceptor, ex vivo binding and
radioimmunoassays has varied. The portion of the standard curve used has
ranged between: 30-70% (Enna, 1978), 10-70% (Janis et al., 1983), 10-90%
(Freedman etal., 1989), 10-90% (Baumgold etal., 1992) and 20-80% (Patel et
al., 1994a). We added known amounts of DPCPX to control brain homogenate
and tested samples in the [3H]DPCPX binding assay. Estimation of drug
concentrations in samples which caused < 10% or > 90% inhibition of
pH]DPCPX binding were less reliable. Brain and serum concentrations for
drugs were subsequently determined for samples causing between 10 and
90% inhibition of [3H]DPCPX binding, giving a 100 fold concentration range
over which drug concentration could be determined. For DPCPX with an
IC5o=0.43 nM, the range would be between approximately 0.043 and 4.3 nM.
As brain homogenate and serum samples from drug treated animals are
diluted 200 fold during sample preparation and assay procedure, the minimum
detection limit for DPCPX would be approximately 8.6 nM. Assay conditions
can be slightly modified for values falling outside this range. For concentrations
below the detection limit, assay sensitivity can be increased by reducing assay
volume, or by increasing the amount of homogenate added (Enna, 1978).
Reducing the assay volume from 1 ml to 0.5 ml with no alteration in the volume
of brain homogenate added, gave similar answers, therefore doubling the
sensitivity of the assay. An upper limitation on addition of brain homogenate
209
was reached as volumes above 70 y\ of 10 vol. blocked filtration. To overcome
this limitation, drug treated brain homogenate was centrifuged and DPCPX
concentration determined in the tissue supernatant, as described for GABA
(Enna, 1978). GABA is water soluble and can be 'extracted' from brain tissue
by simple centrifugation. Adenosine antagonists show varying degrees of
lipophilicity, thereby complicating the procedure. This lipophilicity may be one
reason why concentrations of DPCPX in tissue supernatant were only
approximately 30 to 40% of their respective brain concentrations. The
differences in DPCPX concentration in brain homogenate and tissue
supernatant may just be methodological. As tissue supernatant was collected
from brain homogenate prior to denaturation, and as the homogenate did not
receive the 20 fold dilution it receives on addition to the assay, both factors
may result in some DPCPX not being released from the tissue. Further
experiments would be required to confirm these possibilities. For samples of
brain homogenate which caused > 90% inhibition of pHjDPCPX binding, a
simple 10 fold dilution in Tris-buffer prior to addition to the assay was an
accurate way of determining drug concentration.
For serum samples, DPCPX concentration was determined in the same
way as brain homogenate. Incubation of serum at 80°C before addition to the
assay was probably not necessary as addition of control serum (diluted 10 fold
before addition to the assay) from vehicle treated animals to the pH]DPCPX
binding assay (data not shown) had no effect on the level of [3HJDPCPX
binding. For serum samples which fall below the limit of detection, unlike brain
homogenate, there is no limit on the volume of serum which can be added.
However, results indicate that unless control serum receives an overall dilution
of 100 fold the level of pHJDPCPX binding is reduced. A similar observation
has been made for human serum (Janis et al., 1983).
DPCPX (0.01-1.0 mg kg-1) was administered i.p. to two groups of
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animals, one of which had received a transcardiac perfusion. In both groups
there was a dose dependent increase in DPCPX concentration in brain and
serum, with serum DPCPX consistently higher at all doses. The introduction of
the transcardiac perfusion step appeared to have very little overall effect on
the concentration of DPCPX in brain. This would not be unexpected for
DPCPX as any contribution from drug in the blood to brain homogenate
concentrations would be minimal at the brain to blood ratios measured.
DPCPX concentration in brain homogenate was determined using
radioreceptor and ex vivo binding assays, using the assay limitations
characterised for the radioreceptor assay. DPCPX was not detectable at the
two lowest doses in either group using ex vivo binding. For doses where
DPCPX was detectable, there was good consistency within each group
between the radioreceptor and ex vivo binding assays and good consistency
between both groups. For the radioreceptor assay, brain to serum ratios were
consistent in both groups. These data are similar to DPCPX concentrations in
mouse brain determined using ex vivo binding (Baumgold et al., 1992).
Convenient storage of drug treated samples is feasible, as fresh and frozen
brain and serum gave similar results.
DPCPX (1 mg kg-1) exhibited a time dependent decline in brain and
serum concentration from 20-180 min post injection, with t^ values of 35.2
and 47.1 min respectively. Similarly, DPCPX is still detectable in mouse brain
60 min after injection (Baumgold et al., 1992). The concentrations of DPCPX
relative to its Kj value at this dose are likely to be sufficient at each time point
(175 times the Kj at 180 min) to account for reversal of the behavioural
depression induced by CPA (Marston etal., 1994).
To confirm that the inhibition of [3H]DPCPX binding by brain
homogenate from DPCPX treated animals was due to drug present in brain
tissue, DPSPX and 8-PST, two peripheral adenosine receptor antagonists,
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were tested (Nikodijevic et al., 1991; Baumgold et al., 1992). Neither
compound was detectable in brain tissue despite micromolar concentrations in
serum and neither compound was capable of reversing the hypolocomotion
induced by CPA (Dr H. M. Marston, personal communication). These data are
consistent with those of mice for 8-PST (Baumgold et al., 1992). This indicates
BBB permeability is a prerequisite for detection in brain homogenates, a factor
reflected by a low brain to serum ratio for these two compounds. Confirmation
of the requirement to cross the BBB should be obtained in an ongoing study in
which DPSPX and 8-PST are being given directly into the brain (i.e.v.), in
attempting to reverse hypolocomotion induced by CPA.
DPCPX penetration into the brain was independently assessed by
measuring [3H]DPCPX concentrations in different brain regions following
intravenous administration. There was a time dependent decrease in
PHJDPCPX concentration in all brain areas measured between 20 to 60 min.
pH]DPCPX was distributed equally, throughout all brain regions measured.
pH]DPCPX concentration in each brain area was approximately 140 nM,
consistent with data from the radioreceptor assay of 126 nM at comparable
doses of 0.25 and 0.3 mg kg-1 respectively. Concentrations in all areas are
approximately 10 fold less than those measured in a similar study in rats
(Bisserbe et al., 1992). They demonstrated regional differences in distribution
within the brain, with brain stem levels half that of other brain regions (Bisserbe
et al., 1992). The similarities in the method make the differences difficult to
explain (Bisserbe etai, 1992).
With characterisation complete drug determinations were made in brain
and serum using the radioreceptor assay. FR129946, FR160537 and
FR171562, were examined over a range of doses known to reverse CPA
induced hypolocomotion (Dr H.M. Marston, personal communication). All three
drugs showed a dose dependent increase in brain and serum concentrations,
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20 min after i.p. injection and a time dependent decrease. Brain concentrations
of FR160537 and FR171562 were similar to DPCPX but FR129946 was
slightly lower at equivalent doses. As with DPCPX, the concentrations of all
three antagonists in brain tissue at each time point relative to their Kj values
are likely to be sufficient to account for reversal of behavioural depression
induced by CPA (Marston et al., 1994). At 1 mg kg-1, FR129946 has a similar
half life in brain tissue and serum. The similarity in half life may be due to the
compound being water soluble. FR129946 could have a beneficial profile with
serum concentrations consistently lower than brain tissue, thus minimising
potential peripheral effects. FR 160537 and FR 171562 are not water soluble
with both compounds cleared more slowly from the brain than from serum.
Factors inherent in the radioreceptor and ex vivo binding assays
complicate the exact determination of drug concentrations in brain tissue.
Comparisons between drugs are often made by calculating ED50 values, i.e
the dose of drug in tissue samples which inhibits 50% of radioligand binding
(Sethy & Francis, 1988; Patel et al., 1994a). Interestingly, the curves for the
inhibition of [3H]DPCPX binding and reversal of CPA induced hypolocomotion
had a similar profile, with FR 129946 clearly to the right of the other three
compounds.
A range of adenosine antagonists known to reverse the behavioural
depression induced by CPA were examined. Drugs were given at an
equipotent behavioural dose and brain and serum concentrations were
measured. Standard xanthines, DPCPX, DPX, CPT and 8-PT were all
detectable in brain and serum and had similar brain to blood ratios. All four
compounds were present in brain tissue at concentrations relative to their Kj
values (Table 3.9) that are likely to be sufficient to account for reversal of
behavioural depression induced by CPA (Marston et al., 1994). The peripheral
antagonists DPSPX and 8-PST when given at their highest soluble dose were
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undetectable in brain and had no behavioural effect. The Fujisawa antagonists
showed a far more variable profile. Six compounds were detectable in brain
and serum. Brain to blood ratios were similar for FK453, FR129946, FR160537
and FR171562. However, they are very different for FK352 and FR182303,
with the serum concentration for FK352 and the brain concentration for
FR182303 being close to the limits of detection. Both compounds were only
detectable in the 0.5 ml assay, where the detection limit is increased two fold.
Two drugs, FR182394 and FK838, despite being given at behaviourally active
doses, were not detectable in brain within the detection limits of the assay at
20 min post-injection. Brain concentrations of FR182394 when examined at 10
min post-injection still lay outside the limits of detection. FK838 was examined
at a higher dose and at different time points. At the higher dose (3 mg kg-i)
and at 20 min post-injection where serum levels were higher, FK838 was
detectable in brain tissue at approximately 80 nM. As these samples caused
less than 10% inhibition in the assay, and as serum concentrations of 4330 nM
could result in potential blood contamination of brain tissue equivalent to
approximately 40 nM (0.86% x 4330), no conclusions can be drawn. In light of
the behavioural activity of both compounds these results are difficult to explain
and further experiments are required. The three adenosine antagonists from
other companies were all detectable in brain but only MDL102234 was
detectable in serum. MDL102234 had a similar brain to blood ratio to the other
xanthine antagonists.
As drugs were given at equipotent behavioural doses, the association
between pharmacological and behavioural data was investigated. In
calculating correlation coefficients, compounds that were not measurable were
not included in the data analysis. There was a very poor correlation between
the Kj for drugs at the adenosine Ai receptor and the equipotent dose. An
association between these two variables would probably only exist if all
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compounds had similar pharmacokinetic profiles. There was some association
between brain and serum concentrations at the equipotent dose, which may
reflect that at the doses chosen BBB permeability is similar. There was no
association between brain concentration and the equipotent dose, which may
again reflect the differences in the pharmacokinetics of each compound and
their ability to cross the BBB. There was, however, a better correlation
between serum concentration and the equipotent dose, perhaps reflecting
differences in pharmacokinetics. There was a good correlation between the
brain concentration at the equipotent dose and the in vitro Kj of drugs for the
adenosine A-i receptor. The data between these two variables was best
described by the equation y=0.88-1.78 and a correlation coefficient (r2)=0.81.
The antilog of the intercept is equal to 0.017, indicating that the drugs are
present in brain at approximately 60 times their respective Kj values in order to
reverse this level of behavioural depression. These concentrations may be
sufficient to imply a direct association between receptor occupancy and
behavioural effect. It is interesting to note that despite structural similarities to
other xanthines, CPT not only reverses behavioural depression but also
produces hyperlocomotion in rats, an effect not seen with the other
compounds. A similar effect has been described in mice for CPT (Baumgold et
at, 1992). With CPT present at approximately 500 times its K| value for the
adenosine A-i receptor, the stimulation observed may be through a different
mechanism. It may also be that a critical concentration of drug in relation to its
Kj value for the adenosine A-j receptor must be reached before stimulation is
observed, as FR129946 which had the second highest ratio of 443 fold (Table
3.9) also produced some perceptible behavioural stimulation which did not
attain significance (Dr H.M. Marston, personal communication). The good
correlation between serum concentration at the equipotent dose and the in
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vitro Kj for drugs at the adenosine A-i receptor, is not unexpected as serum
and brain ratios have already been shown to be generally related.
In conclusion, we have developed a radioreceptor assay capable of
measuring the central penetration of adenosine A-i receptor antagonists
following i.p. administration. Quick, easy and reliable determinations can be
made to assess whether new Ai receptor antagonists cross the BBB, before
complex and time consuming behavioural experiments are undertaken. This
methodology could be applied to any receptor system and any tissue if a
suitable radioligand binding assay is available.
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CHAPTER FOUR




In attempting to develop an adenosine A-i antagonist as a potential
cognitive enhancer, one must consider the potential cardiotonic and diuretic
effects of such compounds (Jacobson et al., 1992a). A centrally selective
compound devoid of such activities would be of considerable importance in
conditions like Alzheimers disease, in which patients are predominantly elderly
and more susceptible to these side effects, especially if given long term.
Research into heart and kidney purinoreceptors is extensive and as a
consequence I will concentrate on kidney purinoreceptors. For cardiovascular
purinoreceptors recent reviews have been published (Olsson & Pearson, 1990;
Tucker & Linden, 1993).
In kidney, adenosine is an autocoid playing an important role in
regulating a variety of functions. These include renal blood flow, glomerular
filtration rate, renin secretion, tubuloglomerular feedback, tubular reabsorption
of water and sodium, sympathetic neurotransmitter release and erythropoeitin
secretion (Spielman & Arend, 1991). In conditions such as hypoxia, when ATP
is low and nephrogenic adenosine is increased, adenosine acts on the distal
tubule, inhibiting the transport actions of vasopressin, parathyroid hormone
and noradrenaline, reducing energy demand in the region (Spielman & Arend,
1991). Paradoxically, in the proximal tubule and cortical collecting ducts,
adenosine stimulates apical sodium phosphate (Coulson et al., 1991) and
basolateral sodium bicarbonate transporters (Takeda et al., 1993). Potential
effects in glomerulus (Freissmuth et al., 1987a; Toya et al., 1993), medulla
(Weber et al., 1990b; Burnatowska-Hledin & Spielman, 1991; Weaver &
Reppert, 1992) and collecting ducts (Spielman et al., 1992; Schwiebert et al.,
1992), imply adenosine receptors are widely distributed throughout the kidney,
as in brain. The overall effect of adenosine is antidiuretic, suggesting its ability
to lower glomerular filtration rate and stimulate reabsorption at proximal
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nephron sites, normally overwhelms decreases in distal reabsorptive transport
(Spielman & Arend, 1991; Suzuki et al., 1992). These effects of adenosine can
be changed by altering the route of administration (Yagil, 1993).
Conflicting evidence, on the subtype and location of renal adenosine
receptors, is probably in part caused by their low density in renal tissue
(Williams & Risley, 1980; Murphy & Snyder, 1980; Weber et al., 1990b; Gould
et al., 1995). Pharmacological classification of renal adenosine receptors is
heavily dependent upon adenyl cyclase studies, with radioligand binding
characterisation minimal (Spielman & Arend, 1991). Adenosine At and A2
receptors have been identified in the kidney of various species (Spielman &
Arend, 1991), with effects mediated through multiple effectors in the case of
the Ai receptor and unifocally for the A2 receptor (Spielman et al., 1992;
Coulson et al., 1996). In rat kidney, adenosine receptors have been
identified in medulla (Weber et al., 1990b), A2 receptors in crude membranes
(Wu & Churchill, 1985) and both At and A2 receptors in basolateral
membranes from cortex (Jakubowski et al., 1992). The pharmacological
characteristics of Ai and A2 receptor binding in rat kidney, although only very
weakly characterised, were similar to rat brain (Wu & Churchill, 1985; Brines et
al., 1990; Jakubowski et al., 1992). In contrast, Blanco et al., (1992) found no
evidence of Ai receptors in binding studies using brush border or basolateral
membranes from rat or pig kidney cortex, but did note specific binding with the
A2 agonist [3H]CGS21680. However, the binding characteristics were different
from classical striatal A2a receptors, with effects sensitive to both cholera and
pertussis toxin. Furthermore, a study in which the diuretic effects of adenosine
A-i antagonists were examined in rat showed a slightly different profile to
adenosine Ai binding in rat brain (Suzuki et al., 1992). Functional studies
using KW3902, a potent and selective Ai antagonist, revealed diuretic and
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renal protective effects in rat through a pertussis toxin insensitive mechanism
(Mizumoto et al., 1993). Adenosine A-i receptors have been identified in rabbit
glomeruli and characterised in a collecting tubule cell line (28A) and renal
medullary membranes (Freissmuth et al., 1987a; Spielman et al., 1992). The
gene for the adenosine Ai receptor has been cloned from a rabbit kidney
cDNA library and appears similar to the Ai clone from brain (Bhattacharya et
al., 1993). In human kidney, A-i receptors were identified in glomeruli and A2a
receptors in renal papilla (Woodcock et al., 1986; Toya et al., 1993). Species
differences in kidney adenosine receptor pharmacology and localisation have
been demonstrated using in vitro autoradiography. In human kidney, Ai
receptors were located in cortical tissue, in contrast to a medullary localisation
in guinea pig (Palacios et al., 1987). Long exposure times for pHJCHA, and
low receptor density, prompted the use of [125|]R-pia to examine A-i receptor
localisation in guinea pig and rat kidney (Brines & Forrest, 1987; Weber et al.,
1988). In both species adenosine A-\ receptors were localised in areas of the
medulla. Adenosine At receptor mRNA has also been localised to the medulla
of rat kidney using in situ hybridisation (Weaver & Reppert, 1992). This
contrasts with the histochemical localisation of ecto-5'-nucleotidase activity,
which was identified in brush border membranes but not medulla (Dawson et
al., 1989). A recent study using microdissected nephron segments has shown
adenosine receptor mRNA along the whole length of the nephron (Yamaguchi
et al., 1995).
The potential heterogeneous distribution of adenosine receptors in rat
kidney and the lack of pharmacological characterisation using radioligand
binding studies requires further investigation to determine if central and
peripheral adenosine Ai receptors are identical. [3H]DPCPX and
[3H]CGS21680 were used to investigate the properties of several rat kidney
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membrane preparations. These included crude (Wu & Churchill, 1985;
MacKinnon et al., 1993) and renal papillary membranes (Woodcock et al.,
1984). Despite autoradiographic evidence to the contrary (Palacios et al.,
1987; Weber et al., 1990b), functional studies indicate that adenosine acts on
sites located on the proximal tubule (cortex) (Mizumoto & Karasawa, 1993;
Nomura et al., 1995; Terai et al., 1995b). In view of these data, [3H]DPCPX
binding to a number of kidney cortical membrane preparations was also
examined. In the proximal tubule of rat kidney, the luminal surface is coated
with microvilli (brush border), whereas on the contraluminal side, plasma
membranes form the basal (basolateral) infoldings of the cell. Various
techniques have been used to isolate brush border and basolateral
membranes fractions from kidney proximal tubules (Heidrich et al., 1972).
Techniques have involved self orienting percoll gradients (Sacktor et al.,
1981), sucrose gradients (Kinsella et al., 1979) and magnesium precipitation
(Somogyi et al., 1994). Membranes from rat (Sacktor et al., 1981; Cox et al.,
1983; Somogyi et al., 1994), dog (Kinsella et al., 1979), pig (Lin et al., 1981)
and rabbit (Podevin & Podevin, 1983) kidney, have been used to investigate
transepithelial membrane transport, hormonal interactions, membrane enzyme
activities and membrane binding. Using the methods of Sacktor et al., (1981)
and Cox et al., (1983), basolateral and brush border membrane fractions were
prepared for use in [3H]DPCPX binding studies. Binding of [3H]RX821002, an
u2 adrenoreceptor antagonist (Langin et al., 1989) was also examined as a
positive control.
The distribution of adenosine A-\ receptors and A^ receptor mRNA in rat
kidney was also investigated using in vitro autoradiography with [3H]DPCPX
and by in situ hybridisation using a riboprobe specific for the rat adenosine A-i
receptor in a manner similar to Weaver & Reppert, (1992). These methods
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were used to examine whether adenosine A-i receptors and mRNA are present
in rat kidney in a highly localised manner, which may be undetectable in
membrane binding studies. As the distribution of adenosine Ai receptors in rat
brain is well characterised (Goodman & Snyder, 1982; Weber et at, 1990a),
brain tissue was included in both autoradiographic and in situ hybridisation
studies as a positive control.
4.2. Methods and Materials
4.2.1. Preparation of Rat Kidney Membranes
4.2.1.1. Method 1 (Mackinnon etal., 1993; Crude membrane fraction)
Rats were killed by cervical dislocation, kidneys excised, decapsulated
and homogenised in 25 vol. (v/w) of buffer (50 mM Tris-HCI, 5 mM
(ethylenedinitrilo)tetraacetic acid (EDTA), pH 8.0) at 4°C using a Polytron P 10
disruptor (20 sec). The homogenate was centrifuged at 48000 g in a Centrikon
T-2070 centrifuge for 15 min at 4°C. The supernatant was discarded, the pellet
resuspended in the original volume of homogenisation buffer and
recentrifuged. The pellet was washed twice by centrifugation in buffer (50 mM
Tris-HCI, 0.5 mM EDTA, pH 8.0). The final pellet was resuspended in 10 vol.
(v/w) of 50 mM Tris-HCI (pH 8.0) and stored at -20°C until use.
4.2.1.2. Method 2 (Wu and Churchill, 1985; Crude membrane fraction)
Rats were killed by cervical dislocation, kidneys excised, decapsulated
and homogenised in 15 vol. (v/w) of buffer (50 mM sodium phosphate buffer,
250 mM sucrose, pH 7.4) at 4°C using a Polytron P 10 disruptor for three 10
sec bursts. The homogenate was centrifuged at 1000 g for 10 min at 4°C in a
Beckman 2-21M/E centrifuge, and recentrifuged at 9000 g for 20 min at 4°C.
The resultant supernatant was centrifuged in a Centrikon T-2070 centrifuge at
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105000 g for 30 min at 4°C and the membrane containing pellet resuspended
and stored in 5 vol. (v/w) of 50 mM Tris-HCI (pH 7.4) at -20°C until use.
4.2.1.3. Method 3 (Cox et a!., 1983; Mixed basolateral and brush border
membrane fraction)
Rats were killed by cervical dislocation, kidneys excised and
decapsulated. The renal cortex was dissected on ice and homogenised in 10
vol. (v/w) of isolation medium (250 mM sucrose, 10 mM triethanolamine HCI,
0.1 mM phenylmethylsulphonyl fluoride (PMSF), pH 7.4), using a glass teflon
homogeniser. The homogenate was centrifuged at 700 g for 10 min at 4°C in a
Beckman 2-21M/E centrifuge, the pellet discarded and supernatant
recentrifuged as above. The pellet was discarded and the supernatant
centrifuged at 16000 g for 20 min at 4°C. The resultant supernatant was
collected and was subsequently used to homogenise the white fluffy top layer
of the pellet, using a loose fitting glass teflon homogeniser and recentrifuged
as above. The white fluffy top layer of the pellet was resuspended in 10 ml of
isolation medium and homogenised gently. A further 10 ml of isolation medium
was added before centrifugation as above. The resultant white fluffy top layer
of the pellet (crude basolateral and brush border membrane fraction) was
resuspended in 1 vol. (v/w) of 50 mM Tris-HCI (pH 7.4) and stored at -20°C
until use.
4.2.1.4. Method 4 (Sacktor et a/., 1981; Basolateral and brush border
membrane fraction)
Rats were killed by cervical dislocation, kidneys excised and placed in
ice cold sucrose buffer (250 mM sucrose, 10 mM Tris-HCI, 0.1 mM PMSF, pH
7.6). Kidneys were decapsulated, cortices removed and thoroughly minced in
20 vol. (v/w) of sucrose buffer using a glass teflon homogeniser, followed by
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three 30 sec bursts with a Polytron P 10 disruptor. The homogenate was
centrifuged at 2500 g for 15 min at 4°C in a Beckman 2-21M/E centrifuge and
the resultant supernatant was centrifuged at 24000 g for 20 min at 4°C. The
fluffy upper layer of the pellet was resuspended in 32.2 ml of sucrose buffer
and homogenised using a teflon glass homogeniser. 2.8 ml of 100% Percoll
was added to the crude plasma membranes and mixed vigorously, before
centrifugation in a Centrikon T-2070 centrifuge using a Beckman TH 641 swing
out rotor at 30000 g for 35 min at 4°C. The resultant Percoll gradient had three
layers with basolateral membranes in the middle layer and brush border
membranes on the bottom layer. Each layer was gently removed with a fine
tipped pasteur pipette and diluted in 4 vol. (v/v) of isolation medium containing
100 mM KCI, 100 mM mannitol and 5 mM Tris-Hepes (pH 7.2) before
centrifugation at 34000 g for 30 min at 4°C. The loose fluffy membrane pellet
was separated from the dense glassy Percoll pellet and centrifuged at 34000 g
as before. Membranes were resuspended in 5 vol. (v/w) of 5 mM Tris-Hepes
(pH 7.2) and stored at -20°C until use.
4.2.1.5. Method 5 (Woodcock et al., 1984; Rat renal papilla)
Rats were killed by cervical dislocation, kidneys excised, decapsulated,
washed in ice cold saline, hemisected and the white inner papilla removed.
The tissue was homogenised in 15 vol. (v/w) of sucrose buffer (250 mM
sucrose, 10 mM Tris-HCI, 10 mM MgS04, pH 7.4) at 4°C using a Polytron P 10
disruptor for two 5 sec bursts. The homogenate was centrifuged in a Centrikon
T-2070 centrifuge at 30000 g for 20 min at 4°C and the resulting pellet washed
once with sucrose buffer. The final pellet was resuspended in 5 vol. (v/w) of
sucrose buffer (pH 7.4) and stored at -20°C until use.
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4.2.2. HEK 293 Cell Culture and Membrane Preparation
HEK 293 cells (European Culture Collection) were grown in culture
medium (DMEM, 10% heat inactivated foetal calf serum (FCS), penicillin-
streptomycin (100 u mM) and glutamine (0.3 mg mM)) in a 37°C incubator
(95% 02/5% C02). All procedures were performed using aseptic tissue culture
techniques. On attaining confluence, cells were split by removal of culture
medium and gentle washing in 10 ml of phosphate buffered saline (PBS).
Trypsin (2 ml to a 170 cm2 flask) was added and mixed to remove cells from
the flask. 8 ml of culture medium was added (FCS inactivates the trypsin), and
2.5 ml aliquots were divided into 4 flasks. Each flask was made up to 30 ml in
culture medium. Approximately one week was required for the cells to regain
confluence and the procedure was then repeated.
On attaining confluence, cells were split by removal of culture medium
and gentle washing in 10 ml of PBS. 5 ml of PBS was added, the cells scraped
and centrifuged at 1000 g for 5 min, and the pellet stored at -70°C. On the day
of the assay the pellet was resuspended in 50 mM Tris-HCI (pH 7.4),
homogenised using a glass teflon homogeniser and left on ice for 10 min. The
homogenate was centrifuged at 50000 g for 20 min at 4°C, the pellet
resuspended in Tris-buffer and recentrifuged at 50000 g for 10 min at 4°C. The
final pellet was resuspended in Tris-buffer at the appropriate volume for the
assay.
4.2.3. [3H]DPCPX and [3H]CGS21680 Binding Assays
pHJDPCPX and [3H]CGS21680 binding assays were carried out as
described in chapter 1 (see 1.2.3.1 & 1.2.3.3), using kidney membranes rather
than brain tissue, with the following modifications. For [3H]DPCPX binding, 10
ij\ of DMSO or R-PIA, 290 /vl of Tris-buffer, 100 /yl of ADA (1u mM) and 100 /j\
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of either 1 or 10 nM [3H]DPCPX were preincubated for 2 min at 25°C. Total
binding was determined in the presence of 1% DMSO and 10 pM R-PIA was
used to determine non-specific binding. Addition of kidney membrane
suspension (500 pi; 40-2000 pg) to give a final volume of 1 ml, initiated a 120
min incubation at 25°C. Bound and free ligand were separated using a Brandel
cell harvester and this was followed by 3 washes (3 ml) in ice cold Tris-buffer
over GF/B filters. Filter disks were transferred to scintillation vials and
incubated with 100 pi of 100% formic acid for 10 min, prior to addition of
Emulsifier Safe scintillant (4 ml) and equilibrated overnight. Radioactivity was
determined using a Packard 2500TR scintillation counter with an efficiency of
approximately 50%, with samples counted for 4 min and data expressed as
dpm per sample.
PH]CGS21680 binding was carried out as described for [3H]DPCPX
using ligand concentrations of 2 and 20 nM, except that Tris-buffer contained
10 mM MgCl2 and 10 pM CADO was used to determine non-specific binding.
4.2.4. [3H]RX821002 Binding Assay
pH]RX821002 ([1,4-(6,7(n)-3H]benzo-dioxan-2-methoxy-2-yl)-2-
imidazoline) (60 Ci mmoM; Amersham) binding was carried out under
equilibrium conditions by preincubating 100 pi of test drug and 300 pi of buffer
(10 mM Tris-HCI, 0.5 mM MgCI2, pH 7.4) with 100 pi of 10 nM [3HJRX821002
for 2 min at 25°C. Test drugs were diluted in buffer to give 10 duplicate
concentrations. Total binding was determined in the presence of buffer and
100 pM adrenaline (ADR) was used to determine non-specific binding.
Addition of kidney membrane suspension (500 pi; 100-1000 pg) to give a final
volume of 1 ml, initiated a 60 min incubation at 25°C. Bound and free ligand
were separated using a Brandel cell harvester and this was followed by 3
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washes (3 ml) in ice cold buffer over GF/B filters. Filter disks were transferred
to scintillation vials and radioactivity determined as above.
4.2.5. [3HJDPCPX Binding To HEK 293 Ceil Membranes
pHJDPCPX binding to HEK 293 cell membranes was carried as
described for binding to rat kidney membranes with the following modifications.
The [3H]DPCPX concentration was increased to 5 nM (final 0.5 nM), HEK 293
membranes were added at 40-80 jug of protein per sample and the incubation
period was 30 min.
4.2.6. In VitroAutoradiography
4.2.6.1. Slide Preparation for In Vitro Autoradiography
Double frosted glass microscope slides for in vitro autoradiography
were cleaned in running tap water and oven dried at 60°C. A subbing solution
(10 g gelatin, 0.5 g chromic potassium sulphate in 1 I deionised water) was
heat stirred to a temperature of 60-70°C and filtered through Whatman 91 filter
paper. The solution was allowed to cool to below 40°C and racks containing
clean slides were dipped in the subbing solution. Slides were dried overnight at
60°C in a oven containing a tray of copper sulphate dessicant. The subbing
solution could be used to coat several batches of slides at once but was
discarded after use.
4.2.6.2. Preparation of Brain Sections for In Vitro
Autoradiography
For in vitro autoradiographic studies, rats were anaesthetised with 4%
halothane in oxygen and nitrous oxide (30:70 v:v). The neck was broken, the
head guillotined and the brain carefully removed and frozen in isopentane at
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-45°C (temperature was maintained by cooling in a dry ice / acetone mixture).
Brains were frozen onto orientating microtome chucks with Tissue Tek, dipped
in Lipshaw Embedding Matrix, sprayed with cryospray and equilibrated for 30
min at -20°C. Coronal sections (20 jum) were cut at the level of the ventral
hippocampus (Paxinos and Watson, 1982) on a Bright cryostat (-20°C) and
thaw mounted onto gelatin coated slides. 48 continuous sections were cut (2
sections per slide) and divided into four repeating groups of six slides for
receptor pharmacology. Sections were dried at room temperature and stored
at -70°C prior to use.
4.2.6.3. PH]DPCPX In Vitro Autoradiographic Studies
A pilot experiment based on previous studies (Weber et al., 1990a) was
conducted to establish optimum incubation and washing conditions for
PH]DPCPX autoradiography. The assay buffer used was as described for
membrane binding experiments (50 mM Tris-HCI, pH 7.4), whereas the
incubation time was extended to 90 min and the final [3H]DPCPX
concentration increased 10 fold to 1 nM.
For in vitro autoradiographic studies on the inhibition of [3H]DPCPX
binding by adenosine A-\ antagonists, tissue sections were removed from the
freezer and left at room temperature for 60 min. All autoradiographic
procedures were at room temperature unless otherwise stated. Sections were
incubated in Coplin jars for 90 min in 50 ml of Tris-buffer containing test drug,
[3H]DPCPX (1 nM) and ADA (1 u mM). Unlabelled DPCPX and FR129946
were used as competing drugs and non-specific binding was determined in the
presence of 10 /yM R-PIA. Following incubation, sections were washed 4 times
(30 sec) in separate beakers containing Tris-buffer, dipped in distilled water,
blotted, the excess liquid carefully removed under vacuum with a fine tipped
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pasteur pipette and dried under a hot stream of air. For autoradiographical
analysis, sections were apposed together with tritium standards to [3H]-
sensitive Hyperfilm in X-ray cassettes for 10 weeks at -70°C.
Cassettes were left at room temperature for 60 min before removal of
the [3H]-Hyperfilm and development in a darkroom. Films were bathed in
Kodak D19 developer (diluted 5 fold in tap water) for 4 min, dipped in water
before two 4 min washes in Kodak fixative (diluted 4 fold in tap water) and
finally dipped in water containing detergent (0.1%). Films were then rinsed
under cold running tap water for 30 min and dried in a cabinet at 30°C. Films
were then covered and stored at room temperature prior to analysis.
Autoradiograms were analysed using a computer based image analyser
(MCID, Imaging Research Inc.). After background subtraction by a matrix
shading correction facility, optical density (O.D.) values were converted to
binding density (fmol mg-1 tissue equivalent) using tritium standards
(pH]Microscales) and the specific activity of the radioligand. Standard curves
were calculated as O.D. versus radioactivity in moles per unit area (mm2).
O.D. measurements of each brain area were performed by selecting a
measuring box of appropriate dimension, overlaying the structure in a total
binding section and measuring the optical density of that area four times for
both sections on each slide. Once measurements in a particular section were
complete, the O.D. in corresponding structures treated with different competing
drug concentrations were measured in the same way. Specific O.D. was then
determined by automatic subtraction of non-specific from the respective totals.
IC50 values for each region in the case of competition experiments were
determined as for radioligand binding studies using a one site logistic model.
Areas assessed were entorhinal, deep and superficial cortex and hippocampal
CA1, CA3 and dentate gyrus.
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4.2.7. In Situ Hybridisation
4.2.7.1. Riboprobe Preparation and Labelling
The plasmid pAR1639 (Figure 4.1), which contained the coding region
for the rat adenosine At receptor cDNA was supplied by the Fujisawa
Pharmaceutical Co. Ltd. The plasmid (700 ng pl-t) was in 10 pi of TE buffer
(10 mM Tris-HCI, 1 mM EDTA, pH 8.0) and was constructed with pUC18
vector. The rat adenosine At receptor cDNA was amplified by the Polymerase
Chain Reaction (PCR) and contained the full size open reading frame of the
adenosine Ai receptor but not the 5' and 3' non-coding regions. Plasmid
pAR 1639 is relatively stable at 4°C but should be stored for longer periods at
-20°C. Plasmid pAR1639 contained no RNA promoter sequences necessary
for the production of a riboprobe so the insert containing the rat adenosine At
receptor cDNA had to be removed and cloned into a different plasmid. A
general outline of the overall in situ hybridisation procedure is shown in Figure
4.2.
4.2.7.2. Electrical Transformation (Eiectroporation) and
Cultivation
Plasmid pAR1639 was washed with 25 pi of TE buffer into a 500 pi
microcentrifuge tube giving a plasmid solution of approximately 200 ng pM and
stored at 4°C. 1 pi of plasmid solution was added to 50 pi of Gibco
electrocompetent DH10B E. coli and kept on ice. The mixture was
electroporated (BioRad Gene Pulser) for 10 sec at 2.5 kV for incorporation of
the plasmid into E. coli, followed by immediate addition of 800 pi of SOC
medium (2% tryptone, 0.5% yeast extract, 10 mM NaCI, 2.5 mM KCI, 10 mM
MgCl2 and 20 mM glucose). The mixture was decanted into a 15 ml tube and
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allowing the DNA to diffuse into the cell interior where it is replicated alongside
the bacterial chromosomal DNA). The mixture was then incubated at 37°C for
60 min in a shaking incubator (225 rpm).
LB (Luria-Bertani) medium (1% tryptone, 0.5% yeast extract, 1% NaCI,
pH 7.0) was autoclaved and stored at room temperature. LB agar (LB medium
plus 15 g M agar) was melted at low heat in a microwave (2 min) and
equilibrated in a water bath at 37°C. The ampicillin resistance of the Fujisawa
plasmid (Figure 4.1) was used to select E. coli which had incorporated the
plasmid; ampicillin was added (50 £/g ml-i) to LB agar, poured onto 10 cm
plates and allowed to dry. 50 //I of electroporation mix was added to the centre
of a plate and spread with a flamed glass spreader. A second plate containing
E. coli only was used as a control and plates were left overnight in an
incubator at 37°C. The stock electroporation solution can be stored at 4°C for
up to 2 weeks for re-plating, as colonies may need to be concentrated or
diluted. Long term storage is possible in glycerol at -70°C.
The following day, 10 ml aliquots of LB broth containing ampicillin (50
pg ml-i) were dispensed into 50 ml conical tubes. Five individual colonies were
scraped from the plate using sterile plastic hoops and mixed with an aliquot of
broth for inoculation, with a control tube containing broth only. The six cultures
(five + control) were left overnight in a horizontal shaker (225 rpm) at 37°C and
the stock plate stored at 4°C.
4.2.7.3. DNA Purification
DNA was purified using the Promega Magic™ DNA purification system.
1.5 ml aliquots of the above 5 cultures were added to 1.8 ml microcentrifuge
tubes and centrifuged at 14000 rpm in a Beckman microcentrifuge for 5 min.
The supernatant was decanted, a further 1.5 ml of each culture was added and
recentrifuged as before. Pellets were resuspended in 200 /vl of Cell
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Resuspension Solution (50 mM Tris-HCI, 10 mM EDTA, RNAse A (100 pg
ml-1)), followed by 200 pi of Cell Lysis Solution (0.2 M NaOH, 1% SDS). 200 pi
of Neutralisation Solution (1.32 M potassium acetate, 6.4% glacial acetic acid,
pH 4.8) was added and tubes centrifuged as above, to obtain a clear lysate.
The clear lysate was transferred to a fresh microcentrifuge tube and 1 ml of
Magic Miniprep DNA Purification Resin added and mixed thoroughly. The
mixture was transferred to a Magic Minicolumn using a 2 ml syringe and
extracted under vacuum and then washed with a further 2 ml of Column Wash
Solution (200 mM NaCl, 20 mM Tris-HCI, 5 mM EDTA, pH 7.5). The
minicolumn was centrifuged as above (20 sec) to dry the resin. The column
was transferred to a fresh microcentrifuge tube and 50 pi of TE buffer was
added, left for 1 min and DNA eluted by microcentrifugation for 20 sec.
Approximately 30 pg of plasmid DNA was obtained from each of the five
individual 10 ml bacterial cultures.
4.2.7.4. Restriction Endonuclease Digestion
Restriction endonucleases are enzymes found naturally in bacterial
cells. They are highly specific recognising short sequences (generally
palindromic in nature) in double stranded DNA. On binding to individual
recognition sites, the endonucleases cleave the DNA.
The restriction map of plasmid pAR1639 (Figure 4.1) was examined and
two sites on either side of the adenosine Ai receptor insert were chosen, in
order to check the molecular weight of the DNA template. The restriction digest
for the five samples contained 2 pi of DNA, 0.5 pi of EcoRi, (all enzyme
solutions ~8-10 u pM), 0.5 pi of XBal, 1 pi of Buffer H and 6 pi of distilled water
(d.H20) in a 500 pi microcentrifuge tube, with samples incubated at 37°C for
120 min. On removal, samples were centrifuged at 14000 rpm for 30 sec and
1.5 pi of an "electrophoresis loading dye" (10% glycerol (v/v), 0.1%
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bromophenol blue, 0.1% xylene cyanol) added, which stops the samples
floating away on addition to agarose gels. 10^/1 of all five DNA samples were
added to individual lanes on a 1% agarose gel (see below), along with two
molecular weight markers (X phage and P-gem) (Figure 4.3-Gel 1).
4.2.7.5. Horizontal Agarose Electrophoresis of DNA
DNA of varying sizes can be separated by electrophoresis through
agarose gel. A 1% agarose gel is suitable for separation of products with a
variety of molecular weight ranges (500-7000 bp). 50 ml of TBE buffer (0.045
M Tris-borate, 1 mM EDTA, pH 8.0) was added to 0.5 g of agarose MP and
melted in a microwave at low heat for 2 min. After cooling, 0.5 /vl of ethidium
bromide (10 mg mM) was added, mixed and poured while warm onto an
electrophoresis tray. After the gel has solidified, the tray was placed in a
electrophoretic chamber (Bioblock Consort) and TBE buffer poured over the
gel. Samples were added and the gel was run at 5-10 V crrH until the dye front
reached the bottom of the gel. DNA has an overall negative charge and
migrates from the negative to positive terminal. The gel was examined under
an ultraviolet transilluminator (Vilber Lourmat), with DNA appearing as a bright
band and a polaroid photograph taken.
4.2.7.6. Polymerase Chain Reaction (PCR)
PCR originated in the mid 1980's (Mullis & Faloona, 1987) and is used
to amplify a stretch of DNA between two regions of known sequence. Two
amplimers (short single stranded oligonucleotides) are synthesised to
complement sequences which lie on opposite strands of the DNA, flanking the
segment to be amplified. Oligonucleotides were designed using Gene
Jockey™ (Dr P. Taylor, Cambridge Biosoft) on an Apple Macintosh computer,





























































A-\ receptor cDNA, beginning in transmembrane IV and ending in domain VII.
This area has low homology with the sequences of adenosine A2a, A2b and A3
receptors assessed by homology matrix analysis. The 5' probe was 22 bases
(TCATTGCCTTGGTCTCTGTGCC) in length (nucleotides 359-380), with a
melting temperature (Tm) of 61.9°C for double stranded DNA. The 3' probe
was 22 bases (GACGAAGAAGTTGAAGTAGACC) in length (nucleotides 846-
867) with a Tm of 58.2°C for double stranded DNA. Probes were purchased
from R&D Systems.
A PCR reaction was set up to amplify the desired PCR product, as the
restriction digest (Figure 4.3-Gel 1) showed an insert of the correct molecular
weight for all 5 samples which underwent DNA purification. The digest from
lane 1 was chosen as the DNA template for the PCR reaction. The PCR
reaction (1 pi 5' of probe (20 pM), 1 pi of 3' probe (20 pM), 10 pi of 10 x
polymerase buffer (100 mM Tris-HCI, 500 mM KCI, 0.01% gelatin, pH 8.3), 10
A/I of 25 mM MgCl2, 1 pi of 10 mM nucleotides (DNTP's), 1 pi of Taq DNA
polymerase (4 u pM) and 75 pi of d.H20) was initiated by addition of 1 pi of
template DNA (10-50 ng), or buffer for the control reaction, in a 500 pi
microcentrifuge tube. The reaction contents were mixed and a drop of mineral
oil was added to stop evaporation during the PCR process. PCR was carried
out using the Hybaid Omnigene™ and a fixed protocol; a 2 min denaturation
cycle at 95°C, followed by 30 repeating cycles of three procedures,
denaturation (DNA separates so oligonucleotides can anneal to single strands)
(95°C, 45 sec), annealing (oligonucleotides bind to the complementary
sequence on single stranded DNA) (53°C, 45 sec) and polymerisation
(extension by DNA polymerase which recognises and binds only double
stranded DNA) (72°C, 60 sec) and finally an auto-extension (72°C, 5 min).
Samples were left overnight to cool with no detrimental effect on stability.
The molecular weight of the PCR product was determined by horizontal
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electrophoresis as described previously (see 4.2.7.5.). 10 /vI aliquots of both
PCR reactions were added to 1.5 /vl of loading dye and pipetted onto a 1%
agarose gel, with a molecular weight standard (100 bp marker) and a polaroid
taken (Figure 4.3-Gel 2). A band with a molecular weight of approximately 500
bp matched the size of our predicted PCR product, with no bands in the control
PCR reaction.
4.2.7.7. TA Cloning of PCR Reaction Product
Non-proofreading DNA polymerases such as Taq DNA polymerase,
have a non-template dependent activity which adds a single deoxyadenosine
(A) to the 3' end of PCR products. TA cloning utilises this activity by creating
linearised plasmid vectors with complimentary 3' deoxythymidine (T) residues,
allowing efficient ligation of PCR products into vectors. The circular construct
can then be electrically or chemically transformed into E. coli and the PCR
product amplified in the plasmid carrier.
4.2.7.8. Addition of (A) Overhang: Phenol/Chloroform
Extraction and Ethanol Precipitation
Phenol/chloroform extraction separates nucleic acids from proteins and
is widely used for the removal / inactivation of enzymes. 0.5 jl/I of Taq DNA
polymerase (4 u //M) was added to 50 /vl of PCR reaction mixture, vortexed, a
drop of mineral oil added and then incubated at 72°C for 10 min. The oil was
removed and an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1)
was immediately added and the mixture vortexed vigorously. The phases were
separated by microcentrifugation at 14000 rpm for 5 min and the top (aqueous)
phase was transferred to a fresh tube. An equal volume of chloroform was
added, vortexed vigorously, centrifuged for 2 min as above and the top phase
again transferred to a fresh tube. Addition of sodium acetate, at a final
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concentration of 0.3 M, and 2 vol. (v/v) of absolute alcohol was followed by
mixing and incubation at -20°C for 120 min. The pellet was collected by
microcentrifugation for 15 min as above, the ethanol decanted and the pellet
washed with 70% alcohol. The pellet was lyophilised under vacuum and
resuspended in 40 /vl of TE buffer.
4.2.7.9. Cloning into pCR™ll
Ligation of the PCR product into the Invitrogen plasmid pCR™l! was
performed immediately after phenol/chloroform extraction as the single (A)
overhang will be removed over time. The ligation reaction contained 1 pi of
PCR product, 1 pi of 10 x ligation buffer (60 mM Tris-HCI, 60 mM MgCl2, 50
mM NaCI, 1 mg mM bovine serum albumin (BSA), 70 mM 6-mercaptoethanol,
1 mM ATP, 20 mM dithiothreitol (DTT) and 10 mM spermidine), 2 pi of pCR™II
vector (10 mM Tris-HCI, 1 mM EDTA, pH 7.5) (25 ng pM), 1pl of T4 DNA
ligase (4.0 Weiss u pM) and 5 pi of sterile water. A control self ligation with no
PCR product was also set up. The ligation reactions were incubated overnight
at 14°C prior to transformation.
4.2.7.10. Chemical Transformation of Ligation Product
After overnight incubation, vials containing the ligation reactions were
centrifuged for 30 sec at 14000 rpm. 2 pi of 0.5 M 6-mercaptoethanol was
added to two independent 50 pi vials of One Shot™ TOP10F' competent cells
and mixed gently by stirring with a pipette tip. 2 pi of each ligation product were
separately added to a vial of competent cells, mixed gently by stirring, and left
on ice for 30 min. Stock ligations were stored at -20°C. Vials were heat
shocked for 30 sec at 42°C in a water bath and placed on ice for 2 min. 450 pi
of SOC medium was added and vials were shaken horizontally (225 rpm) for
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60 min in a rotary shaking incubator and then placed on ice. 50 y\ of the
transformation reactions were spread onto LB agar plates which contained
kanamycin (50 pg mM) and had previously been spread with 40 /vl of X-Gal (5-
bromo-4-chloro-3-indolyl-6-D-galactoside) (40 mg mM) in dimethylformamide
and 40 /j\ of IPTG (isopropyl-6-D-thiogalactoside) (100 mM) and allowed to
dry. Once the liquid was absorbed, plates were inverted and placed in an
incubator at 37°C for at least 18 hr.
4.2.7.11. Blue /White Screening
After incubation at 37°C for 18 hr, plates were placed at 4°C for 2 hr to
allow for proper colour development. The Invitrogen plasmid pCR™II contains
a lac promoter and a lacZa; peptide sequence which can be functionally
produced in competent cells. The resulting enzyme 6-galactosidase cleaves X-
gal to give blue colonies. Correct insertion of the PCR product interrupts the
reading frame of the lacZoc peptide and produces white colonies. Those with
no insert, or the self ligation, do not alter the reading frame and colonies
should be blue.
The self ligation worked well, with all colonies blue and the plate with
insert had a mix of both white and blue colonies. 10 ml aliquots of LB broth
containing ampicillin (50 fjg mM) was dispensed into 50 ml conical tubes. Ten
individual white colonies were scraped from the plate using sterile plastic
hoops, streaked onto a fresh ampicillin resistant agar plate and mixed with an
aliquot of broth for inoculation. The new plate and tubes were left overnight at
37°C in an incubator and shaker (225 rpm) respectively and the stock plate
stored at 4°C.
Only four of the ten colonies on the plate were still white the next day,
so these four were used for DNA preparation as described previously (see
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4.2.7.3.)- After DNA purification, two separate restriction digests were carried
out on each DNA preparation. As the Invitrogen plasmid pCR™II contains
EcoRi restriction sites on either side of the insert, the first digest should cut out
the whole 508 bp PCR product. On examination of the predicted sequence of
the PCR product, another restriction enzyme Sacl should cut the PCR product
almost in half, producing two separate fragments of 275 and 323 bp. The first
digest contained 1 pi of DNA, 0.5 pi of EcoRi, 1 pi of Buffer H and 7.5 pi of
d.H20 in a 500 pi microcentrifuge tube, with samples incubated at 37°C for 90
min. The second contained 1 pi of DNA, 0.5 pi of Sacl, 1 pi of Buffer J and 7.5
pi of d.H20 in a 500 pi microcentrifuge tube, with samples incubated at 37°C
for 18 hr.
Following incubation, samples were centrifuged at 14000 rpm for 30 sec
and 1.5 pi of loading dye was added. Horizontal electrophoresis was carried
out as described previously (see 4.2.7.5.), with 10 pi of each sample added to
individual lanes on a 1% agarose gel, along with appropriate molecular weight
markers (X phage, P-gem and 100 bp). The gels were examined under
ultraviolet light and polaroids taken (Figure 4.3-Gels 3 & 4). The gels indicated
that three of the four digests had the correct insert.
4.2.7.12. Automated Fluorescent DNA Cycle Sequencing
The three products in the correct molecular weight range were kindly
sequenced by Dr P L. Taylor (MRC Reproductive Biology Unit, Edinburgh).
Briefly, cycle sequencing is a rapid and convenient method for performing
enzymatic extension reactions for DNA sequencing. The strategy of chain
termination by incorporation of radiolabeled dideoxy nucleoside triphosphates
(ddNTP's) originally described by (Sanger et al., 1977) has recently been
combined with fluorescent technology. The principles of the original
radioisotopic method, and the recently developed non-radioisotopic methods,
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are identical. Each method generates a population of labelled oligonucleotides
that begin from a fixed point and end randomly at a fixed residue. Every base
in the DNA has an equal chance of being the variable terminus, resulting in a
population of oligonucleotides which differ in length by one base. The
population of fragments are resolved by electrophoresis through a denaturing
polyacrylamide gel.
The Sanger method requires the use of four separate reaction tubes,
each with only one of the four nucleosides in the form of a radiolabeled
ddNTP. Each of these four reactions are electrophoresed in individual lanes of
the resolving gel, with the sequence determined by the pattern of bands
observed on an autoradiogram of the resulting gel.
However, modern techniques utilise the incorporation of ddATP,
ddGTP, ddCTP and ddTTP, conjugated to identifiable fluorophores and all
added to a single tube. During the cycle sequencing reaction, the
oligonucleotide chains synthesised are terminated by a fluorescently labelled
ddNTP. When electrophoresed through a denaturing polyacrylamide gel, these
oligonucleotides are separated by size. The automated sequencing apparatus
(Applied Biosystems) uses a laser source to excite the fluorophores as they
migrate past a detection point. Computer software subsequently constructs a
screen image of the gel, with coloured bands representing each nucleotide
base of the DNA chain. The actual DNA sequence is then automatically
computed and can be analysed as required. DNA sequence analysis and
manipulation were performed using Gene Jockey™. The data from the
sequencing of all three products was accurate, with product four (Figure 4.3-
Gels 3 & 4 and Figure 4.4) chosen for radioactive labelling with p3p],
4.2.7.13. [33P]-Labelling of the Riboprobe
150 [j\ of product 4 (Figure 4.3-Gels 3 & 4) was added to 30 ml of LB
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broth containing kanamycin (50 pg m'"1) and ampicillin (50 pg ml-1) and
cultured overnight at 37°C in a rotary shaker (225 rpm). DNA was prepared
using the Promega Magic™ DNA purification system as described previously
(see 4.2.7.3.)- After DNA purification, a restriction digest was carried out
containing 1 pi of DNA, 0.5 pi of EcoRi, 1 pi of Buffer H and 7.5 pi of d.H20 in
a 500 pi microcentrifuge tube and incubated at 37°C for 90 min. The sample
was centrifuged at 14000 rpm for 30 sec before 1.5 pi of loading dye was
added. Horizontal electrophoresis was carried out as described previously (see
4.2.7.5.) with 10 pi of DNA added to an individual lane on a 1% agarose gel,
with appropriate molecular weight markers (P-gem and 100 bp). The gel was
examined under ultraviolet light and a polaroid taken (Figure 4.3-Gel 5).
The amount of DNA present in the preparation was determined using a
Uvikon 860 spectrophotometer, with absorbance measured at 260 / 280 nM.
The preparation contained 30 pg of DNA in 250 pi of TE buffer. For riboprobe
labelling, requirements were 3 pg of DNA in 8 pi, so the DNA was precipitated
by addition of 2 vol. of 100% ethanol and 0.1 vol. of 3 M sodium acetate (pH
5), and left at -20° C for 120 min. The preparation was spun at 10000 rpm at
4°C for 30 min. The pellet was washed in 70% ethanol, recentrifuged at 14000
rpm for 2 min and resuspended in TE buffer at the required concentration.
The pCR™ll plasmid containing the insert must be linearised to produce
the riboprobe. The restriction map of the plasmid was examined and two
different restriction enzyme sites on either side of the insert were chosen for
production of sense and antisense probes. The pCR™ 11 plasmid has two RNA
polymerases, SP6 and T7, which work in opposite directions, allowing
synthesis of both sense and antisense riboprobes from the same product. The
antisense digest contained 8 pi of DNA, 3 pi of BamHi, 2 pi of Buffer B and 7
pi of d.H20 in a 500 pi microcentrifuge tube. The sense digest contained 8 pi
of DNA, 3 pi of Xbal, 2 pi of Buffer H and 7 pi of d.H20 in a 500 pi
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microcentrifuge tube, with both samples incubated at 37°C overnight.
Samples were centrifuged at 14000 rpm for 30 sec and horizontal
electrophoresis was as described previously (see 4.2.7.5.). Samples were
diluted 10 fold before addition of loading dye and pipetted onto individual lanes
of a 1% agarose gel, with two different X phage molecular weight markers. The
gel was examined under ultraviolet light and a polaroid taken (Figure 4.3-
Gel 6).
Both sense and antisense digests underwent a proteinase K digestion
to destroy the restriction endonucleases. 19 /-/I of each digest was added to a
500 pi microcentrifuge tube containing 7 pi of nuclease free H20, 3 pi of 10 x
proteinase K buffer (0.1 M Tris-HCI, 0.05 M EDTA, 1% SDS, pH 7.8), 1 pi of
proteinase K (10 mg mM) and incubated at 37°C for 30 min. Digests then
underwent a phenol/chloroform extraction and ethanol precipitation similar to
that described previously. Briefly, 100 pi of phenol:chloroform:isoamyl alcohol
(25:24:1) and 70 pi of nuclease free H20 were added to the digest and
vortexed. Phases were separated by microcentrifugation at 14000 rpm for 15
sec and the top (aqueous) phase transferred to a fresh tube. An equal volume
of chloroform was added, vortexed and centrifuged as above with the top
phase again transferred to a fresh tube. 10 pi of sodium acetate (3 M) (pH 5.2)
and 250 pi of ice cold 100% ethanol was added, followed by mixing and
incubation at -20°C for 60 min. The pellet was precipitated by centrifugation at
14000 rpm for 10 min at 4°C. The supernatant was decanted and 500 pi of
70% ethanol added and centrifuged at 14000 rpm for 2 min at 4°C. The
supernatant was removed, the pellet air dried and reconstituted in 10 pi of
d.H20.
[33p]-Labelling of both sense and antisense probes was carried out at
room temperature, with the following constituents added to two 500 pi
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microcentrifuge tubes: 2.5 pI of 10 x Transcription buffer (TSC) (200 mM Tris-
HCI, 30 mM MgCI2, 10 mM spermidine, pH 7.5), 1 pI of 100 mM DTT, 1 pi of
RNase inhibitor (40 u pM), 1 pi of rATP (10 mM), 1 pi of rCTP (10 mM), 1 pi of
rGTP (10 mM), 1 pi of rUTP (0.2 mM), 10 pi of DNA template, 5 pi of [33P]UTP
(10 pCi pM), 1 pi of RNA polymerase (20 u pM) (SP6 or T7) and 0.5 pi of
d.H20. The SP6 polymerase was used for the production of the sense probe
and T7 polymerase for the antisense probe. The tubes were mixed and
incubated at 37°C for 45 min. For optimal polymerisation, another 1 pi of the
appropriate RNA polymerase was added to each tube, mixed and incubated as
before. 2 pi of tRNA (10 mg mM) followed by 1 pi of RNase free DNase-1 (10
u pM) was added to remove the DNA template and the mixture was incubated
for 10 min at 37°C. Both probes then underwent a phenol/chloroform extraction
and ethanol precipitation as described above, with pellets resuspended in 20
pi of d.H20 and stored at -20°C.
4.2.7.14. Preparation of Slides for P3P]-Labelling
For in situ hybridisation, double frosted glass microscope slides were
washed and baked. Slides were immersed in a 2% solution of freshly prepared
3-aminopropyltriethoxy-silane (APES) (350 ml) which can be used for 200-300
slides. Slides were dipped in 99% IMS then d.H20 and dried overnight at
37°C. To minimise potential RNA contamination at all stages, gloves were
worn and slides covered to reduce exposure to air.
4.2.7.15. Preparation of Brain and Kidney Sections for [33P]-
Labelling
Rats were anaesthetised as described for in vitro autoradiography (see
4.2.6.2.). The neck was broken, the head guillotined, the brain and kidneys
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carefully removed and frozen on cardice in a sealed container. Gloves were
worn at all times and tissue exposure to air minimised. Tissues were frozen on
to orientating microtome chucks with Tissue Tek and dipped in Lipshaw
embedding matrix. Using a Bright cryostat, 20 /ym coronal sections were cut at
the level of the ventral hippocampus in brain and hemisagital sections in
kidney, then thaw mounted onto the appropriate slides. Sections for in situ
hybridisation were placed in a sealed container. For each tissue, 48
continuous sections were cut (2 sections per slide) and divided into four
repeating groups of six slides (slide 1 & 2 in situ, slide 3 & 4 cell staining and
slide 5 & 6 autoradiography, see below). Sections were dried at room
temperature and stored at -70°C until use.
For the comparative in situ hybridisation and in vitro autoradiographic
studies using brain and kidney sections, autoradiography was performed as
described previously (see 4.2.6.3.), with total binding determined in the
presence of 0.1% DMSO and non-specific binding determined using 10 pM
R-PIA.
4.2.7.16. In Situ Hybridisation Procedure Using
[33P]Riboprobes
All equipment for in situ procedures were washed and baked. All
solutions were made in distilled water that had been autoclaved or treated with
0.1% diethylpyrocarbonate (DEPC). Sections were removed from the freezer
and transferred quickly to sterile racks on cardice, thus preventing thawing and
release of RNases. Sections were dried quickly with a hair drier and
immediately transferred to a glass trough containing 350 ml of fresh 4%
paraformaldehyde (pH 7.2) in DEPC treated phosphate buffered saline (PBS)
for 5 min. Slides were then transferred through two troughs containing 0.1 M
sodium phosphate buffer (pH 7.4) for 5 min each, with stirring and shaking,
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followed by 2 min in 350 ml of DEPC-distilled water. Slides were then washed
in 350 ml of 80 mM triethanolamine (TEA) buffer (pH 8.0) for 2 min, followed
by a 10 min wash in TEA buffer containing 0.25% freshly added acetic
anhydride. The slides were placed in 350 ml of 2 x standard sodium citrate
(SSC) buffer (pH 7.0) and left soaking prior to addition of prehybridisation
buffer.
Slides were individually removed and blotted using sterile gauze. 100 /vl
of 0.2 /vM Millipore filtered prehybridisation buffer (50% deionised formamide,
4 x STE buffer (0.4 M NaCI, 40 mM Tris-HCI, 4 mM EDTA, pH 8.0), 1 x
Denhardt's, yeast tRNA (0.125 mg mM), denatured salmon sperm DNA (0.125
mg mM), and 10 mM DTT) was added and incubated at 42°C for 60 min.
[33P]-Labelled sense and antisense riboprobes were diluted in
hybridisation buffer (prehybridisation buffer with 10% dextran sulphate) to give
approximately 106 CPM per slide and incubated at 60°C for 3 min. Slides were
blotted and 100 ij\ of riboprobe added to each section. FMC Gelbond film
(hydrophilic side up), was used as a coverslip, with slides placed in 10 cm petri
dishes containing small vials of sterile water to prevent dessication and
incubated overnight at 50°C.
Two glass troughs containing RNase buffer (10 mM Tris-HCI, 500 mM
NaCI, 1 mM EDTA, RNase (20 jLvg mM), pH 8.0), one supplemented with 1 mM
DTT, were placed in a water bath at 37°C. Slides were taken from the
incubator and washed in 4 x SSC to remove coverslips, transferred to a new
slide rack, then placed in 350 ml of 4 x SSC (plus 2 mM DTT), for 15 min at
room temperature. The rack was transferred to 350 ml of RNase buffer at 37°C
for 30 min and this incubation was repeated in RNase buffer containing 1 mM
DTT. Slides were then taken through three sequential 30 min washes at room
temperature in 4 x, 2 x and 0.1 x SSC (wash stringency can be increased by
increasing the temperature and decreasing the salt concentration), followed by
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three further sequential 3 min washes at room temperature in 50%, 85% and
100% IMS containing 300 mM ammonium acetate. Slides were placed on the
bench and left covered overnight to dry.
In a darkroom, Kodak emulsion was preheated for 60 min in a water
bath (45°C) and slides prewarmed on a hot plate. The emulsion was poured
into a slide dipping chamber and slides were placed back to back, dipped twice
in emulsion, blotted on a paper towel and dried in a slide rack for 10 min. The
slide rack was placed in a sealed plastic box within two other boxes and left at
room temperature for 120 min. Finally, slides were placed in a polacetyl box
containing a perforated vial of silica gel, double wrapped in tin foil and stored
at 4°C for the appropriate period of time.
4.2.7.17. Development of [33P]-Labelled Sections
Slides were removed from the cold room and allowed to warm to 15°C.
Four troughs containing: (a) 350 ml of Kodak D-19 developer, (b) d.H20, (c)
10% Kodak polymax (fixative) in d.F^O and (d) d.F^O were placed on ice, to
attain a temperature of 15°C. Slides were washed sequentially in the four
troughs for 4 min, 20 sec, 10 min and 15 min respectively. Slides were washed
under running water for 20 min, dipped in haematoxylin for 2 min, rinsed in
fresh running water, rinsed in 1% alcohol for 20 sec and placed in tap water.
Slides were examined under light field microscopy and if nuclei staining was
adequate, slides were dehydrated through three 20 sec dips in 70%, 90% and
100% ethanol. Slides were placed in histo-clear for 5 min and stored in xylene
in a fume hood. Slides were removed from xylene, pertex added, coverslips
placed gently over the tissue sections and left to dry.
Black and white photographs of brain and kidney sections were taken
using an Olympus BH2 microscope, under light and dark field, at a
magnification level of x 12 and x 35.
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4.2.8. Data Analysis
Competition binding curves were constructed for binding of PH]DPCPX,
pH]CGS21680 and [3H]RX821002 to rat kidney membranes and HEK 293 cell
membranes, as described in Chapter 1 (see 1.2.4.1). Pharmacological
parameters were determined using the appropriate equations and the iterative
curve fitting programme Sigma plot, as described in Chapter 1 (see 1.2.4).
4.2.9. Statistical Analysis
The data shown in the figures displayed are a representation of one
experiment, all of which have been carried out at least three times, unless
otherwise stated. Data in tables and text are shown as mean ± the standard
error of the mean (S.E.M.) of at least three different experiments.
4.2.10. Materials
Molecular biological products used were from Invitrogen, Promega,
Gibco and R&D Systems. The radioligands were; [3H]DPCPX (109 Ci mmoM;
NEN), [3H]CGS21680 (41.2 Ci mmoM; NEN), pH]RX821002 (60 Ci mmoM;
Amersham) and [33PJUTP (250 pCi /10 pCi /vM; NEN). All other products used
in binding studies, in situ hybridisation and in vitro autoradiography were from
Sigma, Boehringer Mannheim, BDH and Kodak.
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4.3. Results
4.3.1. [3H]DPCPX and [3H]CGS21680 Binding to Rat Kidney
Membranes
In an attempt to characterise binding to adenosine receptors in rat
kidney membranes, five membrane preparations were tested (see 4.2.1.).
Initially crude membrane preparations were tried, followed by the isolation of
membranes from particular sections of the kidney in an attempt to increase
binding site density.
Method 1 (p222): No specific binding of PHJDPCPX (0.1 nM) or
[3H]CGS21680 (2 nM) to crude kidney membranes was detected at protein
concentrations up to 0.5 mg per sample, with an incubation period of 120 min.
Method 2 (p222): No specific binding of pH]DPCPX (0.1 and 1 nM) or
pH]CGS21680 (2 and 20 nM) to crude kidney membranes was detected at
protein concentrations up to 0.5 mg per sample, with an incubation period of
120 min.
Method 3 (p223): No specific binding of pH]DPCPX (0.1 and 1 nM) or
PH]CGS21680 (2 and 20 nM) to the mixed basolateral / brush border fraction
was detected at protein concentrations up to 2 mg per sample, with an
incubation period of 120 min. No specific binding of pH]DPCPX (0.1 nM) was
detected in any of the individual pellet or supernatant fractions, produced
during the differential centrifugation procedure.
Method 4 (p223): No specific binding of pH]DPCPX (0.1 and 1 nM) or
PH]CGS21680 (2 and 20 nM) to individual basolateral or brush border
fractions was detected at protein concentrations up to 2 mg per sample, with
an incubation period of 120 min.
Method 5 (p224): No specific binding of pHJDPCPX (0.1 and 1 nM) or
pH]CGS21680 (2 and 20 nM) to the medullary preparation was detected at
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protein concentrations up to 0.5 mg per sample, with an incubation period of
120 min.
Inhibition of [3H]DPCPX and [3H]CGS21680 binding to rat cortical and
striatal membranes respectively by adenosine agonists and antagonists was
conducted simultaneously. Specific binding with the appropriate
pharmacological specificity was noted in both cases (data not shown).
4.3.2. [3H]RX821002 Binding to Rat Kidney Membranes
Adrenoreceptors, which have been divided into three major subtypes
«i, «2 and p, are found throughout the body and adrenergic drugs are known
to act on kidney (O'Rourke et a/., 1994; Bylund et al., 1995). As discussed for
purinoreceptors (Ch.1), IUPHAR addressed the complications of the
classification of adrenoreceptor subtypes, caused by the availability of new
pharmacological tools and the cloning of recombinant receptors (Bylund et al.,
1995). As with purinoreceptors, historical precedent makes this difficult and the
guidelines for u-i adrenoreceptor classification have already been updated
(Hieble et al., 1995; Vanhoutte et al., 1996). Compounds available for
investigating the various receptor subtypes (Bylund et al., 1995) in different
tissues include the «2 adrenoreceptor radioligands [3H]RX821002 (Langin et
al., 1989) and [3HJMK912 (Uhlen et al., 1992). It is thought that a2a and «2b
adrenoreceptors are expressed in kidney, with the a2b subtype predominant
(Uhlen & Wikberg, 1991a, b). Uhlen and colleagues have proposed further
subdivisions of «2a and U2b adrenoreceptors (Uhlen & Wikberg, 1991c; Uhlen
et al., 1993; Byiund et al., 1995). The presence of adrenoreceptors in the rat
kidney membrane preparations described in the previous section were
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investigated using the a2 adrenoreceptor antagonist radioligand [3H]RX821002
as a positive control to prove the viability of membranes used in [3H]DPCPX
and [3H]CGS21680 binding studies.
4.3.2.1. Effect of Protein Concentration on [3H]RX821002
Binding to Rat Kidney Membranes
[3H]RX821002 (1 nM) binding to rat kidney membrane preparations
was carried out in parallel with pH]DPCPX and [3H]CGS21680 binding studies.
Kidney membranes were incubated for 60 min at 25°C, with non-specific
binding determined in the presence of 100 ^M adrenaline. The mixed (Method
3) and separate basolateral / brush border (Method 4) kidney membrane
preparations (see 4.2.1.3 and 4.2.1.4) were used for binding studies. Unlike
[3HJDPCPX, an increase in specific [3HJRX821002 binding was observed with
increasing amounts of membrane protein in the assay for both preparations,
with data shown for the separate brush border and basolateral fractions from
Method 4 (Figure 4.5); results using the mixed preparation (Method 3) were
almost identical. No specific [3H]RX821002 binding was detected when using
membranes from kidney medulla (Method 5, see 4.2.1.5.). In all further
experiments, the brush border membrane fraction (approximately 100 yg of
protein per sample) (Method 4) was used.
4.3.2.2. Time Course of [3H]RX821002 Binding to Rat Kidney
Brush Border Membranes
A time course of [3HJRX821002 (1 nM) binding to rat kidney membranes
was carried out at 25°C, with equilibrium attained by 2 min (Figure 4.6). In all
other experiments, [3HJRX821002 (1 nM) binding to kidney membranes was
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pg protein per sample
Figure 4.5 [3H]DPCPX and [3H]RX821002 Binding to (a) Basolateral
and (b) Brush Border Membranes From Rat Kidney Cortex.
[3H]DPCPX binding is represented by circles and [3H]RX821002 binding by triangles.
Open symbols are for total binding and filled symbols are for non-specific binding.
































































Figure 4.6 Time Course of [3H]RX821002 Binding to
Rat Kidney Brush Border Membranes.
The data represent a single time course experiment, with each
point performed in duplicate. Membranes were incubated with
1 nM [3H]RX821002 for various times at 25°C.
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carried out at 25°C for 30 min.
4.3.2.3. Concentration Dependence of [3HJRX821002 Binding to
Rat Kidney Brush Border Membranes
Hot saturation analysis of [3H]RX821002 binding to rat kidney brush
border membranes was carried out once using increasing concentrations of
[3H]RX821002 (Figure 4.7). Curve fitting using a hyperbolic model gave an
equilibrium dissociation constant (KD) of 2.57 nM and a Bmax of 2.68 pmol mg-1
protein. pH]RX821002 was used at a final concentration of 1 nM in the
following experiments.
4.3.2.4. Inhibition of PH]RX821002 Binding to Rat Kidney
Brush Border Membranes by Adrenergic Agonists and
Antagonists
Inhibition of [3H]RX821002 binding to rat kidney brush border
membranes was examined using two antagonists yohimbine and prazosin and
two agonists clonidine and noradrenaline. All four compounds inhibited
[3H]RX821002 binding (Figure 4.8), with Kj values and Hill slopes shown in
Table 4.1. For the antagonists, yohimbine was more potent than prazosin, and
for the agonists clonidine more potent than noradrenaline. Hill slopes for both
antagonists and agonists were approximately 0.6 to 0.8.
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Figure 4.7 Concentration Dependence of [3H]RX821002
Binding to Rat Kidney Brush Border Membranes.




Figure 4.8 Inhibition of [3H]RX821002 Binding to Rat Kidney
Brush Border Membranes by Adrenergic Receptor Agonists
and Antagonists.
The data represent a typical experiment, with each point performed in
duplicate and with mean data obtained from three experiments (Table 4.1).
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Table 4.1 Inhibition of PH]RX821002 Binding to Rat
Kidney Brush Border Membranes by Adrenergic
Receptor Antagonists and Agonists
Compound K| (nM) (nH)
Antagonists
Yohimbine 11.1 ±2.14 0.78±0.05
Prazosin 183 ±22.9 0.65 ±0.05
Agonists
Clonidine 35.3 ±7.37 0.84 ±0.09
Noradrenaline 459 ±30.6 0.62 ±0.05
Kj values and Hill slopes determined as described in the methods
for [3H]RX821002 binding studies to rat kidney brush border
membranes. Values expressed as mean ± S.E.M. (n=3).
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4.3.3. Characterisation of [3H]DPCPX Binding Sites In Rat
Brain Slices Using In VitroAutoradiography
Inhibition of [3H]DPCPX binding to rat brain slices and the distribution of
adenosine A-\ receptors was assessed using in vitro autoradiography. Studies
were performed to provide positive control data to which results in the kidney
can be compared (see below). DPCPX and the Fujisawa adenosine Ai
antagonist FR129946 were used as competitive inhibitors in a [3H]DPCPX
binding assay using rat brain sections. The distribution of [3H]DPCPX binding
sites was examined; high levels of binding were noted in hippocampal CA1,
lower levels in CA3, dentate gyrus and deep cortex, minimal binding in
superficial cortex and no binding in entorhinal cortex. For both DPCPX and
FR129946, there was an obvious concentration dependent decrease in
pHJDPCPX binding as shown in Figure 4.9 for FR129946. For DPCPX, IC50
values were 1.27 ± 0.09 nM in CA1, 1.29 ± 0.20 nM in dentate gyrus and 1.30
± 0.28 nM in deep cortex. For FR 129946, IC50 values were 10.47 ± 0.38 nM in
CA1, 9.77 ± 3.39 nM in dentate gyrus and 10.2 ±2.1 nM in deep cortex. IC50
values were lower than those in [3H]DPCPX membrane binding studies.
4.3.4. In vitro [3H]DPCPX Autoradiography and In Situ
Hybridisation in Rat Kidney
In vitro autoradiography was used to examine whether a discrete
localisation of [3H]DPCPX binding sites, undetectable using membrane binding
assays, were detectable in rat kidney. Simultaneous experiments using rat
brain slices (see 4.3.3.) acted as a positive control. For in vitro
autoradiography, slides were developed after ten weeks and analysed. The
distribution of [3H]DPCPX binding sites in brain was as described above,
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showing high levels of binding in hippocampal CA1, CA3 and dentate gyrus.
Levels were also high in deep layers of cortex, the medial geniculate nucleus
and negligible in entorhinal cortex. Binding in the presence of 10 /jM R-PIA
was undetectable (Figure 4.10). Kidney sections showed a high level of
binding in cortex and very little binding in medulla. However, binding was not
inhibited by R-PIA, with non-specific sections almost identical to total binding
sections.
In situ hybridisation studies, conducted in parallel with in vitro
autoradiography, were used to examine whether adenosine A-i receptor mRNA
was detectable in rat kidney, with brain tissue again used as a positive control.
A preliminary set of slides were developed after 2 weeks to assess the level of
receptor expression. Results using the antisense probe showed positive
staining in hippocampal CA1, CA3 and dentate gyrus using dark field
microscopy (Figure 4.11a), indicating adenosine A-i receptor mRNA was
located in similar regions to pHjDPCPX binding sites. Using light field
microscopy, staining appeared to be localised in the pyramidal layer of CAI
and the granular layer of dentate gyrus (Figure 4.11b). No distinct staining was
apparent in any regions of kidney, with outer cortex shown (Figure 4.11c & d).
There was a generally high level of non-specific binding in brain and kidney,
which prompted the development of the remaining slides after 4 weeks.
Results at four weeks were almost identical to those at two weeks.
Unfortunately no conclusions could be drawn, as on examination of control
slides labelled with the sense probe, the distribution and staining appeared
similar to the antisense probe.
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Figure 4.11 Distribution of Adenosine Ai Receptor mRNA in
Rat Brain and Kidney.
Dark and light field images of emulsion autoradiographs are shown at the
level of the ventral hippocampus in brain (a & b) and shown for the outer
cortical section of kidney (c & d).
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4.3.5. [3H]DPCPX Binding to HEK 293 Cell Membranes
Species differences in adenosine A-i receptor pharmacology were
described in Ch. 1, and were eluded to for kidney in the introduction to this
chapter. The failure to identify conditions in which adenosine radioligand
binding or adenosine A-i receptor mRNA could be detected in rodent kidney,
led to other options being considered. With human kidney unavailable, we
investigated adenosine radioligand binding to the human embryonic kidney cell
line (HEK 293). This cell line has previously been used for the stable
expression of cloned receptors including adenosine (Furlong et al., 1992;
Aguilar et al., 1995). This cell line is also known to contain endogenous
p-adrenoreceptors (Aguilar et al., 1995). As the non-xanthine Fujisawa
antagonists retain high affinity in both rat and human brain tissue, estimating
their affinity at renal receptors was of obvious interest. Preliminary
investigations were performed using [3H]DPCPX and PH]CGS21680 to
investigate constitutive adenosine binding in this embryonic cell line.
4.3.5.1. Time Course of [3H]DPCPX Binding to HEK 293 Cell
Membranes
A time course of pHJDPCPX (0.5 nM) binding to HEK 293 cell
membranes was carried out at 25°C, with equilibrium attained by 2 min (Figure
4.12). In all further experiments [3HJDPCPX (0.5 nM) binding to HEK 293 cell
membranes was carried out at 25°C for 30 min.
4.3.5.2. Concentration Dependence of [3H]DPCPX Binding to
HEK 293 Cell Membranes
Competition binding studies using 0.5 nM pHJDPCPX and increasing
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Figure 4.12 Time Course of [3H]DPCPX Binding to
HEK 293 Cell Membranes.
The data represent a single time course experiment, with each
point performed in duplicate. Membranes were incubated with
0.5 nM [3H]DPCPX for various times at 25°C.
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0.05) and a Bmax of 95.9 ± 22.5 pmol mg-i protein (n=4) (Figure 4.13).
4.3.5.3. Inhibition of PH]DPCPX Binding to HEK 293 Cell
Membranes by Adenosine Antagonists and Agonists
Inhibition of pH]DPCPX binding to HEK 293 cell membranes was
examined using 3 antagonists and 3 agonists. All six compounds inhibited
pHJDPCPX binding (Figure 4.14), with Kj values and Hill slopes shown in
Table 4.2. The affinity of both antagonists and agonists was low, with Hill
slopes near unity. The affinity and order of potency for both agonist and
antagonists was different from that observed in brain tissue (Table 4.2). Work
from within our own group (Mr T. Maemoto, personal communication)
demonstrated that untransfected CHO cells developed some specific
pH]DPCPX binding as the passage number increased. As the HEK 293 cells
used were at a high passage number, new cells were obtained and the six
compounds tested only once. The affinities of DPCPX (89.6 nM), FR160537
(1260 nM), FR 129946 (10100 nM), R-PIA (529.7 nM), S-PIA (5870 nM) and
NECA (15925 nM) were similar to those previously obtained using high
passage cells (Table 4.2).
Potential binding of the A2a agonist radioligand [3HJCGS21680 to HEK
293 cell membranes was also examined. There was no specific binding to
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Figure 4.13 Concentration Dependence of [3H]DPCPX
Binding to HEK 293 Cell Membranes.
The data represent a typical experiment, with each point performed
in duplicate and with mean data obtained from at least three
experiments (text for mean values).
268
Drug Concentration (M)
Figure 4.14 Inhibition of [3H]DPCPX Binding to HEK 293 Cell
Membranes by Adenosine Receptor Antagonists and Agonists.
The data represent a typical experiment, with each point performed in duplicate
and with mean data obtained from at least three experiments (Table 4.2).
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4.4. Discussion
Adenosine has a range of effects in kidney, mediated by A-i, A2 and
possibly A3 receptors (Spielman & Arend, 1991; Zhou et al., 1992; Dixon et al.,
1996). Adenosine receptors are reported to exist in both kidney cortex and
medulla in various species. The pharmacological characterisation of these
receptors has been heavily dependent on functional assays using adenyl
cyclase studies, with radioligand binding studies limited. Characterisation of
adenosine receptor binding sites in different areas of rat kidney was attempted
using [3H]DPCPX and [3H]CGS21680. Two crude kidney membrane
preparations were examined, with one previously used to demonstrate the
existence of an A2-like binding site using [3H]CADO (Wu & Churchill, 1985).
No specific binding was detectable in the two preparations using either
pH]DPCPX or [3H]CGS21680. The low affinity, weakly characterised binding
demonstrated by Wu & Churchill, (1985) may therefore have been due to the
presence of A2b (Rivkees & Reppert, 1992) or A3 (Zhou et al, 1992) receptors.
A wealth of evidence points to the proximal tubule being the target structure
responsible for the diuretic action of adenosine A1 receptor antagonists in
various species. This includes data from rat (Mizumoto & Karasawa, 1993;
Nomura et al., 1995; Terai et al., 1995b), dog (Terai et al., 1995b), rabbit
(Freissmuth et al., 1987b; Takeda et al., 1993) and human (Buren et al., 1993;
Balakrishnan et al, 1993). In the proximal tubule of rat kidney, the luminal
surface is coated with microvilli (brush border) and on the contraluminal side,
plasma membranes form the basal (basolateral) infoldings of the cell. Both
mixed and separate preparations of brush border and basolateral membranes
were prepared from rat kidney cortex. As with the two crude membrane
preparations, no specific binding was detected for either [3H]DPCPX or
[3H]CGS21680 at various ligand and membrane protein concentrations.
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Blanco et al., (1992) used these two ligands to study binding to adenosine
receptors in brush border and basolateral membranes from pig and rat kidney.
They were also unable to detect A-i receptor-like binding in brush border or
basolateral membranes of pig cortex using PHJDPCPX, but unfortunately
made no comment on binding using rat kidney membranes. They did,
however, characterise a very low affinity binding site for [3H]CGS21680, in
brush border membranes of pig (KD of 150 nM) and rat (KD of 90 nM) kidney,
that was different from the high affinity binding to the A2a receptor in pig brain
(12 nM). In the present study, the inability to detect this pH]CGS21680 binding
site may have been related to the methodology used, as Blanco et al., (1992)
used magnesium precipitation to obtain brush border membranes. The present
data also contrast with those of Jakubowski et al, (1992), who demonstrated
the presence of A1 and A2 receptor-like binding sites using [3H]PIA (KD of 0.34
nM) and [3H]NECA (Kq of 110 nM) in rat basolateral membranes. The lack of
pharmacological data using these ligands limits further interpretation. The
inability to detect A-i binding sites in rat kidney cortical preparations is perhaps
not surprising as autoradiographic (Brines & Forrest, 1987) and in situ
hybridisation (Weaver & Reppert, 1992) studies report that adenosine Ai
binding sites and adenosine A-i receptor mRNA are located in the medulla.
Further evidence supporting this proposal was produced in a recent study in
which the localisation of adenosine Ai receptor mRNA was examined in
microdissected rat nephron segments (Yamaguchi et al., 1995). A diverse
expression along the nephron was shown, with very low levels in the proximal
convoluted tubule (Yamaguchi et al., 1995). This contrasts with the
histochemical localisation of ecto-5'-nucleotidase, one of the enzymes
responsible for the production of adenosine (Dawson et al., 1989), because
enzyme activity was found in brush border and other cortical regions, with no
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activity in medulla. The lack of correlation between localisation of this enzyme
and autoradiographic and in situ hybridisation studies may not be of
significance, as the correlation between adenosine receptor distribution and
the presence of this enzyme was also poor in brain (Fastbom et ai., 1987b).
The former studies (Brines & Forrest, 1987; Weaver & Reppert, 1992;
Yamaguchi et al., 1995) have all alluded to the presence of adenosine
receptors in the medullary region of rat kidney. In an abstract, Weber et at,
(1990b) demonstrated [3H]DPCPX binding to crude inner stripe and papillary
membranes from the medulla with a KD of 0.25 nM. The higher Bmax of the
papillary fraction led us to prepare medullary membranes in an attempt to
characterise [3H]DPCPX binding sites. A method was used that had previously
demonstrated the presence of A2-like receptors using an adenylate cyclase
assay (Woodcock et at, 1984). As with previous membrane preparations, no
specific binding was detectable for either [3HJDPCPX or [3FI]CGS21680 at
various ligand and membrane protein concentrations. Although Woodcock et
at, (1984) used up to 2 mg of protein per sample, we would have probably
expected some [3H]CGS21680 binding at 0.5 mg of protein. The membrane
preparation may not have been viable as [3FI]RX821002 binding could not be
detected, in contrast to kidney cortical membrane preparations. A recent
abstract identified binding in rat kidney membranes using [3FI]DPCPX, with a
Kq of 0.58 nM and a Bmax of 11.9 fmoi mg-1 protein (Gould et al., 1995). Gould
et at, (1995) preincubated membranes with 50 times more adenosine
deaminase than we used, and incubated at 4°C for 5 hr. It is possible that
these alterations in methodology are necessary to detect [3H]DPCPX binding
in rat kidney membranes.
The inability to detect specific binding of [3H]DPCPX or [3HJCGS21680
in both crude and complex cortical and medullary preparations prompted the
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use of [3H]RX821002. This u2 adrenoreceptor antagonist radioligand was used
as a positive control to confirm the viability of the membrane preparations. This
ligand has been shown to bind to a variety of kidney membrane preparations
and kidney cell lines, in a manner consistent with binding to a2
adrenoreceptors (Uhlen & Wikberg, 1993; O'Rourke et al., 1994). Specific
binding of pH]RX821002 to basolateral and brush border membrane fractions
increased linearly over the protein concentrations used. Subsequent
experiments were conducted with approximately 100 j;g of membrane protein,
ensuring less than 10% of added ligand was bound whilst maintaining
sufficient specific binding to conduct pharmacological studies. Binding was
rapid with equilibrium reached by 2 min and analysis of saturation data gave a
Kd of 2.57 nM. Four compounds useful in delineating the a receptor subtypes
found in kidney were used to determine the nature of the binding site labelled
by [3H]RX821002 (O'Rourke et al., 1994; Bylund et al., 1995). Two agonists,
noradrenaline (a/p) and clonidine (a2) and two antagonists, yohimbine («2/«i)
and prazosin («i/«2) inhibited [3H]RX821002 binding to rat kidney membranes
in a concentration dependent manner. [3H]RX821002 is a selective u2
radioligand with low affinity for u-i and imidazoline binding sites; with
nanomolar affinity for yohimbine again a classical characteristic of binding to
a2 adrenoreceptors, this would suggest negligible contamination from other
binding sites (Uhlen et al., 1993; Bylund et al., 1995). Competition binding
curves had shallow Hill slopes for agonists and antagonists indicating the
presence of two binding sites. These data are consistent with those of Uhlen &
Wikberg, (1991a, b) (Table 4.3), who showed [3H]RX821002 labelled two
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Table 4.3 PH]RX821002 Binding to Rat Kidney Membranes
Uhlen & Wikberg, Uhlen & Wikberg, Present
1991a 1991b Study








«2a=57.7 nM 11.1 nM
a2b=15.7 nM
u2a=1360 nM 183 nM
«2b=52.1 nM
a2a=84.4 nM 35.3 nM
«2b=71 -3 nM
Not tested 459 nM
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distinct subtypes in rat kidney, with the characteristics of u2a and «2b
adrenoreceptors. Further compounds would need to be tested to substantiate
this hypothesis with regard to the present data. [3H]RX821002 labels all four
a2 adrenoceptor subtypes, a2a, a2b, a2c, and a2d, (O'Rourke et al., 1994)
and the presence of other subtypes cannot be ruled out. However, Uhlen &
Wikberg (1991a) did point out that fitting a three site model provided no further
improvement over a two site model.
The possibility that adenosine A1 receptors may be discretely localised
in areas of the kidney that were not detected in membrane binding studies
prompted the use of in vitro autoradiography and in situ hybridisation. These
techniques have been used to detect adenosine Ai receptor-like binding and
adenosine A-i receptor mRNA in rodent kidney (Palacios et al., 1987; Weaver
& Reppert, 1992). For comparison with kidney, brain sections were processed
simultaneously as a positive control, as the autoradiographic (Goodman &
Synder, 1982; Weber et al., 1990a) and immunohistochemical (Rivkees et al.,
1995c; Swanson et al., 1995) localisation of A-i receptors is well characterised
in rat brain.
The inhibition of [3H]DPCPX binding in rat brain slices by DPCPX and
FR129946, two compounds with identical selectivity for the adenosine A-\
receptor, was assessed using quantitative autoradiography. The distribution of
pH]DPCPX binding in rat brain was similar to that previously described (Weber
et al., 1990a), with high levels in hippocampal CA1, lower levels in CA3,
dentate gyrus and deep cortex and no binding in entorhinal cortex. DPCPX
and FR 129946 inhibited [3H]DPCPX binding in a concentration dependent
manner, with identical affinities in both hippocampal and cortical areas.
Inhibition of pH]DPCPX binding by the putative cognitive enhancer KFM19 in
human hippocampus, followed a similar pattern in a variety of brain areas
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(Decked et al., 1993). In comparison with membrane binding studies, the
affinity of both DPCPX (3 fold) and FR129946 (5 fold) is lower. This is not
uncommon in autoradiographic studies and may represent difficulty in
removing endogenous adenosine from receptors, with adenosine deaminase
being a large enzyme that does not penetrate deeper cell layers (Weber et al.,
1990a; Parkinson et al., 1996). It was also important to demonstrate that
Fujisawa antagonists act on these areas of the brain as autoradiographic
studies in post mortem brains of Alzheimers patients show a significant
decrease in adenosine receptors in CA1 and dentate gyrus (Jansen et al.,
1990). In an attempt to keep the conditions of autoradiographic and membrane
radioligand binding studies similar, we had performed a preliminary experiment
examining different radioligand concentrations, wash times and buffers.
Autoradiographic studies on adenosine binding sites generally use 170 mM
Tris-buffer (Goodman & Snyder, 1982; Palacios et al., 1987; Weber et al.,
1990a; Parkinson et al., 1996), however we found this provided no
improvement over 50 mM Tris-buffer. It was noted, however, that [3H]DPCPX
binding was also localised to white matter tracts as well as the characterised
areas when using the former concentration of buffer. This observation had
previously been made by Weber et al., (1990a) and Parkinson et al., (1996) in
rat and gerbil brain, respectively. Both groups associated this effect with
potential axonal transport of the receptor to the presynaptic terminal. The
labelling of white matter tracts had not previously been described in
autoradiographic studies using the agonist pH]CHA, which predominantly
labels the high affinity state of the receptor (Goodman & Snyder, 1982). This
observation may, however, be of importance as recent papers on the
histochemical localisation of adenosine receptors places them on axons
(Swanson et al., 1995; Rivkees et al., 1995c). It may be interesting to postulate
that under the correct conditions, [3HJDPCPX is either labelling a receptor that
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is being transported but which is uncoupled from a G protein and hence not
recognised by agonist radioligands, or that it has in fact labelled a low affinity
state/receptor in white matter tracts, that is not detectable by agonist ligands
but is similar to that identified by immunohistochemical methods (Swanson et
al., 1995; Rivkees et at, 1995c).
Having confirmed that the autoradiographic distribution of [3HJDPCPX
binding in rat brain was similar to that previously described by Weber et al.,
(1990a), brain and kidney sections were examined in parallel. [3H]DPCPX
binding to brain sections was totally abolished by the presence of 10 /vM R-PIA
in the incubation medium. In contrast, there appeared to be no specific
pH]DPCPX binding that was inhibited by R-PIA in any region of the kidney.
The high level of non-specific binding in kidney cortex has also been reported
using [125|]ria (Brines & Forrest, 1987). Labelling of the inner stripe of the
outer medulla and the inner papilla was, however reported, neither of which
was apparent in the present autoradiograms (Brines & Forrest, 1987). To my
knowledge, this abstract appears to be the only report on the autoradiographic
localisation of adenosine A-i receptors in rat kidney. Two articles on the
visualisation of peripheral adenosine Ai receptors compare human and guinea
pig kidney (Palacios et al, 1987) and rat brain and guinea pig kidney (Weber
et al., 1988). The former demonstrated species differences with receptors
located in the cortex of human kidney and the medulla of guinea pig kidney but
the latter, despite using rat brain, made no mention of rat kidney. The present
study, despite convincing positive control data in brain, provide no further
evidence to elucidate the localisation of adenosine A-i receptors in rat kidney. It
may be that discrete localisation and low receptor density (Williams & Risley,
1980; Murphy & Snyder, 1980; Weber et al., 1990b; Gould et al., 1995)
necessitate techniques such as nephron dissection (Yamaguchi et al., 1995) to
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detect A<\ receptors in binding studies. It is also possible that renal and brain
receptors are different (Suzuki et al., 1992), although evidence is weak,
especially as the cloned rabbit adenosine A-i receptor has high homology with
the cloned brain A-i receptor (Bhattacharya etal., 1993).
Adenosine Ai receptor gene expression in rat kidney was demonstrated
by Weaver & Reppert, (1992) using Northern blot analysis and in situ
hybridisation. We constructed a riboprobe similar to the one described by
Weaver & Reppert, (1992) in an attempt to localise adenosine A-i receptor
mRNA in rat kidney. The riboprobe chosen for the Ai receptor had very low
homology with the other cloned adenosine receptors and therefore should be
specific. The production of the probe was successful and sequencing of the
probe confirmed that it was almost identical to the chosen sequence (Figure
4.4). The brain and kidney sections used for in situ hybridisation were the
adjacent sections to those used for [3H]DPCPX autoradiography. After
completion of the labelling procedure, a preliminary set of slides were
developed after two weeks and sections were viewed using dark and light field
microscopy. In brain, the distribution of the adenosine Ai receptor hybridisation
signal was similar to that seen for the autoradiograms. However, in kidney no
specific signal could be identified but there was a generally high level of non¬
specific binding in all regions. This contrasts with Weaver and Reppert, (1992),
who found specific labelling in the inner and outer medulla. Results in the
literature do, however vary, with some groups detecting signals for adenosine
A-i receptor mRNA in rat kidney (Reppert et al., 1991; Weaver & Reppert,
1992) and others not (Mahan etal., 1991; Johansson et al., 1993; Dixon et al.,
1996.). The problem with trying to obtain any relevant information from the
present in situ hybridisation studies was compounded by the fact that slides
labelled with the sense probe gave similar results to the antisense probe in
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brain and kidney. This may be due to some homology between sense and
antisense probes or non-specific binding to areas of high cell density. Further
studies are required to optimise the methodology.
Adenosine A-i receptors have been identified in human kidney cortex
(Palacios et al., 1987), and the density of these receptors is reported to be
higher in human glomeruli than in other species (Toya et al., 1993). The
human Ai receptor gene consists of at least six exons and five introns and can
undergo alternative splicing in the 5'-untranslated region, which effects the
level of A-i receptor expression in a tissue specific manner (Ren & Stiles,
1994a, b). Human kidney contains the correct exon sequences associated with
increased levels of expression and this may account for the higher binding site
densities reported (Toya et al., 1993). The possibility of higher adenosine
receptor density in human kidney, and the failure to establish conditions in
which adenosine radioligand binding or adenosine A-i receptor mRNA could be
detected in rodent kidney, led to other options being investigated. With human
kidney unavailable to compare directly to the data obtained for human brain
(see 1.3.4.), we investigated adenosine radioligand binding to the human
embryonic kidney cell line (HEK 293). pHJDPCPX bound specifically to
membranes from HEK 293 cells, while no [3HJCGS21680 binding was
detectable. Experiments were conducted using approximately 40-80 pg of
membrane protein, to ensure less than 10% of added ligand was bound whilst
maintaining sufficient specific binding to conduct pharmacological studies.
Binding was rapid with equilibrium reached by 2 min. However, the KD of 97.8
± 6.80 nM and the Bmax of 95.9 ± 22.5 pmol mg-1 protein in HEK 293 cell
membranes was different from that of human brain (Kq=2.18 ± 0.35 nM and
Bmax=4.97 ± 0.98 pmol mg-1 protein). In order to determine the nature of the
binding site labelled by [3H]DPCPX in HEK 293 cell membranes, the affinities
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of three agonists and three antagonists were determined. All six compounds
inhibited [3H]DPCPX binding to HEK 293 cell membranes in a concentration
dependent manner. For agonists the order of potency was R-PIA > S-PIA >
NECA. For these three agonists, this does not resemble the order of potency
used to classify any of the known adenosine receptors (Table 1.1) but does,
however, resemble that of the high affinity bovine A1 receptor (Olah, et al.,
1992; Tucker, et al., 1992). For antagonists the order of potency was
DPCPX > FR160537 > FR129946, which was again different to both rat and
human brain membranes. Both agonists and antagonists had very low affinities
and Hill slopes near unity, indicating the existence of one low affinity site. The
low affinity of NECA and the distinct agonist order of potency would appear to
rule out binding to classical adenosine receptors. This is despite the fact that
adenosine ^ (Rivkees et al., 1995b), A2a (Salvatore et al., 1993) and A3
(Sajjedi & Firestein, 1993) transcripts have all been reported to exist in human
kidney. The presence of low affinity endogenous adenosine radioligand
binding in fibroblast based cell lines like HEK 293 cells does not appear
uncommon, although its existence is generally ignored (Rivkees & Reppert,
1992; Pierce et al., 1992; Zhou et al., 1992; van Galen et al., 1994).
Endogenous A2b mRNA has been reported to exist in monkey kidney COS6M
cells and many fibroblast cell lines (Rivkees & Reppert, 1992). Human
embryonic kidney fibroblasts were also reported to have a low affinity
adenosine receptor but did not have A2b transcripts (Pierce et al., 1992). The
low affinity A2b receptor was first identified in human fibroblasts (Bruns, 1980),
however NECA was more potent than R-PIA so this is unlikely to be the source
of binding. Endogenous binding has been reported in CHO cells using the
A-1/A3 ligand [125|]APNEA but it did not have the pharmacological
characteristics of an adenosine receptor (van Galen et al., 1994). Zhou et al.,
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(1992) reported endogenous A2 binding using [3H]NECA in COS7 cells but
none in CHO cells. In our own laboratory (Mr T. Maemoto, personal
communication), it was noted that untransfected CHO cells attained some
specific pHJDPCPX binding as the passage number increased. To investigate
the possibility that the binding observed for [3H]DPCPX to HEK 293 cell
membranes was a consequence of the increasing passage number, a new cell
line was obtained. However, [3H]DPCPX binding to HEK 293 cell membranes
was similar in the new batch of ceils. The high micromolar affinity for NECA
and high Bmax seen in the present study would appear more similar to the high
capacity "nonreceptor" site (Bruns et al., 1986). Alternatively, the low affinity
binding observed in the present study may just be an artifact associated with
this embryonic cell line, as high affinity binding of adenosine A-i receptor
radioligands has been identified in human glomeruli (Toya eta!., 1993).
In conclusion these studies found no evidence for the presence of
[3H]DPCPX or [3H]CGS21680 binding sites in rat kidney, although
[3H]RX821002 binding was detectable in kidney cortical membrane
preparations. Similarly, high affinity pHjDPCPX binding sites were not




In this thesis a number of aspects of adenosine receptor pharmacology
have been examined. This has included, investigation of species differences in
adenosine A-i receptor pharmacology in brain membranes, modulation of
ligand binding to adenosine Ai and A2a receptors by magnesium and
Gpp(NH)p, the establishment of a radioreceptor assay capable of measuring
the central penetration of adenosine Ai receptor antagonists, and the
examination of rat renal adenosine A-i receptor pharmacology and localisation.
In vitro radioligand binding assays were used to determine the affinity
and selectivity of agonists and antagonists for adenosine A-i and A2a receptors.
All antagonists had Hill slopes close to unity in both [3H]DPCPX and
pH]CGS21680 binding assays, with antagonists binding to a single population
of sites in both cases. For agonists, Hill slopes were significantly less than
unity in the [3H]DPCPX binding assay, reflecting the ability of agonists to
recognise two different affinity states of the receptor. This is similar to other
GPCRs, with the two states representing the receptor being coupled to and
uncoupled from G proteins (Gilman, 1987; Birnbaumer etal., 1990). Hill slopes
for agonists in the [3HJCGS21680 binding assay were closer to, but still
significantly less than unity for the majority of compounds, with agonists
predominantly binding to the high affinity state of the receptor. The [3H]DPCPX
binding assay was modified for use in different species. Adenosine receptor
agonists and standard xanthine antagonists had similar affinities in rat and
mouse brain. In contrast these compounds were an order of magnitude less
potent in guinea pig and human brain membranes. This is despite over 90%
homology at the amino acid sequence level between the adenosine A-i
receptors of different species (see main introduction). For adenosine and
certain other receptor types, changing a single amino acid is sufficient to
produce large variations in the affinity of compounds in different species
284
(Oksenberg etal., 1992; Link etal., 1992; Kao eta!., 1992; Jensen etal., 1993;
Tucker et al., 1994; Townsend-Nicholson & Schofield, 1994). In addition to
single amino acids, a variety of domains throughout the structure of the
adenosine A-i receptor have been shown to be involved in both agonist and
antagonist binding (Olah etal., 1994; Tucker et al., 1994; Townsend-Nicholson
& Schofield, 1994). The novel non-xanthine adenosine A1 antagonists from
Fujisawa retained their high affinity for adenosine Ai receptors in all species
examined, including human. The non-xanthine Fujisawa antagonists appear
unaffected by the changes in receptor structure, perhaps binding to an area,
which is conserved within different species. These observations are of great
importance, when assessing whether a compound may be useful in man. The
use of rat tissue to assess the pharmacological properties of adenosine
agonists and xanthine antagonists may be inappropriate, resulting in the
overestimation of drug potency in man. If human tissue is unavailable to study
adenosine A-i receptors, guinea pig tissue may give a more realistic reflection
of a compounds effectiveness in man. The non-xanthine Fujisawa adenosine
Ai antagonists appear unaffected by species differences in receptor structure
and as a consequence, data obtained from rat studies can hopefully be
extrapolated to human.
The modulation of adenosine Ai and A2a ligand binding properties by
magnesium and Gpp(NH)p was complex, although similar effects have been
observed for other GPCRs (Gilman, 1987; Birnbaumer et al., 1990). The
modulation of antagonist binding levels by magnesium and Gpp(NH)p is
difficult to explain. The likeliest explanation for both effects, especially the 20%
increase in [3H]DPCPX binding in the presence of Gpp(NH)p, is a small
alteration in antagonist affinity that was not detected. Alternative explanations
postulated for the increase in antagonist binding in the presence of guanine
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nucleotides have included; antagonists preferentially binding to the uncoupled
form of the receptor, the presence of 'cryptic' binding sites and adenosine
possibly forming pseudoirreversible complexes in the membrane (Leung &
Green, 1989; Prater et al., 1992; Cohen eta/., 1996). In common with other
GPCRs, agonists bind to a high and low affinity state of the receptor, whose
equilibrium can be modified by magnesium and Gpp(NH)p. The increase (on
adding MgCI2) and decrease (on adding Gpp(NH)p) in agonist affinity in the
[3H]DPCPX binding assay was examined using a two site model. The change
in agonist affinity appeared to be the result of an alteration in the proportion of
the high and low affinity states labelled, with no change in the affinity of either
state. The adenosine A-i agonist radioligand [3H]CCPA, under the conditions
used, labelled predominantly the high affinity state, with its Kd consistent with
the high affinity component for CCPA recognised using [3H]DPCPX. The BmaX
for [3H]CCPA was also consistent with this idea as it was equivalent to the
Bmax for the high affinity state in the [3H]DPCPX binding assay. The adenosine
A2a agonist radioligand [3H]CGS21680, as with the Ai agonist appears to
predominantly label the high affinity state of the receptor. With magnesium
required in the assay buffer to obtain a reasonable level of specific binding,
high affinity agonist binding would be expected, as with other GPCRs (Gilman,
1987; Birnbaumer et al., 1990). The increase in [3H]CGS21680 binding in the
presence of magnesium appeared to be the result of the increase in agonist
affinity, which presumably reflects an increase in the proportion of high affinity
state labelled. The decrease in binding in the presence of Gpp(NH)p was due
to a decrease in affinity. The availability of the new A2a antagonist radioligands
[3H]KF17837S (Nonaka et al., 1994) and [3H]SCH58261 (Zocchi et al., 1996),
should help elucidate the mechanisms responsible for the observed effects. It
is clear for both A-i and A2a binding assays, that careful consideration must be
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given to the choice of assay buffer in light of the profound effects of
magnesium. Additionally, when examining binding in whole cell preparations,
the effects of intracellular guanine nucleotides must be considered.
A modified radioreceptor assay, using [3H]DPCPX was developed and
characterised. This assay is capable of measuring the central penetration of
adenosine Ai receptor antagonists following peripheral administration. The
procedure involved a transcardiac flush with saline to reduce potential
contamination of brain tissue samples from drug present in cerebral blood
vessels (Patel et al., 1994a). A 30 sec flush with saline reduced potential
contamination of brain tissue from drug in blood by 62%. The intrinsic binding
capacity of drug treated brain homogenate was removed by denaturation
(80°C for 15 min) and then homogenate samples were essentially added as a
'competing drug' to an in vitro radioligand binding assay, where one standard
source of membranes is used. This avoids the complication in ex vivo binding
assays, where each animal serves as the source of both drug and receptors
and therefore assumes that the receptor density and the [3H]ligand affinity is
the same in vehicle and drug treated animals (Burki, 1986). Two peripheral
adenosine receptor antagonists DPSPX and 8-PST were not detectable in
brain despite micromolar serum concentrations, suggesting BBB permeability
is a prerequisite for detection in brain homogenates (Nikodijevic et al., 1991;
Baumgold et al., 1992). A range of adenosine antagonists were given at a
behaviourally equivalent equipotent dose; i.e. a dose of antagonist known to
produce an 80% reversal of CPA-induced hypolocomotion. For the drugs that
were detectable in brain tissue, there was a good association between in vitro
Kj and brain concentration at the equipotent dose. With antagonists present in
brain tissue at concentrations sufficient to mediate the observed behavioural
effect and with peripheral antagonists ineffective, the results indicate that the
compounds are BBB permeable and capable of reversing a centrally mediated
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behavioural effect. For the two compounds which were behaviourally active but
which fell below the limit of detection in the assay, further studies are required.
The method is simple, reliable and capable of being used as a high throughput
assay for determining whether compounds cross the BBB and how long they
remain there. Compounds can be measured over a minimum of a 100 fold
concentration from at least 10 fold above and below the IC50 value of each
drug for the receptor. Unlike HPLC, it also has the advantage of detecting the
presence of active metabolites. If a suitable radioligand binding assay is
available the method could be modified for use with other receptors and
applied to different tissues and even intracellular receptor or enzyme systems.
Adenosine and its receptors are distributed widely throughout the body.
It is essential to establish if central and peripheral receptors are the same. A
centrally selective adenosine Ai antagonist with limited peripheral effects may
be beneficial for use as a cognitive enhancer (Jacobson et ai., 1992a; Suzuki
et al., 1993). As adenosine Ai antagonists are potent diuretics, we examined
the pharmacology and localisation of rat renal adenosine A1 receptors, neither
of which is well characterised (Spielman & Arend, 1991). A combined
approach involving radioligand binding, in vitro autoradiography and in situ
hybridisation was used. No specific adenosine receptor binding was found in
crude or complex cortical and medullary kidney preparations, at radioligand
concentrations in excess of those used to detect adenosine Ai receptors in rat
and human brain. The membrane preparations appeared viable with binding of
the «2 adrenoreceptor antagonist pH]RX821002 characterised. Even using this
combined approach and despite positive signals for the adenosine A1 receptor
in brain using in vitro autoradiography, no signal was observed in kidney. A
wealth of evidence points to multiple roles for adenosine in the kidney
(Spielman & Arend, 1991). Despite this, there are conflicting reports on the
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ability to detect adenosine A-i receptor mRNA in rat kidney (see 4.4). A low
receptor density and discrete localisation may be responsible, for our inability
to detect adenosine Ai receptors in rat kidney. The potential of a higher
adenosine receptor density in human kidney led to the use of HEK 293 cells
(Toya et at., 1993; Ren & Stiles, 1994a, b). The low affinity binding
characterised, may be an artifact and therefore future studies would require
the use of human kidney.
Neurochemical and electrophysiological experiments have pointed to a
neuromodulatory role for adenosine. In general, presynaptic adenosine A-i
receptors are responsible for inhibition of neurotransmitter release and
postsynaptic A-i receptors cause a decrease in excitability. Adenosine A-i
antagonists may reverse the inhibitory effects of adenosine, leading to synaptic
facilitation at pre- and post synaptic sites and increased neurotransmitter
release. Fujisawa have synthesised a range of novel non-xanthine adenosine
A-i antagonists based on the structure of FK453. These compounds are highly
selective for the adenosine A-i receptor and are potent adenosine Ai
antagonists in human brain membranes. These high affinity, blood brain barrier
permeable adenosine Ai receptor antagonists may be capable of enhancing
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ADP: Adenosine 5' diphosphate
AMP: Adenosine 5' monophosphate
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APES: 3-aminopropyltriethoxy-silane
ATP: Adenosine 5' triphosphate
BSA: Bovine serum albumin





DMEM: Dulbecco's modified eagles medium
DNA: Deoxyribonucleic acid
DNTP's: Deoxynucleoside triphosphates
dpm: Disintegrations per minute
DTT: Dithiothreitol
EDTA: (Ethylenedinitrilo)tetraacetic acid
FCS: Foetal calf serum
G protein: Guanyl nucleotide binding protein
GPCRs: G protein coupled receptors
Gpp(NH)p: 5'-Guanylimidodiphosphate
GTP: Guanosine 5' triphosphate
IMS: Industrial methylated spirits
IPTG: Isopropyl-p-D-thiogalactoside
LB: Luria Bertani (medium or agar)
O.D.: Optical density
PCR: Polymerase chain reaction
PBS: Phosphate buffered saline
PMSF: Phenylmethylsulphonyl fluoride
rpm: Revolutions per minute
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